10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

xQUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended June 30, 2017

OR

oTRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to           

Commission file numbers: 001-34465 and 001-31441

SELECT MEDICAL HOLDINGS CORPORATION

SELECT MEDICAL CORPORATION

(Exact name of Registrant as specified in its Charter)

Delaware
Delaware
(State or Other Jurisdiction of
Incorporation or Organization) 20-1764048
23-2872718
(I.R.S. Employer
Identification Number)

4714 Gettysburg Road, P.O. Box 2034
Mechanicsburg, PA 17055
(Address of Principal Executive Offices and Zip code)

(717) 972-1100

(Registrants’ telephone number, including area code)

Indicate by check mark whether the Registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods as such Registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days.   Yes x  No o

Indicate by check mark whether the Registrants have submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the Registrants were required to submit and post such files).   Yes x  No o

Indicate by check mark whether the Registrant, Select Medical Holdings Corporation, is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer x	Accelerated filer o
Non-accelerated filer o	Smaller reporting company o
(Do not check if a smaller reporting company)	Emerging Growth Company o

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    o

Indicate by check mark whether the Registrant, Select Medical Corporation, is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o	Accelerated filer o
Non-accelerated filer x	Smaller reporting company o
(Do not check if a smaller reporting company)	Emerging Growth Company o

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    o

Indicate by check mark whether the Registrants are shell companies (as defined in Rule 12b-2 of the Exchange Act).  Yes o  No x

As of July 31, 2017, Select Medical Holdings Corporation had outstanding 132,936,770 shares of common stock.

This Form 10-Q is a combined quarterly report being filed separately by two Registrants: Select Medical Holdings Corporation and Select Medical Corporation. Unless the context indicates otherwise, any reference in this report to “Holdings” refers to Select Medical Holdings Corporation and any reference to “Select” refers to Select Medical Corporation, the wholly owned operating subsidiary of Holdings, and any of Select’s subsidiaries. Any reference to “Concentra” refers to Concentra Inc., the indirect operating subsidiary of Concentra Group Holdings, LLC (“Concentra Group Holdings”), and its subsidiaries. References to the “Company,” “we,” “us,” and “our” refer collectively to Holdings, Select, and Concentra Group Holdings and its subsidiaries.

TABLE OF CONTENTS

PART I	FINANCIAL INFORMATION	3
ITEM 1.	CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
	Condensed consolidated balance sheets	3
	Condensed consolidated statements of operations	4
	Condensed consolidated statements of changes in equity and income	6
	Condensed consolidated statements of cash flows	7
	Notes to condensed consolidated financial statements	8
ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	30
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	50
ITEM 4.	CONTROLS AND PROCEDURES	50
PART II	OTHER INFORMATION	51
ITEM 1.	LEGAL PROCEEDINGS	51
ITEM 1A.	RISK FACTORS	53
ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	53
ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	54
ITEM 4.	MINE SAFETY DISCLOSURES	54
ITEM 5.	OTHER INFORMATION	54
ITEM 6.	EXHIBITS	54
SIGNATURES

PART I FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Condensed Consolidated Balance Sheets

(unaudited)

(in thousands, except share and per share amounts)

	Select Medical Holdings Corporation				Select Medical Corporation
	December 31,		June 30,		December 31,			June 30,
	2016		2017		2016			2017
ASSETS
Current Assets:
Cash and cash equivalents	$	99,029	$	73,799	$	99,029		$	73,799
Accounts receivable, net of allowance for doubtful accounts of $63,787 and $67,769 at 2016 and 2017, respectively	573,752		714,236		573,752			714,236
Prepaid income taxes	12,423		—		12,423			—
Other current assets	77,699		83,211		77,699			83,211
Total Current Assets	762,903		871,246		762,903			871,246
Property and equipment, net	892,217		911,532		892,217			911,532
Goodwill	2,751,000		2,766,296		2,751,000			2,766,296
Identifiable intangible assets, net	340,562		335,704		340,562			335,704
Other assets	173,944		169,433		173,944			169,433
Total Assets	$	4,920,626	$	5,054,211	$	4,920,626		$	5,054,211
LIABILITIES AND EQUITY
Current Liabilities:
Bank overdrafts	$	39,362	$	34,134	$	39,362		$	34,134
Current portion of long-term debt and notes payable	13,656		26,577		13,656			26,577
Accounts payable	126,558		123,631		126,558			123,631
Accrued payroll	146,397		119,187		146,397			119,187
Accrued vacation	83,261		92,250		83,261			92,250
Accrued interest	22,325		19,277		22,325			19,277
Accrued other	140,076		146,853		140,076			146,853
Income taxes payable	—		6,976		—			6,976
Total Current Liabilities	571,635		568,885		571,635			568,885
Long-term debt, net of current portion	2,685,333		2,734,132		2,685,333			2,734,132
Non-current deferred tax liability	199,078		197,411		199,078			197,411
Other non-current liabilities	136,520		141,279		136,520			141,279
Total Liabilities	3,592,566		3,641,707		3,592,566			3,641,707
Commitments and contingencies (Note 8)
Redeemable non-controlling interests	422,159		468,850		422,159			468,850
Stockholders’ Equity:
Common stock of Holdings, $0.001 par value, 700,000,000 shares authorized, 132,596,758 and 132,929,545 shares issued and outstanding at 2016 and 2017, respectively	132		133		—			—
Common stock of Select, $0.01 par value, 100 shares issued and outstanding	—		—		0			0
Capital in excess of par	443,908		454,892		925,111			936,428
Retained earnings (accumulated deficit)	371,685		393,294		(109,386		)	(88,109		)
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders’ Equity	815,725		848,319		815,725			848,319
Non-controlling interest	90,176		95,335		90,176			95,335
Total Equity	905,901		943,654		905,901			943,654
Total Liabilities and Equity	$	4,920,626	$	5,054,211	$	4,920,626		$	5,054,211

The accompanying notes are an integral part of these condensed consolidated financial statements.

3

Condensed Consolidated Statements of Operations

(unaudited)

(in thousands, except per share amounts)

	Select Medical Holdings Corporation						Select Medical Corporation
	For the Three Months Ended June 30,						For the Three Months Ended June 30,
	2016			2017			2016			2017
Net operating revenues	$	1,097,631		$	1,120,675		$	1,097,631		$	1,120,675
Costs and expenses:
Cost of services	916,985			920,230			916,985			920,230
General and administrative	25,870			28,275			25,870			28,275
Bad debt expense	17,517			18,174			17,517			18,174
Depreciation and amortization	36,205			38,333			36,205			38,333
Total costs and expenses	996,577			1,005,012			996,577			1,005,012
Income from operations	101,054			115,663			101,054			115,663
Other income and expense:
Equity in earnings of unconsolidated subsidiaries	4,546			5,666			4,546			5,666
Non-operating gain	13,035			—			13,035			—
Interest expense	(44,332		)	(37,655		)	(44,332		)	(37,655		)
Income before income taxes	74,303			83,674			74,303			83,674
Income tax expense	33,450			32,374			33,450			32,374
Net income	40,853			51,300			40,853			51,300
Less: Net income attributable to non-controlling interests	6,918			9,245			6,918			9,245
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	$	33,935		$	42,055		$	33,935		$	42,055
Basic	$	0.26		$	0.32
Diluted	$	0.26		$	0.32
Weighted average shares outstanding:
Basic	127,626			128,624
Diluted	127,820			128,777

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

Condensed Consolidated Statements of Operations

(unaudited)

(in thousands, except per share amounts)

	Select Medical Holdings Corporation						Select Medical Corporation
	For the Six Months Ended June 30,						For the Six Months Ended June 30,
	2016			2017			2016			2017
Net operating revenues	$	2,185,961		$	2,232,036		$	2,185,961		$	2,232,036
Costs and expenses:
Cost of services	1,839,247			1,848,587			1,839,247			1,848,587
General and administrative	54,138			56,350			54,138			56,350
Bad debt expense	33,914			38,799			33,914			38,799
Depreciation and amortization	70,722			80,872			70,722			80,872
Total costs and expenses	1,998,021			2,024,608			1,998,021			2,024,608
Income from operations	187,940			207,428			187,940			207,428
Other income and expense:
Loss on early retirement of debt	(773		)	(19,719		)	(773		)	(19,719		)
Equity in earnings of unconsolidated subsidiaries	9,198			11,187			9,198			11,187
Non-operating gain (loss)	38,122			(49		)	38,122			(49		)
Interest expense	(83,180		)	(78,508		)	(83,180		)	(78,508		)
Income before income taxes	151,307			120,339			151,307			120,339
Income tax expense	50,510			45,576			50,510			45,576
Net income	100,797			74,763			100,797			74,763
Less: Net income attributable to non-controlling interests	12,029			16,838			12,029			16,838
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	$	88,768		$	57,925		$	88,768		$	57,925
Basic	$	0.68		$	0.44
Diluted	$	0.68		$	0.44
Weighted average shares outstanding:
Basic	127,563			128,544
Diluted	127,709			128,703

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

Condensed Consolidated Statements of Changes in Equity and Income

(unaudited)

(in thousands)

				Select Medical Holdings Corporation Stockholders
	Redeemable Non-controlling interests			Common Stock Issued		Common Stock Par Value		Capital in Excess of Par			Retained Earnings			Total Stockholders’ Equity			Non-controlling Interests			Total Equity
Balance at December 31, 2016	$	422,159		132,597		$	132	$	443,908		$	371,685		$	815,725		$	90,176		$	905,901
Net income attributable to Select Medical Holdings Corporation											57,925			57,925						57,925
Net income attributable to non-controlling interests	13,140													—			3,698			3,698
Issuance and vesting of restricted stock				268		1		8,700						8,701						8,701
Repurchase of common shares				(45	)	0		(332		)	(268		)	(600		)				(600		)
Exercise of stock options				109		0		963						963						963
Issuance of non-controlling interests								1,653						1,653			3,634			5,287
Purchase of non-controlling interests	(127		)								7			7						7
Distributions to non-controlling interests	(3,113		)											—			(2,303		)	(2,303		)
Redemption adjustment on non-controlling interests	36,292										(36,292		)	(36,292		)				(36,292		)
Other	499										237			237			130			367
Balance at June 30, 2017	$	468,850		132,929		$	133	$	454,892		$	393,294		$	848,319		$	95,335		$	943,654
				Select Medical Corporation Stockholders
	Redeemable Non-controlling interests			Common Stock Issued		Common Stock Par Value		Capital in Excess of Par			Retained Earnings			Total Stockholders’ Equity			Non-controlling Interests			Total Equity
Balance at December 31, 2016	$	422,159		0		$	0	$	925,111		$	(109,386	)	$	815,725		$	90,176		$	905,901
Net income attributable to Select Medical Corporation											57,925			57,925						57,925
Net income attributable to non-controlling interests	13,140													—			3,698			3,698
Additional investment by Holdings								963						963						963
Dividends declared and paid to Holdings											(600		)	(600		)				(600		)
Contribution related to restricted stock awards and stock option issuances by Holdings								8,701						8,701						8,701
Issuance of non-controlling interests								1,653						1,653			3,634			5,287
Purchase of non-controlling interests	(127		)								7			7						7
Distributions to non-controlling interests	(3,113		)											—			(2,303		)	(2,303		)
Redemption adjustment on non-controlling interests	36,292										(36,292		)	(36,292		)				(36,292		)
Other	499										237			237			130			367
Balance at June 30, 2017	$	468,850		0		$	0	$	936,428		$	(88,109	)	$	848,319		$	95,335		$	943,654

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

Condensed Consolidated Statements of Cash Flows

(unaudited)

(in thousands)

	Select Medical Holdings Corporation						Select Medical Corporation
	For the Six Months Ended June 30,						For the Six Months Ended June 30,
	2016			2017			2016			2017
Operating activities
Net income	$	100,797		$	74,763		$	100,797		$	74,763
Adjustments to reconcile net income to net cash provided by operating activities:
Distributions from unconsolidated subsidiaries	12,039			10,933			12,039			10,933
Depreciation and amortization	70,722			80,872			70,722			80,872
Provision for bad debts	33,914			38,799			33,914			38,799
Equity in earnings of unconsolidated subsidiaries	(9,198		)	(11,187		)	(9,198		)	(11,187		)
Loss on extinguishment of debt	773			6,527			773			6,527
Gain on sale of assets and businesses	(43,461		)	(9,523		)	(43,461		)	(9,523		)
Loss on disposal of assets	55			—			55			—
Impairment of equity investment	5,339			—			5,339			—
Stock compensation expense	8,174			9,270			8,174			9,270
Amortization of debt discount, premium and issuance costs	7,077			5,974			7,077			5,974
Deferred income taxes	(13,286		)	(1,474		)	(13,286		)	(1,474		)
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	(44,096		)	(179,003		)	(44,096		)	(179,003		)
Other current assets	11,011			(5,557		)	11,011			(5,557		)
Other assets	4,508			4,621			4,508			4,621
Accounts payable	(15,852		)	759			(15,852		)	759
Accrued expenses	20,632			(4,833		)	20,632			(4,833		)
Income taxes	29,090			19,399			29,090			19,399
Net cash provided by operating activities	178,238			40,340			178,238			40,340
Investing activities
Acquisition of businesses, net of cash acquired	(421,519		)	(18,508		)	(421,519		)	(18,508		)
Purchases of property and equipment	(80,258		)	(105,302		)	(80,258		)	(105,302		)
Investment in businesses	(1,590		)	(9,874		)	(1,590		)	(9,874		)
Proceeds from sale of assets and businesses	71,366			34,552			71,366			34,552
Net cash used in investing activities	(432,001		)	(99,132		)	(432,001		)	(99,132		)
Financing activities
Borrowings on revolving facilities	320,000			630,000			320,000			630,000
Payments on revolving facilities	(380,000		)	(550,000		)	(380,000		)	(550,000		)
Proceeds from term loans	600,127			1,139,487			600,127			1,139,487
Payments on term loans	(229,649		)	(1,173,692		)	(229,649		)	(1,173,692		)
Revolving facility debt issuance costs	—			(4,392		)	—			(4,392		)
Borrowings of other debt	22,082			9,444			22,082			9,444
Principal payments on other debt	(9,926		)	(10,437		)	(9,926		)	(10,437		)
Repayments of bank overdrafts	(2,138		)	(5,228		)	(2,138		)	(5,228		)
Repurchase of common stock	(506		)	(600		)	—			—
Dividends paid to Holdings	—			—			(506		)	(600		)
Proceeds from exercise of stock options	657			963			—			—
Equity investment by Holdings	—			—			657			963
Proceeds from issuance of non-controlling interests	3,103			3,553			3,103			3,553
Purchase of non-controlling interests	(1,294		)	(120		)	(1,294		)	(120		)
Distributions to non-controlling interests	(4,708		)	(5,416		)	(4,708		)	(5,416		)
Net cash provided by financing activities	317,748			33,562			317,748			33,562
Net increase (decrease) in cash and cash equivalents	63,985			(25,230		)	63,985			(25,230		)
Cash and cash equivalents at beginning of period	14,435			99,029			14,435			99,029
Cash and cash equivalents at end of period	$	78,420		$	73,799		$	78,420		$	73,799
Supplemental Information
Cash paid for interest	$	69,315		$	76,650		$	69,315		$	76,650
Cash paid for taxes	$	35,518		$	27,626		$	35,518		$	27,626

The accompanying notes are an integral part of these condensed consolidated financial statements.

7

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. Basis of Presentation

The unaudited condensed consolidated financial statements of Select Medical Holdings Corporation (“Holdings”) include the accounts of its wholly owned subsidiary, Select Medical Corporation (“Select”). Holdings conducts substantially all of its business through Select and its subsidiaries. Holdings and Select and its subsidiaries are collectively referred to as the “Company.” The unaudited condensed consolidated financial statements of the Company as of June 30, 2017, and for the three and six month periods ended June 30, 2016 and 2017, have been prepared pursuant to the rules and regulations of the Securities Exchange Commission (the “SEC”) for interim reporting and accounting principles generally accepted in the United States of America (“GAAP”). Accordingly, certain information and disclosures required by GAAP, which are normally included in the notes to consolidated financial statements, have been condensed or omitted pursuant to those rules and regulations, although the Company believes the disclosure is adequate to make the information presented not misleading. In the opinion of management, such information contains all adjustments, which are normal and recurring in nature, necessary for a fair statement of the financial position, results of operations and cash flow for such periods. All significant intercompany transactions and balances have been eliminated.

The results of operations for the three and six months ended June 30, 2017 are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2017. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2016 contained in the Company’s Annual Report on Form 10-K filed with the SEC on February 23, 2017.

2. Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingencies, at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Recent Accounting Pronouncements

In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-01, Business Combinations (Topic 805), Clarifying the Definition of a Business, which clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. ASU 2017-01 states that if substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the transaction should be accounted for as an asset acquisition. In addition, the ASU clarifies the requirements for a set of activities to be considered a business and narrows the definition of an output. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill and consolidation. ASU 2017-01 is effective for annual periods beginning after December 15, 2017. Early adoption is permitted.

In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740), Intra-Entity Transfers of Assets Other Than Inventory. Current GAAP prohibits the recognition of current and deferred income taxes for an intra-entity asset transfer until the asset has been sold to an outside party. The ASU requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The standard will be effective for fiscal years beginning after December 15, 2017. The Company plans to adopt the guidance effective January 1, 2018. Adoption of the guidance will be applied on a modified retrospective approach through a cumulative effect adjustment to retained earnings as of the effective date.

8

In February 2016, the FASB issued ASU 2016-02, Leases. This ASU includes a lessee accounting model that recognizes two types of leases; finance and operating. This ASU requires that a lessee recognize on the balance sheet assets and liabilities for all leases with lease terms of more than twelve months. Lessees will need to recognize almost all leases on the balance sheet as a right-of-use asset and a lease liability. For income statement purposes, the FASB retained the dual model, requiring leases to be classified as either operating or finance. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee will depend on its classification as a finance or operating lease. For short-term leases of twelve months or less, lessees are permitted to make an accounting election by class of underlying asset not to recognize right-of-use assets or lease liabilities. If the alternative is elected, lease expense would be recognized generally on the straight-line basis over the respective lease term.

The amendments in ASU 2016-02 will take effect for public companies for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Earlier application is permitted as of the beginning of an interim or annual reporting period. A modified retrospective approach is required for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements.

Upon adoption, the Company will recognize significant assets and liabilities on the consolidated balance sheets as a result of the operating lease obligations of the Company. Operating lease expense will still be recognized as rent expense on a straight-line basis over the respective lease terms in the consolidated statements of operations.

The Company will implement the new standard beginning January 1, 2019. The Company’s implementation efforts are focused on designing accounting processes, disclosure processes, and internal controls in order to account for its leases under the new standard.

In May 2014, March 2016, April 2016, and December 2016, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, ASU 2016-08, Revenue from Contracts with Customers, Principal versus Agent Considerations, ASU 2016-10, Revenue from Contracts with Customers, Identifying Performance Obligations and Licensing, ASU 2016-12, Revenue from Contracts with Customers, Narrow Scope Improvements and Practical Expedients, and ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customer (collectively “the standards”), respectively, which supersede most of the current revenue recognition requirements. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. The standards require the selection of a retrospective or cumulative effect transition method.

The Company will implement the new standard beginning January 1, 2018 using the retrospective transition method.  Adoption of the new standard will result in material changes to the presentation of net operating revenues and bad debt expense in the consolidated statements of operations, but the presentation of the amount of income from operations and net income will be unchanged upon adoption of the new standards. The principal change is how the new standard requires healthcare providers to estimate the amount of variable consideration to be included in the transaction price up to an amount which is probable that a significant reversal will not occur. The most common form of variable consideration the Company experiences are amounts for services provided that are ultimately not realizable from a customer. Under the current standards, the Company’s estimate for unrealizable amounts was recorded to bad debt expense. Under the new standards, the Company’s estimate for unrealizable amounts will be recognized as a constraint to revenue and will be reflected as an allowance. Substantially all of the bad debt expense as of June 30, 2016 and June 30, 2017 will be reclassified as an allowance when the Company retrospectively applies the guidance in the standards on January 1, 2018.

The Company’s remaining implementation efforts are focused principally on refining the accounting processes, disclosure processes, and internal controls.

9

Recently Adopted Accounting Pronouncements

In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes, which changed the presentation of deferred income taxes. The standard changed the presentation of deferred income taxes through the requirement that all deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The Company adopted the standard on January 1, 2017. The consolidated balance sheet at December 31, 2016 has been retrospectively adjusted. Adoption of the new standard impacted the Company’s previously reported results as follows:

	December 31, 2016
	As Reported		As Adjusted
	(in thousands)
Current deferred tax asset	$	45,165	$	—
Total current assets	808,068		762,903
Other assets	152,548		173,944
Total assets	4,944,395		4,920,626
Non-current deferred tax liability	222,847		199,078
Total liabilities	3,616,335		3,592,566
Total liabilities and equity	4,944,395		4,920,626

Reclassifications

Certain reclassifications have been made to prior year amounts in order to conform to current year presentation. As discussed above, the condensed consolidated balance sheet at December 31, 2016 has been changed in order to conform to the current year balance sheet presentation for the adoption of ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes.

3.  Acquisitions

Physiotherapy Acquisition

On March 4, 2016, Select acquired 100% of the issued and outstanding equity securities of Physiotherapy Associates Holdings, Inc. (“Physiotherapy”) for $406.3 million, net of $12.3 million of cash acquired.

For the Physiotherapy acquisition, the Company allocated the purchase price to tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair value in accordance with the provisions of Accounting Standards Codification (“ASC”) 805, Business Combinations. During the quarter ended March 31, 2017, the Company finalized the purchase price allocation.

The following table reconciles the allocation of the consideration given for identifiable net assets and goodwill acquired to the net cash paid for the acquired business (in thousands):

Cash and cash equivalents	$	12,340
Identifiable tangible assets, excluding cash and cash equivalents	87,832
Identifiable intangible assets	32,484
Goodwill	343,187
Total assets	475,843
Total liabilities	54,685
Acquired non-controlling interests	2,514
Net assets acquired	418,644
Less: Cash and cash equivalents acquired	(12,340		)
Net cash paid	$	406,304

Goodwill of $343.2 million has been recognized in the business combination, representing the excess of the consideration given over the fair value of identifiable net assets acquired. The value of goodwill is derived from Physiotherapy’s future earnings potential and its assembled workforce. Goodwill has been assigned to the outpatient rehabilitation reporting unit and is not deductible for tax purposes. However, prior to its acquisition by the Company, Physiotherapy completed certain acquisitions that resulted in tax deductible goodwill with an estimated value of $8.8 million, which the Company will deduct through 2030.

10

Due to the integration of Physiotherapy into our outpatient rehabilitation operations, it is not practicable to separately identify net revenue and earnings of Physiotherapy on a stand-alone basis.

The following pro forma unaudited results of operations have been prepared assuming the acquisition of Physiotherapy occurred on January 1, 2015. These results are not necessarily indicative of results of future operations nor of the results that would have actually occurred had the acquisition been consummated on the aforementioned date. The Company’s results of operations for the three months ended June 30, 2016 and for the three and six months ended June 30, 2017 include Physiotherapy for the entire period. There were no pro forma adjustments during these periods; therefore, no pro forma information is presented for the periods.

	For the Six Months Ended June 30, 2016
	(in thousands, except per share amounts)
Net revenue	$	2,239,491
Net income attributable to Holdings	86,948
Income per common share:
Basic	$	0.66
Diluted	$	0.66

The net income tax impact was calculated at a statutory rate, as if Physiotherapy had been a subsidiary of the Company as of January 1, 2015. Pro forma results for the six months ended June 30, 2016 were adjusted to exclude approximately $3.2 million of Physiotherapy acquisition costs.

Other Acquisitions

The Company completed acquisitions within our specialty hospitals, outpatient rehabilitation, and Concentra segments during the six months ended June 30, 2017. The Company provided total consideration of $20.2 million, consisting principally of $18.5 million of cash, net of cash received, and the issuance of non-controlling interests. The assets received in these acquisitions consisted principally of accounts receivable, property and equipment, identifiable intangible assets, and goodwill, of which $0.7 million, $0.3 million, and $14.5 million of goodwill was recognized in our specialty hospitals, outpatient rehabilitation, and Concentra reporting units, respectively.

11

4. Intangible Assets and Liabilities

Goodwill

The following table shows changes in the carrying amount of goodwill by reporting unit for the six months ended June 30, 2017:

	Specialty Hospitals			Outpatient Rehabilitation		Concentra		Total
	(in thousands)
Balance as of December 31, 2016	$	1,447,406		$	643,557	$	660,037	$	2,751,000
Acquired	654			311		14,505		15,470
Measurement period adjustment	(342		)	168		—		(174		)
Balance as of June 30, 2017	$	1,447,718		$	644,036	$	674,542	$	2,766,296

See Note 3 for details of the goodwill acquired during the period.

Identifiable Intangible Assets and Liabilities

The following table provides the gross carrying amounts, accumulated amortization, and net carrying amounts for the Company’s identifiable intangible assets and liabilities:

	December 31, 2016							June 30, 2017
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
	(in thousands)
Indefinite-lived assets:
Trademarks	$	166,698	$	—		$	166,698	$	166,698	$	—		$	166,698
Certificates of need	17,026		—			17,026		19,207		—			19,207
Accreditations	2,235		—			2,235		2,074		—			2,074
Finite-lived assets:
Customer relationships	142,198		(23,185		)	119,013		143,953		(30,681		)	113,272
Favorable leasehold interests	13,089		(2,317		)	10,772		13,295		(3,255		)	10,040
Non-compete agreements	26,655		(1,837		)	24,818		27,267		(2,854		)	24,413
Total identifiable intangible assets	$	367,901	$	(27,339	)	$	340,562	$	372,494	$	(36,790	)	$	335,704
Finite-lived liabilities:
Unfavorable leasehold interests	$	5,139	$	(1,410	)	$	3,729	$	5,343	$	(1,957	)	$	3,386

The Company’s customer relationships and non-compete agreements amortize over their estimated useful lives. Amortization expense was $4.3 million for both the three months ended June 30, 2016 and 2017. Amortization expense was $8.1 million and $8.7 million for the six months ended June 30, 2016 and 2017, respectively.

The Company’s favorable and unfavorable leasehold interests are amortized to rent expense over the remaining term of their respective leases to reflect a market rent per period based upon the market conditions present at the acquisition date. The Company’s unfavorable leasehold interests are not separately presented on the condensed consolidated balance sheets but are included as a component of accrued other and other non-current liabilities.

The Company’s accreditations and trademarks have renewal terms and the costs to renew these intangible assets are expensed as incurred. At June 30, 2017, the accreditations and trademarks have a weighted average time until next renewal of 1.5 years and 2.4 years, respectively.

12

5. Long-Term Debt and Notes Payable

For purposes of this indebtedness footnote, references to Select exclude Concentra because the Concentra credit facilities are non-recourse to Holdings and Select.

The Company’s long-term debt and notes payable as of June 30, 2017 are as follows (in thousands):

	Principal Outstanding		Unamortized Premium (Discount)			Unamortized Issuance Costs			Carrying Value		Fair Value
Select:
6.375% senior notes	$	710,000	$	892		$	(7,510	)	$	703,382	$	732,152
Credit facilities:
Revolving facility	300,000		—			—			300,000		276,000
Term loan	1,147,125		(13,480		)	(13,540		)	1,120,105		1,158,596
Other	25,700		—			—			25,700		25,700
Total Select debt	$	2,182,825	$	(12,588	)	$	(21,050	)	$	2,149,187	$	2,192,448
Concentra:
Credit facilities:
Term loan	$	619,175	$	(2,513	)	$	(11,867	)	$	604,795	$	617,434
Other	6,727		—			—			6,727		6,727
Total Concentra debt	$	625,902	$	(2,513	)	$	(11,867	)	$	611,522	$	624,161
Total debt	$	2,808,727	$	(15,101	)	$	(32,917	)	$	2,760,709	$	2,816,609

Principal maturities of the Company’s long-term debt and notes payable are approximately as follows (in thousands):

	2017		2018		2019		2020		2021		Thereafter		Total
Select:
6.375% senior notes	$	—	$	—	$	—	$	—	$	710,000	$	—	$	710,000
Credit facilities:
Revolving facility	—		—		—		—		—		300,000		300,000
Term loan	5,750		11,500		11,500		11,500		11,500		1,095,375		1,147,125
Other	10,251		3,530		11,827		68		14		10		25,700
Total Select debt	$	16,001	$	15,030	$	23,327	$	11,568	$	721,514	$	1,395,385	$	2,182,825
Concentra:
Credit facilities:
Term loan	$	—	$	—	$	—	$	3,016	$	6,520	$	609,639	$	619,175
Other	1,309		1,394		144		161		160		3,559		6,727
Total Concentra debt	$	1,309	$	1,394	$	144	$	3,177	$	6,680	$	613,198	$	625,902
Total debt	$	17,310	$	16,424	$	23,471	$	14,745	$	728,194	$	2,008,583	$	2,808,727

13

The Company’s long-term debt and notes payable as of December 31, 2016 are as follows (in thousands):

	Principal Outstanding		Unamortized Premium (Discount)			Unamortized Issuance Costs			Carrying Value		Fair Value
Select:
6.375% senior notes	$	710,000	$	1,006		$	(8,461	)	$	702,545	$	710,000
Credit facilities:
Revolving facility	220,000		—			—			220,000		204,600
Term loans	1,147,751		(11,967		)	(13,581		)	1,122,203		1,165,860
Other	22,688		—			—			22,688		22,688
Total Select debt	$	2,100,439	$	(10,961	)	$	(22,042	)	$	2,067,436	$	2,103,148
Concentra:
Credit facilities:
Term loan	$	642,239	$	(2,773	)	$	(13,091	)	$	626,375	$	644,648
Other	5,178		—			—			5,178		5,178
Total Concentra debt	$	647,417	$	(2,773	)	$	(13,091	)	$	631,553	$	649,826
Total debt	$	2,747,856	$	(13,734	)	$	(35,133	)	$	2,698,989	$	2,752,974

Select Credit Facilities

On March 6, 2017, Select entered into a new senior secured credit agreement (the “Select credit agreement”) that provides for $1.6 billion in senior secured credit facilities comprising a $1.15 billion, seven-year term loan (the “Select term loan”) and a $450.0 million, five-year revolving credit facility (the “Select revolving facility” and together with the Select term loan, the “Select credit facilities”), including a $75.0 million sublimit for the issuance of standby letters of credit.

Select used borrowings under the Select credit facilities to: (i) repay in full the series E tranche B term loans due June 1, 2018, the series F tranche B term loans due March 31, 2021, and the revolving facility maturing March 1, 2018 under its then existing credit facilities; and (ii) pay fees and expenses in connection with the refinancing, which resulted in $6.5 million of debt extinguishment losses and $13.2 million of debt modification losses during the first quarter of 2017.

Borrowings under the Select credit facilities bear interest at a rate equal to: (i) in the case of the Select term loan, Adjusted LIBO (as defined in the Select credit agreement) plus 3.50% (subject to an Adjusted LIBO floor of 1.00%), or Alternate Base Rate (as defined in the Select credit agreement) plus 2.50% (subject to an Alternate Base Rate floor of 2.00%); and (ii) in the case of the Select revolving facility, Adjusted LIBO plus a percentage ranging from 3.00% to 3.25% or Alternate Base Rate plus a percentage ranging from 2.00% to 2.25%, in each case based on Select’s leverage ratio.

The Select term loan amortizes in equal quarterly installments in amounts equal to 0.25% of the aggregate original principal amount of the Select term loan commencing on June 30, 2017.  The balance of the Select term loan will be payable on March 8, 2024; however, if the Select 6.375% senior notes, which are due June 1, 2021, are outstanding on March 1, 2021, the maturity date for the Select term loan will become March 1, 2021. The Select revolving facility will be payable on March 8, 2022; however, if the Select 6.375% senior notes are outstanding on February 1, 2021, the maturity date for the Select revolving facility will become February 1, 2021.

Select will be required to prepay borrowings under the Select credit facilities with (i) 100% of the net cash proceeds received from non-ordinary course asset sales or other dispositions, or as a result of a casualty or condemnation, subject to reinvestment provisions and other customary carveouts and, to the extent required, the payment of certain indebtedness secured by liens having priority over the debt under the Select credit facilities or subject to a first lien intercreditor agreement, (ii) 100% of the net cash proceeds received from the issuance of debt obligations other than certain permitted debt obligations, and (ii) 50% of excess cash flow (as defined in the Select credit agreement) if Select’s leverage ratio is greater than 4.50 to 1.00 and 25% of excess cash flow if Select’s leverage ratio is less than or equal to 4.50 to 1.00 and greater than 4.00 to 1.00, in each case, reduced by the aggregate amount of term loans, revolving loans and certain other debt optionally prepaid during the applicable fiscal year.  Select will not be required to prepay borrowings with excess cash flow if Select’s leverage ratio is less than or equal to 4.00 to 1.00.

14

The Select revolving facility requires Select to maintain a leverage ratio (as defined in the Select credit agreement), which is tested quarterly, not to exceed 6.25 to 1.00. After March 31, 2019, the leverage ratio must not exceed 6.00 to 1.00.  Failure to comply with this covenant would result in an event of default under the Select revolving facility and, absent a waiver or an amendment from the revolving lenders, preclude Select from making further borrowings under the Select revolving facility and permit the revolving lenders to accelerate all outstanding borrowings under the Select revolving facility. The termination of the Select revolving facility commitments and the acceleration of amounts outstanding thereunder would constitute an event of default with respect to the Select term loan. As of June 30, 2017, Select’s leverage ratio was 5.86 to 1.00.

The Select credit facilities also contain a number of other affirmative and restrictive covenants, including limitations on mergers, consolidations and dissolutions; sales of assets; investments and acquisitions; indebtedness; liens; affiliate transactions; and dividends and restricted payments. The Select credit facilities contain events of default for non-payment of principal and interest when due (subject, as to interest, to a grace period), cross-default and cross-acceleration provisions and an event of default that would be triggered by a change of control.

Borrowings under the Select credit facilities are guaranteed by Holdings and substantially all of Select’s current domestic subsidiaries and will be guaranteed by substantially all of Select’s future domestic subsidiaries and secured by substantially all of Select’s existing and future property and assets and by a pledge of Select’s capital stock, the capital stock of Select’s domestic subsidiaries and up to 65% of the capital stock of Select’s foreign subsidiaries held directly by Select or a domestic subsidiary.

Excess Cash Flow Payment

On March 1, 2017, Concentra made a principal prepayment of $23.1 million associated with the Concentra first lien term loans in accordance with the provision in the Concentra credit facilities that requires mandatory prepayments of term loans as a result of annual excess cash flow, as defined in the Concentra credit facilities.

Fair Value

The Company considers the inputs in the valuation process to be Level 2 in the fair value hierarchy for Select’s 6.375% senior notes and for its credit facilities. Level 2 in the fair value hierarchy is defined as inputs that are observable for the asset or liability, either directly or indirectly, which includes quoted prices for identical assets or liabilities in markets that are not active.

The fair values of the Select credit facilities and the Concentra credit facilities were based on quoted market prices for this debt in the syndicated loan market. The fair value of Select’s 6.375% senior notes was based on quoted market prices. The carrying amount of other debt, principally short-term notes payable, approximates fair value.

15

6.  Segment Information

The Company’s reportable segments consist of: specialty hospitals, outpatient rehabilitation, and Concentra. Other activities include the Company’s corporate shared services and certain other non-consolidating joint ventures and minority investments in other healthcare related businesses. The Company evaluates performance of the segments based on Adjusted EBITDA. Adjusted EBITDA is defined as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, Physiotherapy acquisition costs, non-operating gain (loss), and equity in earnings (losses) of unconsolidated subsidiaries.

The following tables summarize selected financial data for the Company’s reportable segments. The segment results of Holdings are identical to those of Select.

	Three Months Ended June 30,						Six Months Ended June 30,
	2016			2017			2016			2017
	(in thousands)
Net operating revenues:
Specialty hospitals	$	585,816		$	600,960		$	1,184,770		$	1,199,747
Outpatient rehabilitation(1)	256,928			258,106			495,010			513,923
Concentra	254,868			261,586			505,745			517,735
Other	19			23			436			631
Total Company	$	1,097,631		$	1,120,675		$	2,185,961		$	2,232,036
Adjusted EBITDA:
Specialty hospitals	$	82,739		$	98,172		$	169,495		$	186,837
Outpatient rehabilitation(1)	38,132			41,926			67,011			73,277
Concentra	43,039			43,061			77,192			85,653
Other	(22,453		)	(24,479		)	(43,626		)	(48,197		)
Total Company	$	141,457		$	158,680		$	270,072		$	297,570
Total assets:(2)
Specialty hospitals	$	2,457,948		$	2,655,617		$	2,457,948		$	2,655,617
Outpatient rehabilitation	959,748			982,811			959,748			982,811
Concentra	1,328,243			1,310,483			1,328,243			1,310,483
Other	73,950			105,300			73,950			105,300
Total Company	$	4,819,889		$	5,054,211		$	4,819,889		$	5,054,211
Purchases of property and equipment, net:
Specialty hospitals	$	21,313		$	36,691		$	54,988		$	69,048
Outpatient rehabilitation(1)	3,825			6,201			8,798			12,874
Concentra	4,716			7,601			7,927			16,287
Other	3,636			4,156			8,545			7,093
Total Company	$	33,490		$	54,649		$	80,258		$	105,302

A reconciliation of Adjusted EBITDA to income before income taxes is as follows:

	Three Months Ended June 30, 2016
	Specialty Hospitals			Outpatient Rehabilitation(1)			Concentra			Other			Total
	(in thousands)
Adjusted EBITDA	$	82,739		$	38,132		$	43,039		$	(22,453	)
Depreciation and amortization	(13,812		)	(6,202		)	(14,916		)	(1,275		)
Stock compensation expense	—			—			(192		)	(4,006		)
Income (loss) from operations	$	68,927		$	31,930		$	27,931		$	(27,734	)	$	101,054
Equity in earnings of unconsolidated subsidiaries													4,546
Non-operating gain													13,035
Interest expense													(44,332		)
Income before income taxes													$	74,303

16

	Three Months Ended June 30, 2017
	Specialty Hospitals			Outpatient Rehabilitation			Concentra			Other			Total
	(in thousands)
Adjusted EBITDA	$	98,172		$	41,926		$	43,061		$	(24,479	)
Depreciation and amortization	(15,454		)	(5,878		)	(15,429		)	(1,572		)
Stock compensation expense	—			—			(264		)	(4,420		)
Income (loss) from operations	$	82,718		$	36,048		$	27,368		$	(30,471	)	$	115,663
Equity in earnings of unconsolidated subsidiaries													5,666
Interest expense													(37,655		)
Income before income taxes													$	83,674

	Six Months Ended June 30, 2016
	Specialty Hospitals			Outpatient Rehabilitation(1)			Concentra			Other			Total
	(in thousands)
Adjusted EBITDA	$	169,495		$	67,011		$	77,192		$	(43,626	)
Depreciation and amortization	(27,705		)	(10,238		)	(30,292		)	(2,487		)
Stock compensation expense	—			—			(384		)	(7,790		)
Physiotherapy acquisition costs	—			—			—			(3,236		)
Income (loss) from operations	$	141,790		$	56,773		$	46,516		$	(57,139	)	$	187,940
Loss on early retirement of debt													(773		)
Equity in earnings of unconsolidated subsidiaries													9,198
Non-operating gain													38,122
Interest expense													(83,180		)
Income before income taxes													$	151,307

	Six Months Ended June 30, 2017
	Specialty Hospitals			Outpatient Rehabilitation			Concentra			Other			Total
	(in thousands)
Adjusted EBITDA	$	186,837		$	73,277		$	85,653		$	(48,197	)
Depreciation and amortization	(33,954		)	(12,218		)	(31,552		)	(3,148		)
Stock compensation expense	—			—			(570		)	(8,700		)
Income (loss) from operations	$	152,883		$	61,059		$	53,531		$	(60,045	)	$	207,428
Loss on early retirement of debt													(19,719		)
Equity in earnings of unconsolidated subsidiaries													11,187
Non-operating loss													(49		)
Interest expense													(78,508		)
Income before income taxes													$	120,339

(1)The outpatient rehabilitation segment includes the operating results of the Company’s contract therapy businesses through March 31, 2016 and Physiotherapy beginning March 4, 2016.

(2)Reflects the retrospective adoption of ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. Total assets as of June 30, 2016 were retrospectively conformed to reflect the adoption of the standard, resulting in a reduction to total assets of $18.5 million.

17

7.  Income per Common Share

Holdings applies the two-class method for calculating and presenting income per common share. The two-class method is an earnings allocation formula that determines earnings per share for each class of stock participation rights in undistributed earnings.

The following table sets forth the calculation of income per share in Holdings’ condensed consolidated statements of operations and the differences between basic weighted average shares outstanding and diluted weighted average shares outstanding used to compute basic and diluted earnings per share, respectively.

	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2017		2016		2017
	(in thousands, except per share amounts)
Numerator:
Net income attributable to Select Medical Holdings Corporation	$	33,935	$	42,055	$	88,768	$	57,925
Less: Earnings allocated to unvested restricted stockholders	972		1,341		2,552		1,849
Net income available to common stockholders	$	32,963	$	40,714	$	86,216	$	56,076
Denominator:
Weighted average shares—basic	127,626		128,624		127,563		128,544
Effect of dilutive securities:
Stock options	194		153		146		159
Weighted average shares—diluted	127,820		128,777		127,709		128,703
Basic income per common share:	$	0.26	$	0.32	$	0.68	$	0.44
Diluted income per common share:	$	0.26	$	0.32	$	0.68	$	0.44

8.  Commitments and Contingencies

Litigation

The Company is a party to various legal actions, proceedings, and claims (some of which are not insured), and regulatory and other governmental audits and investigations in the ordinary course of its business. The Company cannot predict the ultimate outcome of pending litigation, proceedings, and regulatory and other governmental audits and investigations. These matters could potentially subject the Company to sanctions, damages, recoupments, fines, and other penalties. The Department of Justice, Centers for Medicare & Medicaid Services (“CMS”), or other federal and state enforcement and regulatory agencies may conduct additional investigations related to the Company’s businesses in the future that may, either individually or in the aggregate, have a material adverse effect on the Company’s business, financial position, results of operations, and liquidity.

To address claims arising out of the Company’s operations, the Company maintains professional malpractice liability insurance and general liability insurance, subject to self-insured retention of $2.0 million per medical incident for professional liability claims and $2.0 million per occurrence for general liability claims. The Company also maintains umbrella liability insurance covering claims which, due to their nature or amount, are not covered by or not fully covered by the Company’s other insurance policies. These insurance policies also do not generally cover punitive damages and are subject to various deductibles and policy limits. Significant legal actions, as well as the cost and possible lack of available insurance, could subject the Company to substantial uninsured liabilities. In the Company’s opinion, the outcome of these actions, individually or in the aggregate, will not have a material adverse effect on its financial position, results of operations or cash flows.

Healthcare providers are subject to lawsuits under the qui tam provisions of the federal False Claims Act. Qui tam lawsuits typically remain under seal (hence, usually unknown to the defendant) for some time while the government decides whether or not to intervene on behalf of a private qui tam plaintiff (known as a relator) and take the lead in the litigation. These lawsuits can involve significant monetary damages and penalties and award bounties to private plaintiffs who successfully bring the suits. The Company is and has been a defendant in these cases in the past, and may be named as a defendant in similar cases from time to time in the future.

18

Evansville Litigation

On October 19, 2015, the plaintiff-relators filed a Second Amended Complaint in United States of America, ex rel. Tracy Conroy, Pamela Schenk and Lisa Wilson v. Select Medical Corporation, Select Specialty Hospital—Evansville, LLC (“SSH-Evansville”), Select Employment Services, Inc., and Dr. Richard Sloan. The case is a civil action filed in the United States District Court for the Southern District of Indiana by private plaintiff-relators on behalf of the United States under the federal False Claims Act. The plaintiff-relators are the former CEO and two former case managers at SSH-Evansville, and the defendants currently include the Company, SSH-Evansville, a subsidiary of the Company serving as common paymaster for its employees, and a physician who practices at SSH-Evansville. The plaintiff-relators allege that SSH-Evansville discharged patients too early or held patients too long, improperly discharged patients to and readmitted them from short stay hospitals, up-coded diagnoses at admission, and admitted patients for whom long-term acute care was not medically necessary. They also allege that the defendants engaged in retaliation in violation of federal and state law. The Second Amended Complaint replaced a prior complaint that was filed under seal on September 28, 2012 and served on the Company on February 15, 2013, after a federal magistrate judge unsealed it on January 8, 2013. All deadlines in the case had been stayed after the seal was lifted in order to allow the government time to complete its investigation and to decide whether or not to intervene. On June 19, 2015, the United States Department of Justice notified the District Court of its decision not to intervene in the case.

In December 2015, the defendants filed a Motion to Dismiss the Second Amended Complaint on multiple grounds, including that the action is disallowed by the False Claims Act’s public disclosure bar, which disqualifies qui tam actions that are based on fraud already publicly disclosed through enumerated sources, unless the relator is an original source, and that the plaintiff-relators did not plead their claims with sufficient particularity, as required by the Federal Rules of Civil Procedure.

Thereafter, the United States filed a notice asserting a veto of the defendants’ use of the public disclosure bar for claims arising from conduct from and after March 23, 2010, which was based on certain statutory changes to the public disclosure bar language included in the Affordable Care Act. On September 30, 2016, the District Court partially granted and partially denied the defendants’ Motion to Dismiss. It ruled that the plaintiff-relators alleged substantially the same conduct as had been publicly disclosed and that the plaintiff relators are not original sources, so that the public disclosure bar requires dismissal of all non-retaliation claims arising from conduct before March 23, 2010. The District Court also ruled that the statutory changes to the public disclosure bar gave the United States the power to veto its applicability to claims arising from conduct on and after March 23, 2010, and therefore did not dismiss those claims based on the public disclosure bar. However, the District Court ruled that the plaintiff-relators did not plead certain of their claims relating to interrupted stay manipulation and premature discharging of patients with the requisite particularity, and dismissed those claims. The District Court declined to dismiss the plaintiff relators’ claims arising from conduct from and after March 23, 2010 relating to delayed discharging of patients and up-coding and the plaintiff relators’ retaliation claims. The plaintiff-relators then proposed a case management plan seeking nationwide discovery involving all of the Company’s LTCHs for the period from March 23, 2010 through the present, which the defendants have opposed. The Company intends to vigorously defend this action, but at this time the Company is unable to predict the timing and outcome of this matter.

Knoxville Litigation

On July 13, 2015, the United States District Court for the Eastern District of Tennessee unsealed a qui tam Complaint in Armes v. Garman, et al, No. 3:14-cv-00172-TAV-CCS, which named as defendants Select, Select Specialty Hospital—Knoxville, Inc. (“SSH-Knoxville”), Select Specialty Hospital—North Knoxville, Inc. and ten current or former employees of these facilities. The Complaint was unsealed after the United States and the State of Tennessee notified the court on July 13, 2015 that each had decided not to intervene in the case. The Complaint is a civil action that was filed under seal on April 29, 2014 by a respiratory therapist formerly employed at SSH-Knoxville. The Complaint alleges violations of the federal False Claims Act and the Tennessee Medicaid False Claims Act based on extending patient stays to increase reimbursement and to increase average length of stay; artificially prolonging the lives of patients to increase Medicare reimbursements and decrease inspections; admitting patients who do not require medically necessary care; performing unnecessary procedures and services; and delaying performance of procedures to increase billing. The Complaint was served on some of the defendants during October 2015.

In November 2015, the defendants filed a Motion to Dismiss the Complaint on multiple grounds. The defendants first argued that False Claims Act’s first-to-file bar required dismissal of plaintiff-relator’s claims. Under the first-to-file bar, if a qui tam case is pending, no person may bring a related action based on the facts underlying the first action. The defendants asserted that the plaintiff-relator’s claims were based on the same underlying facts as were asserted in the Evansville litigation, discussed above. The defendants also argued that the plaintiff-relator’s claims must be dismissed under the public disclosure bar, and because the plaintiff-relator did not plead his claims with sufficient particularity.

19

In June 2016, the District Court granted the defendants’ Motion to Dismiss and dismissed with prejudice the plaintiff-relator’s lawsuit in its entirety. The District Court ruled that the first-to-file bar precludes all but one of the plaintiff-relator’s claims, and that the remaining claim must also be dismissed because the plaintiff-relator failed to plead it with sufficient particularity. In July 2016, the plaintiff-relator filed a Notice of Appeal to the United States Court of Appeals for the Sixth Circuit. Then, on October 11, 2016, the plaintiff-relator filed a Motion to Remand the case to the District Court for further proceedings, arguing that the September 30, 2016 decision in the Evansville litigation, discussed above, undermines the basis for the District Court’s dismissal. After the Court of Appeals denied the Motion to Remand, the plaintiff-relator then sought an indicative ruling from the District Court that it would vacate its prior dismissal ruling and allow plaintiff-relator to supplement his Complaint, which the defendants have opposed. The case has been fully briefed in the Court of Appeals. The Company intends to vigorously defend this action, but at this time the Company is unable to predict the timing and outcome of this matter.

Wilmington Litigation

On January 19, 2017, the United States District Court for the District of Delaware unsealed a qui tam Complaint in United States of America and State of Delaware ex rel. Theresa Kelly v. Select Specialty Hospital—Wilmington, Inc. (“SSH-Wilmington”), Select Specialty Hospitals, Inc., Select Employment Services, Inc., Select Medical Corporation, and Crystal Cheek, No. 16-347-LPS. The Complaint was initially filed under seal on May 12, 2016 by a former chief nursing officer at SSH-Wilmington and was unsealed after the United States filed a Notice of Election to Decline Intervention on January 13, 2017. The corporate defendants were served on March 6, 2017. In the complaint, the plaintiff-relator alleges that the Select defendants and an individual defendant, who is a former health information manager at SSH-Wilmington, violated the False Claims Act and the Delaware False Claims and Reporting Act based on allegedly falsifying medical practitioner signatures on medical records and failing to properly examine the credentials of medical practitioners at SSH-Wilmington. In response to the Select defendants’ motion to dismiss the Complaint, on May 17, 2017 the plaintiff-relator filed an Amended Complaint asserting the same causes of action. The Select defendants filed a Motion to Dismiss the Amended Complaint, which is now pending, based on numerous grounds, including that the Amended Complaint did not plead any alleged fraud with sufficient particularity, failed to plead that the alleged fraud was material to the government’s payment decision, failed to plead sufficient facts to establish that the Select defendants knowingly submitted false claims or records, and failed to allege any reverse false claim.

On March 24, 2017, the plaintiff-relator initiated a second action by filing a Complaint in the Superior Court of the State of Delaware in Theresa Kelly v. Select Medical Corporation, Select Employment Services, Inc., and SSH-Wilmington, C.A. No. N17C-03-293 CLS. The Delaware Complaint alleges that the defendants retaliated against her in violation of the Delaware Whistleblowers’ Protection Act for reporting the same alleged violations that are the subject of the federal Amended Complaint. The defendants filed a motion to dismiss, or alternatively to stay, the Delaware Complaint based on the pending federal Amended Complaint and the failure to allege facts to support a violation of the Delaware Whistleblowers’ Protection Act.  The motion is currently pending.

The Company intends to vigorously defend these actions, but at this time the Company is unable to predict the timing and outcome of this matter.

Contract Therapy Subpoena

On May 18, 2017, the Company received a subpoena from the U.S. Attorney’s Office for the District of New Jersey seeking various documents principally relating to the Company’s contract therapy division, which contracted to furnish rehabilitation therapy services to residents of skilled nursing facilities (“SNFs”) and other providers. The Company operated its contract therapy division through a subsidiary until March 31, 2016, when the Company sold the stock of the subsidiary. The subpoena seeks documents that appear to be aimed at assessing whether therapy services were furnished and billed in compliance with Medicare SNF billing requirements, including whether therapy services were coded at inappropriate levels and whether excessive or unnecessary therapy was furnished to justify coding at higher paying levels. The Company does not know whether the subpoena has been issued in connection with a qui tam lawsuit or in connection with possible civil, criminal or administrative proceedings by the government. The Company is producing documents in response to the subpoena and intends to fully cooperate with this investigation. At this time, the Company is unable to predict the timing and outcome of this matter.

20

9.  Condensed Consolidating Financial Information

Select’s 6.375% senior notes are fully and unconditionally and jointly and severally guaranteed, except for customary limitations, on a senior basis by all of Select’s wholly owned subsidiaries (the “Subsidiary Guarantors”). The Subsidiary Guarantors are defined as subsidiaries where Select, or a subsidiary of Select, holds all of the outstanding ownership interests. Certain of Select’s subsidiaries did not guarantee the 6.375% senior notes (the “Non-Guarantor Subsidiaries” and Concentra Group Holdings and its subsidiaries, the “Non-Guarantor Concentra”).

Select conducts a significant portion of its business through its subsidiaries. Presented below is condensed consolidating financial information for Select, the Subsidiary Guarantors, the Non-Guarantor Subsidiaries, and Non-Guarantor Concentra at December 31, 2016 and June 30, 2017 and for the three and six months ended June 30, 2016 and 2017.

The equity method has been used by Select with respect to investments in subsidiaries. The equity method has been used by Subsidiary Guarantors with respect to investments in Non-Guarantor Subsidiaries. Separate financial statements for Subsidiary Guarantors are not presented.

Certain reclassifications have been made to prior reported amounts in order to conform to the current year guarantor structure.

21

Select Medical Corporation

Condensed Consolidating Balance Sheet

June 30, 2017

(unaudited)

	Select (Parent Company Only)			Subsidiary Guarantors		Non-Guarantor Subsidiaries			Non-Guarantor Concentra		Eliminations			Consolidated Select Medical Corporation
	(in thousands)
Assets
Current Assets:
Cash and cash equivalents	$	72		$	5,533	$	4,946		$	63,248	$	—		$	73,799
Accounts receivable, net	—			467,412		120,272			126,552		—			714,236
Intercompany receivables	—			1,489,631		58,333			—		(1,547,964		) (a)	—
Other current assets	17,584			28,326		12,786			24,515		—			83,211
Total Current Assets	17,656			1,990,902		196,337			214,315		(1,547,964		)	871,246
Property and equipment, net	56,568			620,364		54,964			179,636		—			911,532
Investment in affiliates	4,523,727			118,248		—			—		(4,641,975		) (b) (c)	—
Goodwill	—			2,091,754		—			674,542		—			2,766,296
Identifiable intangible assets, net	—			109,913		—			225,791		—			335,704
Other assets	42,452			98,649		36,528			16,199		(24,395		) (d)	169,433
Total Assets	$	4,640,403		$	5,029,830	$	287,829		$	1,310,483	$	(6,214,334	)	$	5,054,211
Liabilities and Equity
Current Liabilities:
Bank overdrafts	$	34,134		$	—	$	—		$	—	$	—		$	34,134
Current portion of long-term debt and notes payable	23,052			644		244			2,637		—			26,577
Accounts payable	10,362			75,105		22,387			15,777		—			123,631
Intercompany payables	1,489,631			58,333		—			—		(1,547,964		) (a)	—
Accrued payroll	7,526			80,245		3,545			27,871		—			119,187
Accrued vacation	3,927			58,895		12,214			17,214		—			92,250
Accrued interest	17,096			5		4			2,172		—			19,277
Accrued other	44,032			60,078		10,533			32,210		—			146,853
Income taxes payable	2,709			—		—			4,267		—			6,976
Total Current Liabilities	1,632,469			333,305		48,927			102,148		(1,547,964		)	568,885
Long-term debt, net of current portion	2,115,318			266		9,663			608,885		—			2,734,132
Non-current deferred tax liability	—			136,920		736			84,150		(24,395		) (d)	197,411
Other non-current liabilities	44,297			54,100		7,688			35,194		—			141,279
Total Liabilities	3,792,084			524,591		67,014			830,377		(1,572,359		)	3,641,707
Redeemable non-controlling interests	—			—		10,079			458,771		—			468,850
Stockholder’s Equity:
Common stock	0			—		—			—		—			0
Capital in excess of par	936,428			—		—			—		—			936,428
Retained earnings (accumulated deficit)	(88,109		)	1,314,773		(37,110		)	12,447		(1,290,110		) (c)	(88,109		)
Subsidiary investment	—			3,190,466		156,262			5,137		(3,351,865		) (b)	—
Total Select Medical Corporation Stockholder’s Equity	848,319			4,505,239		119,152			17,584		(4,641,975		)	848,319
Non-controlling interests	—			—		91,584			3,751		—			95,335
Total Equity	848,319			4,505,239		210,736			21,335		(4,641,975		)	943,654
Total Liabilities and Equity	$	4,640,403		$	5,029,830	$	287,829		$	1,310,483	$	(6,214,334	)	$	5,054,211

(a)  Elimination of intercompany balances.

(b)  Elimination of investments in consolidated subsidiaries.

(c)  Elimination of investments in consolidated subsidiaries’ earnings.

(d)  Reclass of non-current deferred tax asset to report net non-current deferred tax liability in consolidation.

22

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Three Months Ended June 30, 2017

(unaudited)

	Select (Parent Company Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Eliminations			Consolidated Select Medical Corporation
	(in thousands)
Net operating revenues	$	23		$	687,886		$	171,180		$	261,586		$	—		$	1,120,675
Costs and expenses:
Cost of services	644			561,304			144,211			214,071			—			920,230
General and administrative	28,227			48			—			—			—			28,275
Bad debt expense	—			9,829			3,627			4,718			—			18,174
Depreciation and amortization	1,573			18,149			3,182			15,429			—			38,333
Total costs and expenses	30,444			589,330			151,020			234,218			—			1,005,012
Income (loss) from operations	(30,421		)	98,556			20,160			27,368			—			115,663
Other income and expense:
Intercompany interest and royalty fees	(2,263		)	3,596			(1,333		)	—			—			—
Intercompany management fees	63,504			(53,435		)	(10,069		)	—			—			—
Equity in earnings of unconsolidated subsidiaries	—			5,646			20			—			—			5,666
Interest expense	(19,623		)	(8,234		)	(2,360		)	(7,438		)	—			(37,655		)
Income before income taxes	11,197			46,129			6,418			19,930			—			83,674
Income tax expense (benefit)	(2,324		)	27,307			309			7,082			—			32,374
Equity in earnings of consolidated subsidiaries	28,534			4,200			—			—			(32,734		) (a)	—
Net income	42,055			23,022			6,109			12,848			(32,734		)	51,300
Less: Net income attributable to non-controlling interests	—			—			2,175			7,070			—			9,245
Net income attributable to Select Medical Corporation	$	42,055		$	23,022		$	3,934		$	5,778		$	(32,734	)	$	42,055

(a) Elimination of equity in earnings of subsidiaries.

23

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Six Months Ended June 30, 2017

(unaudited)

	Select (Parent Company Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Eliminations			Consolidated Select Medical Corporation
	(in thousands)
Net operating revenues	$	631		$	1,377,279		$	336,391		$	517,735		$	—		$	2,232,036
Costs and expenses:
Cost of services	1,176			1,142,527			282,521			422,363			—			1,848,587
General and administrative	56,263			87			—			—			—			56,350
Bad debt expense	—			21,577			6,933			10,289			—			38,799
Depreciation and amortization	3,148			39,489			6,683			31,552			—			80,872
Total costs and expenses	60,587			1,203,680			296,137			464,204			—			2,024,608
Income (loss) from operations	(59,956		)	173,599			40,254			53,531			—			207,428
Other income and expense:
Intercompany interest and royalty fees	(4,159		)	6,914			(2,755		)	—			—			—
Intercompany management fees	125,202			(106,069		)	(19,133		)	—			—			—
Loss on early retirement of debt	(19,719		)	—			—			—			—			(19,719		)
Equity in earnings of unconsolidated subsidiaries	—			11,139			48			—			—			11,187
Non-operating loss	—			(49		)	—			—			—			(49		)
Interest expense	(42,431		)	(16,307		)	(4,833		)	(14,937		)	—			(78,508		)
Income (loss) before income taxes	(1,063		)	69,227			13,581			38,594			—			120,339
Income tax expense (benefit)	(2,198		)	33,243			613			13,918			—			45,576
Equity in earnings of consolidated subsidiaries	56,790			9,775			—			—			(66,565		) (a)	—
Net income	57,925			45,759			12,968			24,676			(66,565		)	74,763
Less: Net income attributable to non-controlling interests	—			—			3,244			13,594			—			16,838
Net income attributable to Select Medical Corporation	$	57,925		$	45,759		$	9,724		$	11,082		$	(66,565	)	$	57,925

(a) Elimination of equity in earnings of subsidiaries.

24

Select Medical Corporation

Condensed Consolidating Statement of Cash Flows

For the Six Months Ended June 30, 2017

(unaudited)

	Select (Parent Company Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Eliminations			Consolidated Select Medical Corporation
	(in thousands)
Operating activities
Net income	$	57,925		$	45,759		$	12,968		$	24,676		$	(66,565	) (a)	$	74,763
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries	—			10,902			31			—			—			10,933
Depreciation and amortization	3,148			39,489			6,683			31,552			—			80,872
Provision for bad debts	—			21,577			6,933			10,289			—			38,799
Equity in earnings of unconsolidated subsidiaries	—			(11,139		)	(48		)	—			—			(11,187		)
Equity in earnings of consolidated subsidiaries	(56,790		)	(9,775		)	—			—			66,565		(a)	—
Loss on extinguishment of debt	6,527			—			—			—			—			6,527
Gain on sale of assets and businesses	(8		)	(4,828		)	(4,687		)	—			—			(9,523		)
Stock compensation expense	8,700			—			—			570			—			9,270
Amortization of debt discount, premium and issuance costs	4,342			—			—			1,632			—			5,974
Deferred income taxes	5,987			—			—			(7,461		)	—			(1,474		)
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	—			(125,418		)	(29,435		)	(24,150		)	—			(179,003		)
Other current assets	(5,631		)	5,452			(2,517		)	(2,861		)	—			(5,557		)
Other assets	3,184			(16,925		)	17,426			936			—			4,621
Accounts payable	(413		)	(1,550		)	(10		)	2,732			—			759
Accrued expenses	(5,618		)	(4,817		)	8,704			(3,102		)	—			(4,833		)
Income taxes	9,366			—			—			10,033			—			19,399
Net cash provided by (used in) operating activities	30,719			(51,273		)	16,048			44,846			—			40,340
Investing activities
Acquisition of businesses, net of cash acquired	—			(2,305		)	—			(16,203		)	—			(18,508		)
Purchases of property and equipment	(7,093		)	(71,813		)	(10,109		)	(16,287		)	—			(105,302		)
Investment in businesses	—			(9,874		)	—			—			—			(9,874		)
Proceeds from sale of assets and businesses	8			15,007			19,537			—			—			34,552
Net cash provided by (used in) investing activities	(7,085		)	(68,985		)	9,428			(32,490		)	—			(99,132		)
Financing activities
Borrowings on revolving facilities	630,000			—			—			—			—			630,000
Payments on revolving facilities	(550,000		)	—			—			—			—			(550,000		)
Proceeds from term loans	1,139,487			—			—			—			—			1,139,487
Payments on term loans	(1,150,627		)	—			—			(23,065		)	—			(1,173,692		)
Revolving facility debt issuance costs	(4,392		)	—			—			—			—			(4,392		)
Borrowings of other debt	6,572			—			105			2,767			—			9,444
Principal payments on other debt	(7,353		)	(204		)	(1,183		)	(1,697		)	—			(10,437		)
Repayments of bank overdrafts	(5,228		)	—			—			—			—			(5,228		)
Dividends paid to Holdings	(600		)	—			—			—			—			(600		)
Equity investment by Holdings	963			—			—			—			—			963
Intercompany	(93,455		)	119,528			(26,073		)	—			—			—
Proceeds from issuance of non-controlling interests	—			—			3,553			—			—			3,553
Purchase of non-controlling interests	—			—			(120		)	—			—			(120		)
Distributions to non-controlling interests	—			—			(1,868		)	(3,548		)	—			(5,416		)
Net cash provided by (used in) financing activities	(34,633		)	119,324			(25,586		)	(25,543		)	—			33,562
Net decrease in cash and cash equivalents	(10,999		)	(934		)	(110		)	(13,187		)	—			(25,230		)
Cash and cash equivalents at beginning of period	11,071			6,467			5,056			76,435			—			99,029
Cash and cash equivalents at end of period	$	72		$	5,533		$	4,946		$	63,248		$	—		$	73,799

(a)  Elimination of equity in earnings of consolidated subsidiaries.

25

Select Medical Corporation

Condensed Consolidating Balance Sheet

December 31, 2016

(unaudited)

	Select (Parent Company Only)			Subsidiary Guarantors		Non-Guarantor Subsidiaries			Non-Guarantor Concentra		Eliminations			Consolidated Select Medical Corporation
	(in thousands)
Assets
Current Assets:
Cash and cash equivalents	$	11,071		$	6,467	$	5,056		$	76,435	$	—		$	99,029
Accounts receivable, net	—			363,470		97,770			112,512		—			573,752
Intercompany receivables	—			1,573,960		28,271			—		(1,602,231		) (a)	—
Prepaid income taxes	6,658			—		—			5,765		—			12,423
Other current assets	11,953			33,958		10,269			21,519		—			77,699
Total Current Assets	29,682			1,977,855		141,366			216,231		(1,602,231		)	762,903
Property and equipment, net	48,697			603,408		50,869			189,243		—			892,217
Investment in affiliates	4,493,684			89,288		—			—		(4,582,972		) (b) (c)	—
Goodwill	—			2,090,963		—			660,037		—			2,751,000
Identifiable intangible assets, net	—			109,132		—			231,430		—			340,562
Other assets	45,636			84,803		53,954			16,235		(26,684		) (d)	173,944
Total Assets	$	4,617,699		$	4,955,449	$	246,189		$	1,313,176	$	(6,211,887	)	$	4,920,626
Liabilities and Equity
Current Liabilities:
Bank overdrafts	$	39,362		$	—	$	—		$	—	$	—		$	39,362
Current portion of long-term debt and notes payable	7,227			445		1,324			4,660		—			13,656
Accounts payable	10,775			78,608		22,397			14,778		—			126,558
Intercompany payables	1,573,960			28,271		—			—		(1,602,231		) (a)	—
Accrued payroll	16,963			92,216		4,246			32,972		—			146,397
Accrued vacation	3,440			55,486		10,668			13,667		—			83,261
Accrued interest	20,114			—		—			2,211		—			22,325
Accrued other	39,155			62,384		4,639			33,898		—			140,076
Total Current Liabilities	1,710,996			317,410		43,274			102,186		(1,602,231		)	571,635
Long-term debt, net of current portion	2,048,154			601		9,685			626,893		—			2,685,333
Non-current deferred tax liability	—			133,852		596			91,314		(26,684		) (d)	199,078
Other non-current liabilities	42,824			53,537		5,727			34,432		—			136,520
Total Liabilities	3,801,974			505,400		59,282			854,825		(1,628,915		)	3,592,566
Redeemable non-controlling interests	—			113		10,056			411,990		—			422,159
Stockholder’s Equity:
Common stock	0			—		—			—		—			0
Capital in excess of par	925,111			—		—			—		—			925,111
Retained earnings (accumulated deficit)	(109,386		)	1,269,014		(38,313		)	1,364		(1,232,065		) (c)	(109,386		)
Subsidiary investment	—			3,180,922		128,556			41,429		(3,350,907		) (b)	—
Total Select Medical Corporation Stockholder’s Equity	815,725			4,449,936		90,243			42,793		(4,582,972		)	815,725
Non-controlling interests	—			—		86,608			3,568		—			90,176
Total Equity	815,725			4,449,936		176,851			46,361		(4,582,972		)	905,901
Total Liabilities and Equity	$	4,617,699		$	4,955,449	$	246,189		$	1,313,176	$	(6,211,887	)	$	4,920,626

(a)  Elimination of intercompany balances.

(b)  Elimination of investments in consolidated subsidiaries.

(c)  Elimination of investments in consolidated subsidiaries’ earnings.

(d)  Reclass of non-current deferred tax asset to report net non-current deferred tax liability in consolidation.

26

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Three Months Ended June 30, 2016

(unaudited)

	Select (Parent Company Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Eliminations			Consolidated Select Medical Corporation
	(in thousands)
Net operating revenues	$	20		$	723,859		$	118,884		$	254,868		$	—		$	1,097,631
Costs and expenses:
Cost of services	606			605,730			103,767			206,882			—			916,985
General and administrative	25,844			26			—			—			—			25,870
Bad debt expense	—			10,285			2,093			5,139			—			17,517
Depreciation and amortization	1,276			17,316			2,697			14,916			—			36,205
Total costs and expenses	27,726			633,357			108,557			226,937			—			996,577
Income (loss) from operations	(27,706		)	90,502			10,327			27,931			—			101,054
Other income and expense:
Intercompany interest and royalty fees	(1,532		)	3,274			(1,742		)	—			—			—
Intercompany management fees	38,783			(32,430		)	(6,353		)	—			—			—
Equity in earnings of unconsolidated subsidiaries	—			4,519			27			—			—			4,546
Non-operating gain	10,463			2,572			—			—			—			13,035
Interest expense	(25,544		)	(6,684		)	(1,852		)	(10,252		)	—			(44,332		)
Income (loss) before income taxes	(5,536		)	61,753			407			17,679			—			74,303
Income tax expense (benefit)	(473		)	26,370			672			6,881			—			33,450
Equity in earnings of consolidated subsidiaries	38,998			(1,133		)	—			—			(37,865		) (a)	—
Netincome(loss)	33,935			34,250			(265		)	10,798			(37,865		)	40,853
Less: Net income attributable to non-controlling interests	—			18			824			6,076			—			6,918
Net income (loss) attributable to Select Medical Corporation	$	33,935		$	34,232		$	(1,089	)	$	4,722		$	(37,865	)	$	33,935

(a) Elimination of equity in earnings of subsidiaries.

27

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Six Months Ended June 30, 2016

(unaudited)

	Select (Parent Company Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Eliminations			Consolidated Select Medical Corporation
	(in thousands)
Net operating revenues	$	437		$	1,439,439		$	240,340		$	505,745		$	—		$	2,185,961
Costs and expenses:
Cost of services	950			1,211,439			206,774			420,084			—			1,839,247
General and administrative	54,231			(93		)	—			—			—			54,138
Bad debt expense	—			21,003			4,058			8,853			—			33,914
Depreciation and amortization	2,487			32,648			5,295			30,292			—			70,722
Total costs and expenses	57,668			1,264,997			216,127			459,229			—			1,998,021
Income (loss) from operations	(57,231		)	174,442			24,213			46,516			—			187,940
Other income and expense:
Intercompany interest and royalty fees	(2,590		)	6,044			(3,454		)	—			—			—
Intercompany management fees	94,139			(82,127		)	(12,012		)	—			—			—
Loss on early retirement of debt	(773		)	—			—			—			—			(773		)
Equity in earnings of unconsolidated subsidiaries	—			9,146			52			—			—			9,198
Non-operating gain (loss)	40,895			(2,773		)	—			—			—			38,122
Interest expense	(45,890		)	(13,318		)	(3,491		)	(20,481		)	—			(83,180		)
Income before income taxes	28,550			91,414			5,308			26,035			—			151,307
Income tax expense	8,139			31,985			607			9,779			—			50,510
Equity in earnings of consolidated subsidiaries	68,357			1,873			—			—			(70,230		) (a)	—
Net income	88,768			61,302			4,701			16,256			(70,230		)	100,797
Less: Net income attributable to non-controlling interests	—			33			2,695			9,301			—			12,029
Net income attributable to Select Medical Corporation	$	88,768		$	61,269		$	2,006		$	6,955		$	(70,230	)	$	88,768

(a) Elimination of equity in earnings of subsidiaries.

28

Select Medical Corporation

Condensed Consolidating Statement of Cash Flows

For the Six Months Ended June 30, 2016

(unaudited)

	Select (Parent Company Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Eliminations			Consolidated Select Medical Corporation
	(in thousands)
Operating activities
Net income	$	88,768		$	61,302		$	4,701		$	16,256		$	(70,230	) (a)	$	100,797
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries	—			12,000			39			—			—			12,039
Depreciation and amortization	2,487			32,648			5,295			30,292			—			70,722
Provision for bad debts	—			21,003			4,058			8,853			—			33,914
Equity in earnings of unconsolidated subsidiaries	—			(9,146		)	(52		)	—			—			(9,198		)
Equity in earnings of consolidated subsidiaries	(68,357		)	(1,873		)	—			—			70,230		(a)	—
Loss on extinguishment of debt	773			—			—			—			—			773
Gain on sale of assets and businesses	(40,895		)	(2,566		)	—			—			—			(43,461		)
Loss on disposal of assets	—			37			12			6			—			55
Impairment of equity investment	—			5,339			—			—			—			5,339
Stock compensation expense	7,790			—			—			384			—			8,174
Amortization of debt discount, premium and issuance costs	5,371			—			2			1,704			—			7,077
Deferred income taxes	997			—			—			(14,283		)	—			(13,286		)
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	—			(22,896		)	(9,711		)	(11,489		)	—			(44,096		)
Other current assets	(2,938		)	7,342			(1,273		)	7,880			—			11,011
Other assets	(4,268		)	(341		)	(424		)	9,541			—			4,508
Accounts payable	(2,241		)	(17,695		)	(3,371		)	7,455			—			(15,852		)
Accrued expenses	(10,175		)	36,088			(2,441		)	(2,840		)	—			20,632
Income taxes	9,101			—			—			19,989			—			29,090
Net cash provided by (used in) operating activities	(13,587		)	121,242			(3,165		)	73,748			—			178,238
Investing activities
Acquisition of businesses, net of cash acquired	(408,654		)	(605		)	(8,395		)	(3,865		)	—			(421,519		)
Purchases of property and equipment	(8,545		)	(52,591		)	(11,195		)	(7,927		)	—			(80,258		)
Investment in businesses	—			(1,590		)	—			—			—			(1,590		)
Proceeds from sale of assets and businesses	63,418			7,942			6			—			—			71,366
Net cash used in investing activities	(353,781		)	(46,844		)	(19,584		)	(11,792		)	—			(432,001		)
Financing activities
Borrowings on revolving facilities	320,000			—			—			—			—			320,000
Payments on revolving facilities	(375,000		)	—			—			(5,000		)	—			(380,000		)
Proceeds from term loans	600,127			—			—			—			—			600,127
Payments on term loans	(227,399		)	—			—			(2,250		)	—			(229,649		)
Borrowings of other debt	9,765			—			9,500			2,817			—			22,082
Principal payments on other debt	(7,278		)	(385		)	(876		)	(1,387		)	—			(9,926		)
Repayments of bank overdrafts	(2,138		)	—			—			—			—			(2,138		)
Dividends paid to Holdings	(506		)	—			—			—			—			(506		)
Equity investment by Holdings	657			—			—			—			—			657
Intercompany	49,141			(68,206		)	19,065			—			—			—
Proceeds from issuance of non-controlling interests	—			—			3,103			—			—			3,103
Purchase of non-controlling interests	—			(1,294		)	—			—			—			(1,294		)
Distributions to non-controlling interests	—			(108		)	(3,294		)	(1,306		)	—			(4,708		)
Net cash provided by (used in) financing activities	367,369			(69,993		)	27,498			(7,126		)	—			317,748
Net increase in cash and cash equivalents	1			4,405			4,749			54,830			—			63,985
Cash and cash equivalents at beginning of period	4,070			3,706			625			6,034			—			14,435
Cash and cash equivalents at end of period	$	4,071		$	8,111		$	5,374		$	60,864		$	—		$	78,420

(a)  Elimination of equity in earnings of consolidated subsidiaries.

29

ITEM 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read this discussion together with our unaudited condensed consolidated financial statements and accompanying notes.

Forward-Looking Statements

This report on Form 10-Q contains forward-looking statements within the meaning of the federal securities laws. Statements that are not historical facts, including statements about our beliefs and expectations, are forward-looking statements. Forward-looking statements include statements preceded by, followed by or that include the words “may,” “could,” “would,” “should,” “believe,” “expect,” “anticipate,” “plan,” “target,” “estimate,” “project,” “intend,” and similar expressions. These statements include, among others, statements regarding our expected business outlook, anticipated financial and operating results, our business strategy and means to implement our strategy, our objectives, the amount and timing of capital expenditures, the likelihood of our success in expanding our business, financing plans, budgets, working capital needs, and sources of liquidity.

Forward-looking statements are only predictions and are not guarantees of performance. These statements are based on our management’s beliefs and assumptions, which in turn are based on currently available information. Important assumptions relating to the forward-looking statements include, among others, assumptions regarding our services, the expansion of our services, competitive conditions, and general economic conditions. These assumptions could prove inaccurate. Forward-looking statements also involve known and unknown risks and uncertainties, which could cause actual results to differ materially from those contained in any forward-looking statement. Many of these factors are beyond our ability to control or predict. Such factors include, but are not limited to, the following:

·changes in government reimbursement for our services due to the implementation of healthcare reform legislation, deficit reduction measures, and/or new payment policies (including, for example, the expiration of the moratorium limiting the full application of the 25 Percent Rule that would reduce our Medicare payments for those patients admitted to a long term acute care hospital from a referring hospital in excess of an applicable percentage admissions threshold) may result in a reduction in net operating revenues, an increase in costs, and a reduction in profitability;

·the impact of the Bipartisan Budget Act of 2013 (the “BBA of 2013”), which established payment limits for Medicare patients who do not meet specified criteria, may result in a reduction in net operating revenues and profitability of our long term acute care hospitals (“LTCHs”);

·the failure of our specialty hospitals to maintain their Medicare certifications may cause our net operating revenues and profitability to decline;

·the failure of our facilities operated as “hospitals within hospitals” to qualify as hospitals separate from their host hospitals may cause our net operating revenues and profitability to decline;

·a government investigation or assertion that we have violated applicable regulations may result in sanctions or reputational harm and increased costs;

·acquisitions or joint ventures may prove difficult or unsuccessful, use significant resources, or expose us to unforeseen liabilities;

·private third-party payors for our services may adopt payment policies that could limit our future net operating revenues and profitability;

·the failure to maintain established relationships with the physicians in the areas we serve could reduce our net operating revenues and profitability;

·shortages in qualified nurses, therapists, physicians, or other licensed providers could increase our operating costs significantly or limit our ability to staff our facilities;

·competition may limit our ability to grow and result in a decrease in our net operating revenues and profitability;

30

·the loss of key members of our management team could significantly disrupt our operations;

·the effect of claims asserted against us could subject us to substantial uninsured liabilities; and

·other factors discussed from time to time in our filings with the SEC, including factors discussed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2016, as such risk factors may be updated from time to time in our periodic filings with the SEC.

Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements, whether as a result of any new information, future events, or otherwise. You should not place undue reliance on our forward-looking statements. Although we believe that the expectations reflected in forward-looking statements are reasonable, we cannot guarantee future results or performance.

Investors should also be aware that while we do, from time to time, communicate with securities analysts, it is against our policy to disclose to securities analysts any material non-public information or other confidential commercial information. Accordingly, stockholders should not assume that we agree with any statement or report issued by any securities analyst irrespective of the content of the statement or report. Thus, to the extent that reports issued by securities analysts contain any projections, forecasts or opinions, such reports are not the responsibility of the Company.

Overview

We began operations in 1997 and, based on number of facilities, are one of the largest operators of specialty hospitals, outpatient rehabilitation clinics, and occupational medicine centers in the United States. As of June 30, 2017, we had operations in 46 states and the District of Columbia. As of June 30, 2017, we operated 123 specialty hospitals in 28 states and 1,608 outpatient rehabilitation clinics in 37 states and the District of Columbia. Concentra, which is operated through a joint venture subsidiary, operated 315 medical centers in 38 states as of June 30, 2017. Concentra also provides contract services at employer worksites and Department of Veterans Affairs community-based outpatient clinics, or “CBOCs.”

We manage our Company through three business segments: specialty hospitals, outpatient rehabilitation, and Concentra. We had net operating revenues of $2,232.0 million for the six months ended June 30, 2017. Of this total, we earned approximately 54% of our net operating revenues from our specialty hospitals segment, approximately 23% from our outpatient rehabilitation segment, and approximately 23% from our Concentra segment. Patients are typically admitted to our specialty hospitals from general acute care hospitals. These patients have specialized needs, with serious and often complex medical conditions. Our outpatient rehabilitation segment consists of clinics that provide physical, occupational, and speech rehabilitation services. Our Concentra segment consists of medical centers and contract services provided at employer worksites and Department of Veterans Affairs CBOCs that deliver occupational medicine, physical therapy, veteran’s healthcare, and consumer health services.

Non-GAAP Measure

We believe that the presentation of Adjusted EBITDA is important to investors because Adjusted EBITDA is commonly used as an analytical indicator of performance by investors within the healthcare industry. Adjusted EBITDA is used by management to evaluate financial performance and determine resource allocation for each of our operating segments. Adjusted EBITDA is not a measure of financial performance under generally accepted accounting principles (“GAAP”). Items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Adjusted EBITDA should not be considered in isolation, or as an alternative to or substitute for net income, income from operations, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted EBITDA as presented may not be comparable to other similarly titled measures of other companies.

We define Adjusted EBITDA as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, Physiotherapy acquisition costs, non-operating gain (loss), and equity in earnings (losses) of unconsolidated subsidiaries. We will refer to Adjusted EBITDA throughout the remainder of Management’s Discussion and Analysis of Financial Condition and Results of Operations.

31

The table below reconciles net income and income from operations to Adjusted EBITDA and should be referenced when we discuss Adjusted EBITDA.

	Three Months Ended June 30,						Six Months Ended June 30,
	2016			2017			2016			2017
	(in thousands)
Net income	$	40,853		$	51,300		$	100,797		$	74,763
Income tax expense	33,450			32,374			50,510			45,576
Interest expense	44,332			37,655			83,180			78,508
Non-operating loss (gain)	(13,035		)	—			(38,122		)	49
Equity in earnings of unconsolidated subsidiaries	(4,546		)	(5,666		)	(9,198		)	(11,187		)
Loss on early retirement of debt	—			—			773			19,719
Income from operations	$	101,054		$	115,663		$	187,940		$	207,428
Stock compensation expense:
Included in general and administrative	3,399			3,775			6,839			7,524
Included in cost of services	799			909			1,335			1,746
Depreciation and amortization	36,205			38,333			70,722			80,872
Physiotherapy acquisition costs	—			—			3,236			—
Adjusted EBITDA	$	141,457		$	158,680		$	270,072		$	297,570

Summary Financial Results

Three Months Ended June 30, 2017

For the three months ended June 30, 2017, our net operating revenues increased 2.1% to $1,120.7 million, compared to $1,097.6 million for the three months ended June 30, 2016. Income from operations increased 14.5% to $115.7 million for the three months ended June 30, 2017, compared to $101.1 million for the three months ended June 30, 2016. Net income increased 25.6% to $51.3 million for the three months ended June 30, 2017, compared to $40.9 million for the three months ended June 30, 2016. Net income for the three months ended June 30, 2016 included a pre-tax non-operating gain of $13.0 million. Our Adjusted EBITDA increased 12.2% to $158.7 million for the three months ended June 30, 2017, compared to $141.5 million for the three months ended June 30, 2016. Our Adjusted EBITDA margin was 14.2% for the three months ended June 30, 2017, compared to 12.9% for the three months ended June 30, 2016.

Six Months Ended June 30, 2017

For the six months ended June 30, 2017, our net operating revenues increased 2.1% to $2,232.0 million, compared to $2,186.0 million for the six months ended June 30, 2016. Income from operations increased 10.4% to $207.4 million for the six months ended June 30, 2017, compared to $187.9 million for the six months ended June 30, 2016. Net income was $74.8 million for the six months ended June 30, 2017, which includes pre-tax losses on early retirement of debt of $19.7 million. Net income was $100.8 million for the six months ended June 30, 2016, which included a pre-tax non-operating gain of $38.1 million and a pre-tax loss on early retirement of debt of $0.8 million. Our Adjusted EBITDA increased 10.2% to $297.6 million for the six months ended June 30, 2017, compared to $270.1 million for the six months ended June 30, 2016. Our Adjusted EBITDA margin was 13.3% for the six months ended June 30, 2017, compared to 12.4% for the six months ended June 30, 2016.

Implementation of Patient Criteria

As discussed below under “Regulatory Changes — Medicare Reimbursement of LTCH Services — Patient Criteria,” our LTCHs transitioned to the new Medicare regulations, which establish new payment limits for Medicare patients discharged from an LTCH who do not meet specified patient criteria, beginning October 1, 2015. Since completing our transition to the new LTCH Medicare patient criteria regulations during the third quarter of 2016, we have experienced an increase in admissions of patients eligible for the full LTCH-PPS standard reimbursement rate.

The table below illustrates the trend of our case mix index and occupancy percentages during the periods in which our LTCHs became subject to the new patient criteria requirements.

	2015			2016			2017
	Occupancy Percentage		Case Mix Index(1)	Occupancy Percentage		Case Mix Index(1)	Occupancy Percentage		Case Mix Index(1)
Three months ended:
March 31	71	%	1.22	71	%	1.24	68	%	1.28
June 30	70	%	1.21	67	%	1.27	66	%	1.28
September 30	70	%	1.18	61	%	1.26
December 31	70	%	1.21	63	%	1.26

(1)Case mix index, which is calculated as the sum of all diagnostic-related group weights for the period divided by the sum of discharges for the same period, is reflective of the level of patient-acuity in our LTCHs.

Our case mix index has increased, which is reflective of the higher-acuity patients we are now admitting under patient criteria. This has resulted in increases in our net revenue per patient day due to higher reimbursement rates for these cases. Our LTCH occupancy percentage reached its lowest level during the third quarter of 2016, which is the first quarter in which all of our LTCHs operated under the new Medicare payment rules. Our LTCHs which operated under the new Medicare payment rules during both the three months ended June 30, 2017 and 2016 experienced improved occupancy during the three months ended June 30, 2017. These LTCHs had an occupancy percentage of 70% for the three months ended June 30, 2017, compared to 69% for the three months ended June 30, 2016.

32

Significant Events

Refinancing

On March 6, 2017, Select entered into a new senior secured credit agreement that provides for $1.6 billion in senior secured credit facilities comprising a $1.15 billion, seven-year term loan and a $450.0 million, five-year revolving credit facility, including a $75.0 million sublimit for the issuance of standby letters of credit. Select used borrowings under the new Select credit facilities to: (i) repay the series E tranche B term loans due June 1, 2018, the series F tranche B term loans due March 31, 2021, and the revolving facility maturing March 1, 2018 under Select’s 2011 senior secured credit facility; and (ii) pay fees and expenses in connection with the refinancing.

Regulatory Changes

Our Annual Report on Form 10-K for the year ended December 31, 2016, filed with the SEC on February 23, 2017, contains a detailed discussion of the regulations that affect our business in Part I — Business — Government Regulations. The following is a discussion of some of the more significant healthcare regulatory changes that have affected our financial performance in the periods covered by this report or are likely to affect our financial performance and financial condition in the future. The information below should be read in conjunction with the more detailed discussion of regulations contained in our Form 10-K.

Medicare Reimbursement

The Medicare program reimburses healthcare providers for services furnished to Medicare beneficiaries, which are generally persons age 65 and older, those who are chronically disabled, and those suffering from end stage renal disease. The program is governed by the Social Security Act of 1965 and is administered primarily by the Department of Health and Human Services and CMS. Net operating revenues generated directly from the Medicare program represented approximately 30% of our net operating revenues for both the six months ended June 30, 2017 and the year ended December 31, 2016.

Medicare Reimbursement of LTCH Services

There have been significant regulatory changes affecting LTCHs that have affected our net operating revenues and, in some cases, caused us to change our operating models and strategies. We have been subject to regulatory changes that occur through the rulemaking procedures of CMS. All Medicare payments to our LTCHs are made in accordance with the long term care hospital prospective payment system (“LTCH-PPS”). Proposed rules specifically related to LTCHs are generally published in April or May, finalized in August, and effective on October 1st of each year.

The following is a summary of significant changes to the Medicare prospective payment system for LTCHs which have affected our financial performance in the periods covered by this report or may affect our financial performance and financial condition in the future.

Fiscal Year 2016.  On August 17, 2015, CMS published the final rule updating policies and payment rates for the LTCH-PPS for fiscal year 2016 (affecting discharges and cost reporting periods beginning on or after October 1, 2015 through September 30, 2016). The standard federal rate was set at $41,763, an increase from the standard federal rate applicable during fiscal year 2015 of $41,044. The update to the standard federal rate for fiscal year 2016 included a market basket increase of 2.4%, less a productivity adjustment of 0.5%, and less a reduction of 0.2% mandated by the Affordable Care Act (“ACA”). The fixed loss amount for high cost outlier cases paid under LTCH-PPS was set at $16,423, an increase from the fixed loss amount in the 2015 fiscal year of $14,972. The fixed loss amount for high cost outlier cases paid under the site neutral payment rate described below was set at $22,538.

Fiscal Year 2017.  On August 22, 2016, CMS published the final rule updating policies and payment rates for the LTCH-PPS for fiscal year 2017 (affecting discharges and cost reporting periods beginning on or after October 1, 2016 through September 30, 2017). The standard federal rate was set at $42,476, an increase from the standard federal rate applicable during fiscal year 2016 of $41,763. The update to the standard federal rate for fiscal year 2017 included a market basket increase of 2.8%, less a productivity adjustment of 0.3%, and less a reduction of 0.75% mandated by the ACA. The fixed-loss amount for high cost outlier cases paid under LTCH-PPS was set at $21,943, an increase from the fixed-loss amount in the 2016 fiscal year of $16,423. The fixed-loss amount for high cost outlier cases paid under the site-neutral payment rate was set at $23,573, an increase from the fixed-loss amount in the 2016 fiscal year of $22,538.

Fiscal Year 2018. On August 2, 2017, CMS released an advanced copy of the final policies and payment rates for the LTCH-PPS for fiscal year 2018 (affecting discharges and cost reporting periods beginning on or after October 1, 2017 through September 30, 2018). The standard federal rate was set at $41,431, a decrease from the standard federal rate applicable during fiscal year 2017 of $42,476. The update to the standard federal rate for fiscal year 2018 includes a market basket increase of 2.7%, less a productivity adjustment of 0.6%, and less a reduction of 0.75% mandated by the ACA. As noted below, the update to the standard federal rate for fiscal year 2018 is impacted further by the Medicare Access and CHIP Reauthorization Act of 2015, which limits the update for fiscal year 2018 to 1.0%. The fixed-loss amount for high cost outlier cases paid under LTCH-PPS was set at $27,382, an increase from the fixed-loss amount in the 2017 fiscal year of $21,943. The fixed-loss amount for high cost outlier cases paid under the site-neutral payment rate was set at $26,601, an increase from the fixed-loss amount in the 2017 fiscal year of $23,573.

33

Patient Criteria

The BBA of 2013, enacted December 26, 2013, establishes a dual-rate LTCH-PPS for Medicare patients discharged from an LTCH. Specifically, for Medicare patients discharged in cost reporting periods beginning on or after October 1, 2015, LTCHs will be reimbursed at the LTCH-PPS standard federal payment rate only if, immediately preceding the patient’s LTCH admission, the patient was discharged from a “subsection (d) hospital” (generally, a short-term acute care hospital paid under the inpatient prospective payment system, or “IPPS”) and either the patient’s stay included at least three days in an intensive care unit (ICU) or coronary care unit (CCU) at the subsection (d) hospital, or the patient was assigned to Medicare severity diagnosis-related group (“MS-LTC-DRG”) for LTCHs for cases receiving at least 96 hours of ventilator services in the LTCH. In addition, to be paid at the LTCH-PPS standard federal payment rate, the patient’s discharge from the LTCH may not include a principal diagnosis relating to psychiatric or rehabilitation services. For any Medicare patient who does not meet these criteria, the LTCH will be paid a lower “site neutral” payment rate, which will be the lower of: (i) IPPS comparable per diem payment rate capped at the Medicare severity diagnosis-related group (“MS-DRG”) payment rate plus any outlier payments; or (ii) 100 percent of the estimated costs for services.

The BBA of 2013 provides for a transition to the site-neutral payment rate for those patients not paid at the LTCH-PPS standard federal payment rate. During the transition period (applicable to hospital cost reporting periods beginning on or after October 1, 2015 and on or before September 30, 2017), a blended rate will be paid for Medicare patients not meeting the new criteria that is equal to 50% of the site-neutral payment rate amount and 50% of the standard federal payment rate amount. For discharges in cost reporting periods beginning on or after October 1, 2017, only the site-neutral payment rate will apply for Medicare patients not meeting the new criteria.

In addition, for cost reporting periods beginning on or after October 1, 2019, qualifying discharges from an LTCH will continue to be paid at the LTCH-PPS standard federal payment rate, unless the number of discharges for which payment is made under the site-neutral payment rate is greater than 50% of the total number of discharges from the LTCH for that period. If the number of discharges for which payment is made under the site-neutral payment rate is greater than 50%, then beginning in the next cost reporting period all discharges from the LTCH will be reimbursed at the site-neutral payment rate. The BBA of 2013 requires CMS to establish a process for an LTCH subject to only the site-neutral payment rate to be reinstated for payment under the dual-rate LTCH-PPS.

Payment adjustments, including the interrupted stay policy and the 25 Percent Rule (discussed below), apply to LTCH discharges regardless of whether the case is paid at the standard federal payment rate or the site-neutral payment rate. However, short stay outlier payment adjustments do not apply to cases paid at the site-neutral payment rate. CMS calculates the annual recalibration of the MS-LTC-DRG relative payment weighting factors using only data from LTCH discharges that meet the criteria for exclusion from the site-neutral payment rate. In addition, CMS applies the IPPS fixed-loss amount for high cost outliers to site-neutral cases, rather than the LTCH-PPS fixed-loss amount. CMS calculates the LTCH-PPS fixed-loss amount using only data from cases paid at the LTCH-PPS payment rate, excluding cases paid at the site-neutral rate.

Medicare Market Basket Adjustments

The ACA instituted a market basket payment adjustment to LTCHs. In fiscal years 2018 and 2019, the market basket update will be reduced by 0.75%. The Medicare Access and CHIP Reauthorization Act of 2015 sets the annual update for fiscal year 2018 at 1% after taking into account the market basket payment reduction of 0.75% mandated by the ACA. The ACA specifically allows these market basket reductions to result in less than a 0% payment update and payment rates that are less than the prior year.

25 Percent Rule

The “25 Percent Rule” is a downward payment adjustment that applies if the percentage of Medicare patients discharged from LTCHs who were admitted from a referring hospital (regardless of whether the LTCH or LTCH satellite is co-located with the referring hospital) exceeds the applicable percentage admissions threshold during a particular cost reporting period. For Medicare patients above the applicable percentage admissions threshold, the LTCH is reimbursed at a rate equivalent to that under general acute care hospital IPPS, which is generally lower than LTCH-PPS rates. Cases that reach outlier status in the referring hospital do not count toward the admissions threshold and are paid under LTCH-PPS.

34

Current law, as amended by the 21st Century Cures Act, precludes CMS from applying the 25 Percent Rule for freestanding LTCHs to cost reporting years beginning before July 1, 2016 and for discharges occurring on or after October 1, 2016 and before October 1, 2017. In addition, current law applies higher percentage admissions thresholds under the 25 Percent Rule for most hospitals within hospitals (“HIHs”) for cost reporting years beginning before July 1, 2016 and effective for discharges occurring on or after October 1, 2016 and before October 1, 2017. For freestanding LTCHs the percentage admissions threshold is suspended during the relief periods. For HIHs the percentage admissions threshold is raised from 25% to 50% during the relief periods. In the special case of rural LTCHs, LTCHs co-located with an urban single hospital, or LTCHs co-located with a Metropolitan Statistical Area (“MSA”) dominant hospital the referral percentage was raised from 50% to 75%. Grandfathered HIHs are exempt from the 25 Percent Rule regulations.

For fiscal year 2018, CMS adopted a regulatory moratorium on the implementation of the 25 Percent Rule. As a result, the 25 Percent Rule applies to discharges occurring on or after October 1, 2018. After the expiration of the regulatory moratorium, our LTCHs (whether freestanding, HIH or satellite) will be subject to a downward payment adjustment for any Medicare patients who were admitted from a co-located or a non-co-located hospital and that exceed the applicable percentage admissions threshold of all Medicare patients discharged from the LTCH during the cost reporting period. These regulatory changes will have an adverse financial impact on the net operating revenues and profitability of many of these hospitals for discharges on or after October 1, 2018.

Short Stay Outlier Policy

CMS established a different payment methodology for Medicare patients with a length of stay less than or equal to five-sixths of the geometric average length of stay for that particular MS-LTC-DRG, referred to as a short stay outlier, or “SSO.” SSO cases are paid based on the lesser of (i) 100% of the average cost of the case, (ii) 120% of the MS-LTC-DRG specific per diem amount multiplied by the patient’s length of stay, (iii) the full MS-LTC-DRG payment, or (iv) a per diem rate derived from blending 120% of the MS-LTC-DRG specific per diem amount with a per diem rate based on the general acute care hospital IPPS.

For fiscal year 2018, CMS adopted changes to the SSO policy such that all SSO cases discharged on or after October 1, 2017 are paid based on a per diem rate derived from blending 120% of the MS-LTC-DRG specific per diem amount with a per diem rate based on the general acute care hospital IPPS. Under this policy, as the length of stay of a SSO case increases, the percentage of the per diem payment amounts based on the full MS-LTCH-DRG standard federal payment rate increases and the percentage of the payment based on the IPPS comparable amount decreases.

Moratorium on New LTCHs, LTCH Satellite Facilities and LTCH beds

Current law imposes a moratorium on the establishment and classification of new LTCHs or LTCH satellite facilities, and on the increase of LTCH beds in existing LTCHs or satellite facilities through September 30, 2017. There are three exceptions to the moratorium for projects that were under development when the moratorium began on April 1, 2014. Only one exception needs to exist for the moratorium not to apply.

Medicare Reimbursement of Inpatient Rehabilitation Facility Services

The following is a summary of significant changes to the Medicare prospective payment system for inpatient rehabilitation facilities (“IRFs”) which have affected our financial performance in the periods covered by this report or may affect our financial performance and financial condition in the future. Medicare payments to our IRFs are made in accordance with the inpatient rehabilitation facility prospective payment system (“IRF-PPS”).

Fiscal Year 2016.  On August 6, 2015, CMS published the final rule updating policies and payment rates for the IRF-PPS for fiscal year 2016 (affecting discharges and cost reporting periods beginning on or after October 1, 2015 through September 30, 2016). The standard payment conversion factor for discharges for fiscal year 2016 was set at $15,478, an increase from the standard payment conversion factor applicable during fiscal year 2015 of $15,198. The update to the standard payment conversion factor for fiscal year 2016 included a market basket increase of 2.4%, less a productivity adjustment of 0.5%, and less a reduction of 0.2% mandated by the ACA. CMS decreased the outlier threshold amount for fiscal year 2016 to $8,658 from $8,848 established in the final rule for fiscal year 2015.

35

Fiscal Year 2017.  On August 5, 2016, CMS published the final rule updating policies and payment rates for the IRF-PPS for fiscal year 2017 (affecting discharges and cost reporting periods beginning on or after October 1, 2016 through September 30, 2017). The standard payment conversion factor for discharges for fiscal year 2017 was set at $15,708, an increase from the standard payment conversion factor applicable during fiscal year 2016 of $15,478. The update to the standard payment conversion factor for fiscal year 2017 included a market basket increase of 2.7%, less a productivity adjustment of 0.3%, and less a reduction of 0.75% mandated by the ACA. CMS decreased the outlier threshold amount for fiscal year 2017 to $7,984 from $8,658 established in the final rule for fiscal year 2016.

Fiscal Year 2018.   On July 31, 2017, CMS released an advanced copy of the final policies and payment rates for the IRF-PPS for fiscal year 2018 (affecting discharges and cost reporting periods beginning on or after October 1, 2017 through September 30, 2018). The standard payment conversion factor for discharges for fiscal year 2018 was set at $15,838, an increase from the standard payment conversion factor applicable during fiscal year 2017 of $15,708. The update to the standard payment conversion factor for fiscal year 2018 includes a market basket increase of 2.6%, less a productivity adjustment of 0.6%, and less a reduction of 0.75% mandated by the ACA. As noted below, the standard payment conversion factor for fiscal year 2018 is impacted further by the Medicare Access and CHIP Reauthorization Act of 2015, which limits the update for fiscal year 2018 to 1.0%. CMS increased the outlier threshold amount for fiscal year 2018 to $8,679 from $7,984 established in the final rule for fiscal year 2017.

Medicare Market Basket Adjustments

The ACA instituted a market basket payment adjustment for IRFs. In fiscal years 2018 and 2019, the market basket update will be reduced by 0.75%. The Medicare Access and CHIP Reauthorization Act of 2015 sets the annual update for fiscal year 2018 at 1% after taking into account the market basket payment reduction of 0.75% mandated by the ACA. The ACA specifically allows these market basket reductions to result in less than a 0% payment update and payment rates that are less than the prior year.

Patient Classification Criteria

In order to qualify as an IRF a hospital must demonstrate that during its most recent twelve month cost reporting period it served an inpatient population of whom at least 60% required intensive rehabilitation services for one or more of 13 conditions specified by regulation. Compliance with the 60% rule is demonstrated through either medical review or the “presumptive” method, in which a patient’s diagnosis codes are compared to a “presumptive compliance” list.  For fiscal year 2018, CMS revised the 60% rule’s presumptive methodology by (i) including certain International Classification of Diseases, Tenth Revision, Clinical Modification (“ICD-10-CM”) diagnosis codes for patients with traumatic brain injury and hip fracture conditions; and (ii) revising the presumptive methodology list for major multiple trauma by counting IRF cases that contain two or more of the ICD-10-CM codes from three major multiple trauma lists in the specified combinations.

Medicare Reimbursement of Outpatient Rehabilitation Services

The Medicare program reimburses outpatient rehabilitation providers based on the Medicare physician fee schedule. For services provided in 2017 through 2019, a 0.5% update will be applied each year to the fee schedule payment rates, subject to an adjustment beginning in 2019 under the Merit-Based Incentive Payment System (“MIPS”). For services provided in 2020 through 2025, a 0.0% percent update will be applied each year to the fee schedule payment rates, subject to adjustments under MIPS and the alternative payment models (“APMs”). In 2026 and subsequent years eligible professionals participating in APMs that meet certain criteria would receive annual updates of 0.75%, while all other professionals would receive annual updates of 0.25%.

Beginning in 2019, payments under the fee schedule are subject to adjustment based on performance in MIPS, which measures performance based on certain quality metrics, resource use, and meaningful use of electronic health records. Under the MIPS requirements a provider’s performance is assessed according to established performance standards and used to determine an adjustment factor that is then applied to the professional’s payment for a year. Each year from 2019 through 2024 professionals who receive a significant share of their revenues through an APM (such as accountable care organizations or bundled payment arrangements) that involves risk of financial losses and a quality measurement component will receive a 5% bonus. The bonus payment for APM participation is intended to encourage participation and testing of new APMs and to promote the alignment of incentives across payors. The specifics of the MIPS and APM adjustments beginning in 2019 and 2020, respectively, will be subject to future notice and comment rule-making.

36

Operating Statistics

The following table sets forth operating statistics for our operating segments for each of the periods presented. The operating statistics reflect data for the period of time we managed these operations:

	Three Months Ended June 30,						Six Months Ended June 30,
	2016			2017			2016			2017
Specialty hospitals data:(1)
Number of hospitals owned—start of period	118			114			118			115
Number of hospitals acquired	3			1			3			1
Number of hospital start-ups	1			—			1			—
Number of hospitals closed/sold	(6		)	(1		)	(6		)	(2		)
Number of hospitals owned—end of period	116			114			116			114
Number of hospitals managed—end of period	8			9			8			9
Total number of hospitals (all)—end of period	124			123			124			123
Long term acute care hospitals	106			102			106			102
Rehabilitation hospitals	18			21			18			21
Available licensed beds(2)	5,154			5,155			5,154			5,155
Admissions(2)	13,094			13,691			26,955			27,586
Patient days(2)	317,119			316,884			655,090			634,249
Average length of stay (days)(2)	24			23			24			23
Net revenue per patient day(2)(3)	$	1,680		$	1,731		$	1,655		$	1,723
Occupancy rate(2)	68		%	68		%	70		%	68		%
Percent patient days—Medicare(2)	55		%	54		%	56		%	54		%
Outpatient rehabilitation data:
Number of clinics owned—start of period	1,441			1,445			896			1,445
Number of clinics acquired	—			—			543			1
Number of clinic start-ups	7			6			13			14
Number of clinics closed/sold	(13		)	(10		)	(17		)	(19		)
Number of clinics owned—end of period	1,435			1,441			1,435			1,441
Number of clinics managed—end of period	165			167			165			167
Total number of clinics (all)—end of period	1,600			1,608			1,600			1,608
Number of visits(2)	2,122,330			2,106,760			3,698,884			4,182,550
Net revenue per visit(2)(4)	$	102		$	103		$	102		$	102
Concentra data:
Number of centers owned—start of period	301			308			300			300
Number of centers acquired	—			5			2			11
Number of center start-ups	—			2			—			4
Number of centers closed/sold	—			—			(1		)	—
Number of centers owned—end of period	301			315			301			315
Number of visits(5)	1,890,348			1,982,255			3,736,063			3,869,070
Net revenue per visit(5)(6)	$	118		$	116		$	118		$	117

(1)Specialty hospitals consist of LTCHs and IRFs.

(2)Data excludes specialty hospitals and outpatient clinics managed by the Company.

(3)Net revenue per patient day is calculated by dividing specialty hospitals direct patient service revenues by the total number of patient days.

(4)Net revenue per visit is calculated by dividing outpatient rehabilitation clinic direct patient service revenue by the total number of visits. For purposes of this computation, outpatient rehabilitation direct patient service clinic revenue does not include managed clinics or contract therapy revenue.

(5)Data excludes onsite clinics and CBOCs.

(6)Net revenue per visit is calculated by dividing center direct patient service revenue by the total number of center visits.

37

Results of Operations

The following table outlines selected operating data as a percentage of net operating revenues for the periods indicated:

	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2017		2016		2017
Net operating revenues	100.0	%	100.0	%	100.0	%	100.0	%
Cost of services(1)	83.5		82.1		84.1		82.8
General and administrative	2.4		2.5		2.5		2.5
Bad debt expense	1.6		1.6		1.6		1.7
Depreciation and amortization	3.3		3.5		3.2		3.7
Income from operations	9.2		10.3		8.6		9.3
Loss on early retirement of debt	—		—		0.0		(0.9	)
Equity in earnings of unconsolidated subsidiaries	0.4		0.5		0.4		0.5
Non-operating gain (loss)	1.2		—		1.7		(0.0	)
Interest expense	(4.0	)	(3.3	)	(3.8	)	(3.5	)
Income before income taxes	6.8		7.5		6.9		5.4
Income tax expense	3.1		2.9		2.3		2.0
Net income	3.7		4.6		4.6		3.4
Net income attributable to non-controlling interests	0.6		0.8		0.5		0.8
Net income attributable to Holdings and Select	3.1	%	3.8	%	4.1	%	2.6	%

(1)Cost of services includes salaries, wages and benefits, operating supplies, lease and rent expense and other operating costs.

38

The following table summarizes selected financial data by business segment for the periods indicated:

	Three Months Ended June 30,								Six Months Ended June 30,
	2016			2017			% Change		2016			2017			% Change
	(in thousands)
Net operating revenues:
Specialty hospitals	$	585,816		$	600,960		2.6	%	$	1,184,770		$	1,199,747		1.3	%
Outpatient rehabilitation(1)	256,928			258,106			0.5		495,010			513,923			3.8
Concentra	254,868			261,586			2.6		505,745			517,735			2.4
Other(2)	19			23			N/M		436			631			N/M
Total Company	$	1,097,631		$	1,120,675		2.1	%	$	2,185,961		$	2,232,036		2.1	%
Income (loss) from operations:
Specialty hospitals	$	68,927		$	82,718		20.0	%	$	141,790		$	152,883		7.8	%
Outpatient rehabilitation(1)	31,930			36,048			12.9		56,773			61,059			7.5
Concentra	27,931			27,368			(2.0	)	46,516			53,531			15.1
Other(2)	(27,734		)	(30,471		)	(9.9	)	(57,139		)	(60,045		)	(5.1	)
Total Company	$	101,054		$	115,663		14.5	%	$	187,940		$	207,428		10.4	%
Adjusted EBITDA:
Specialty hospitals	$	82,739		$	98,172		18.7	%	$	169,495		$	186,837		10.2	%
Outpatient rehabilitation(1)	38,132			41,926			9.9		67,011			73,277			9.4
Concentra	43,039			43,061			0.1		77,192			85,653			11.0
Other(2)	(22,453		)	(24,479		)	(9.0	)	(43,626		)	(48,197		)	(10.5	)
Total Company	$	141,457		$	158,680		12.2	%	$	270,072		$	297,570		10.2	%
Adjusted EBITDA margins:
Specialty hospitals	14.1		%	16.3		%			14.3		%	15.6		%
Outpatient rehabilitation(1)	14.8			16.2					13.5			14.3
Concentra	16.9			16.5					15.3			16.5
Other(2)	N/M			N/M					N/M			N/M
Total Company	12.9		%	14.2		%			12.4		%	13.3		%
Total assets:(3)
Specialty hospitals	$	2,457,948		$	2,655,617				$	2,457,948		$	2,655,617
Outpatient rehabilitation	959,748			982,811					959,748			982,811
Concentra	1,328,243			1,310,483					1,328,243			1,310,483
Other(2)	73,950			105,300					73,950			105,300
Total Company	$	4,819,889		$	5,054,211				$	4,819,889		$	5,054,211
Purchases of property and equipment, net:
Specialty hospitals	$	21,313		$	36,691				$	54,988		$	69,048
Outpatient rehabilitation(1)	3,825			6,201					8,798			12,874
Concentra	4,716			7,601					7,927			16,287
Other(2)	3,636			4,156					8,545			7,093
Total Company	$	33,490		$	54,649				$	80,258		$	105,302

N/M—Not Meaningful.

(1)The outpatient rehabilitation segment includes the operating results of our contract therapy businesses through March 31, 2016 and Physiotherapy beginning March 4, 2016.

(2)Other includes our corporate services and certain other non-consolidating joint ventures and minority investments in other healthcare related businesses.

(3)Reflects the retrospective adoption of ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. Total assets as of June 30, 2016 were retrospectively conformed to reflect the adoption of the standard, resulting in a reduction to total assets of $18.5 million.

39

Three Months Ended June 30, 2017 Compared to Three Months Ended June 30, 2016

In the following, we discuss our results of operations related to net operating revenues, operating expenses, Adjusted EBITDA, depreciation and amortization, income from operations, equity in earnings of unconsolidated subsidiaries, non-operating gain, interest expense, income taxes, and net income attributable to non-controlling interests, which, in each case, are the same for Holdings and Select.

Net Operating Revenues

Our net operating revenues increased 2.1% to $1,120.7 million for the three months ended June 30, 2017, compared to $1,097.6 million for the three months ended June 30, 2016.

Specialty Hospitals Segment.  Net operating revenues increased 2.6% to $601.0 million for the three months ended June 30, 2017, compared to $585.8 million for the three months ended June 30, 2016 for our specialty hospitals segment. The increase in net operating revenues is principally due to several new inpatient rehabilitation facilities which recently commenced operations. The average net revenue per patient day for all of our specialty hospitals increased 3.0% to $1,731 for the three months ended June 30, 2017, compared to $1,680 for the three months ended June 30, 2016. We had 316,884 patient days for the three months ended June 30, 2017, compared to 317,119 days for the three months ended June 30, 2016. The decrease in patient days is principally due to closed specialty hospitals.

Outpatient Rehabilitation Segment.  Net operating revenues increased to $258.1 million for the three months ended June 30, 2017, compared to $256.9 million for the three months ended June 30, 2016 for our outpatient rehabilitation segment. The increase in net operating revenues was principally due to an increase in our net revenue per visit, offset in part by a decline in visits. Net revenue per visit was $103 for the three months ended June 30, 2017, compared to $102 for the three months ended June 30, 2016. We had 2,106,760 visits in our clinics for the three months ended June 30, 2017, compared to 2,122,330 visits for the three months ended June 30, 2016. The decline in visits occurred within some of our Physiotherapy markets.

Concentra Segment.  Net operating revenues increased 2.6% to $261.6 million for the three months ended June 30, 2017, compared to $254.9 million for the three months ended June 30, 2016 for our Concentra segment. The increase in net operating revenues was due to an increase in visits principally from newly acquired and developed medical centers. We had 1,982,255 visits in our centers for the three months ended June 30, 2017, compared to 1,890,348 visits for the three months ended June 30, 2016. The increase in visits principally related to our employer services. Net revenue per visit was $116 for the three months ended June 30, 2017, compared to $118 for the three months ended June 30, 2016. The decrease in net revenue per visit is principally due to an increased proportion of employer service visits, which yield lower per visit rates.

40

Operating Expenses

Our operating expenses include our cost of services, general and administrative expense, and bad debt expense. Our operating expenses were $966.7 million, or 86.2% of net operating revenues, for the three months ended June 30, 2017, compared to $960.4 million, or 87.5% of net operating revenues, for the three months ended June 30, 2016. Our cost of services, a major component of which is labor expense, was $920.2 million, or 82.1% of net operating revenues, for the three months ended June 30, 2017, compared to $917.0 million, or 83.5% of net operating revenues, for the three months ended June 30, 2016. The decrease in our operating expenses relative to our net operating revenues is principally due to the improved operating performance of our start-up specialty hospitals, specialty hospital closures, and a decline in operating expenses in our outpatient rehabilitation segment. Facility rent expense, a component of cost of services, was $57.2 million for the three months ended June 30, 2017, compared to $57.0 million for the three months ended June 30, 2016. General and administrative expenses were $28.3 million for the three months ended June 30, 2017, compared to $25.9 million for the three months ended June 30, 2016. General and administrative expenses as a percentage of net operating revenues were 2.5% for the three months ended June 30, 2017, compared to 2.4% for the three months ended June 30, 2016. Our bad debt expense was $18.2 million for the three months ended June 30, 2017, compared to $17.5 million for the three months ended June 30, 2016. Bad debt expense as a percentage of net operating revenues was 1.6% for both the three months ended June 30, 2017 and 2016.

Adjusted EBITDA

Specialty Hospitals Segment.  Adjusted EBITDA increased 18.7% to $98.2 million for the three months ended June 30, 2017, compared to $82.7 million for the three months ended June 30, 2016 for our specialty hospitals segment. Our Adjusted EBITDA margin for the segment was 16.3% for the three months ended June 30, 2017, compared to 14.1% for the three months ended June 30, 2016. The increase in Adjusted EBITDA for our specialty hospitals segment was primarily driven by the improved operating performance of our LTCHs, reductions in Adjusted EBITDA losses in our start-up specialty hospitals, and the closure of specialty hospitals which had generated Adjusted EBITDA losses during the three months ended  June 30, 2016. Adjusted EBITDA losses in our start-up specialty hospitals were $1.2 million for the three months ended June 30, 2017, compared to $6.6 million for the three months ended June 30, 2016.

Outpatient Rehabilitation Segment.  Adjusted EBITDA increased 9.9% to $41.9 million for the three months ended June 30, 2017, compared to $38.1 million for the three months ended June 30, 2016 for our outpatient rehabilitation segment. Our Adjusted EBITDA margin for the outpatient rehabilitation segment was 16.2% for the three months ended June 30, 2017, compared to 14.8% for the three months ended June 30, 2016. The increase in Adjusted EBITDA for our outpatient rehabilitation segment was due to improved operating performance as a result of lower cost of services during the three months ended June 30, 2017.

Concentra Segment.  Adjusted EBITDA was $43.1 million for the three months ended June 30, 2017, compared to $43.0 million for the three months ended June 30, 2016 for our Concentra segment. Our Adjusted EBITDA margin for the Concentra segment was 16.5% for the three months ended June 30, 2017, compared to 16.9% for the three months ended June 30, 2016. The decline in our Adjusted EBITDA margin for our Concentra segment was the result of higher operating expenses, principally related to increased labor costs, relative to our net operating revenues.

Other.  The Adjusted EBITDA loss was $24.5 million for the three months ended June 30, 2017, compared to an Adjusted EBITDA loss of $22.5 million for the three months ended June 30, 2016. The increase in our Adjusted EBITDA loss was due to an increase in general and administrative costs, which encompass our corporate shared service activities.

Depreciation and Amortization

Depreciation and amortization expense was $38.3 million for the three months ended June 30, 2017, compared to $36.2 million for the three months ended June 30, 2016. The increase was principally due to new inpatient rehabilitation facilities operating in our specialty hospitals segment.

Income from Operations

For the three months ended June 30, 2017, we had income from operations of $115.7 million, compared to $101.1 million for the three months ended June 30, 2016. The increase in income from operations resulted principally from the improved operating performance of our specialty hospitals segment.

41

Equity in Earnings of Unconsolidated Subsidiaries

For the three months ended June 30, 2017, we had equity in earnings of unconsolidated subsidiaries of $5.7 million, compared to $4.5 million for the three months ended June 30, 2016. The increase in our equity in earnings of unconsolidated subsidiaries resulted principally from improved performance of the inpatient rehabilitation businesses in which we have a minority interest.

Non-Operating Gain

We recognized a non-operating gain of $13.0 million during the three months ended June 30, 2016. The non-operating gain was principally due to the sale of nine outpatient rehabilitation clinics and the sale of five specialty hospitals in an exchange transaction.

Interest Expense

Interest expense was $37.7 million for the three months ended June 30, 2017, compared to $44.3 million for the three months ended June 30, 2016. The decrease in interest expense was principally the result of decreases in our interest rates associated with the refinancing of the Select credit facilities during the first quarter of 2017 and the Concentra credit facilities during the third quarter of 2016.

Income Taxes

We recorded income tax expense of $32.4 million for the three months ended June 30, 2017, which represented an effective tax rate of 38.7%. We recorded income tax expense of $33.5 million for the three months ended June 30, 2016, which represented an effective tax rate of 45.0%.

During the three months ended June 30, 2016, we exchanged five specialty hospitals. For tax purposes, the exchange was treated as a discrete tax event during the three months ended June 30, 2016. Our tax basis in the five specialty hospitals was less than our book basis, resulting in a tax gain exceeding our book gain. The additional tax expense resulting from this gain was the principal cause of the higher effective tax rate during this period.

Net Income Attributable to Non-Controlling Interests

Net income attributable to non-controlling interests was $9.2 million for the three months ended June 30, 2017, compared to $6.9 million for the three months ended June 30, 2016. The increase is principally due the minority interest owners’ share of income from Concentra and new inpatient rehabilitation facilities operating within our specialty hospitals segment.

42

Six Months Ended June 30, 2017 Compared to Six Months Ended June 30, 2016

In the following, we discuss our results of operations related to net operating revenues, operating expenses, Adjusted EBITDA, depreciation and amortization, income from operations, loss on early retirement of debt, equity in earnings of unconsolidated subsidiaries, non-operating gain, interest expense, income taxes, and net income attributable to non-controlling interests, which, in each case, are the same for Holdings and Select.

Net Operating Revenues

Our net operating revenues increased 2.1% to $2,232.0 million for the six months ended June 30, 2017, compared to $2,186.0 million for the six months ended June 30, 2016.

Specialty Hospitals Segment.  Net operating revenues increased 1.3% to $1,199.7 million for the six months ended June 30, 2017, compared to $1,184.8 million for the six months ended June 30, 2016 for our specialty hospitals segment. The increase in net operating revenues is principally due to several new inpatient rehabilitation facilities which recently commenced operations. The average net revenue per patient day for our specialty hospitals increased 4.1% to $1,723 for the six months ended June 30, 2017, compared to $1,655 for the six months ended June 30, 2016. For the six months ended June 30, 2017, we had 634,249 patient days, compared to 655,090 days for the six months ended June 30, 2016. The decrease in patient days is principally due to closed specialty hospitals.

Outpatient Rehabilitation Segment.  Net operating revenues increased 3.8% to $513.9 million for the six months ended June 30, 2017, compared to $495.0 million for the six months ended June 30, 2016 for our outpatient rehabilitation segment. The increase in net operating revenues was principally due to the acquisition of Physiotherapy on March 4, 2016, which contributed to the overall growth in our visits. The increase in net operating revenues was offset in part by the sale of our contract therapy businesses on March 31, 2016. Visits increased 13.1% to 4,182,550 for the six months ended June 30, 2017, compared to 3,698,884 visits for the six months ended June 30, 2016. Net revenue per visit was $102 for both the six months ended June 30, 2017 and 2016.

Concentra Segment.  Net operating revenues increased 2.4% to $517.7 million for the six months ended June 30, 2017, compared to $505.7 million for the six months ended June 30, 2016 for our Concentra segment.  The increase in net operating revenues was due to an increase in visits principally from newly acquired and developed medical centers. Visits in our centers increased 3.6% to 3,869,070 for the six months ended June 30, 2017, compared to 3,736,063 visits for the six months ended June 30, 2016. The increase in visits principally related to our employer services. Net revenue per visit was $117 for the six months ended June 30, 2017, compared to $118 for the six months ended June 30, 2016. The decrease in net revenue per visit is principally due to an increased proportion of employer service visits, which yield lower per visit rates.

Operating Expenses

Our operating expenses include our cost of services, general and administrative expense, and bad debt expense. Our operating expenses were $1,943.7 million, or 87.0% of net operating revenues, for the six months ended June 30, 2017, compared to $1,927.3 million, or 88.2% of net operating revenues, for the six months ended June 30, 2016. Our cost of services, a major component of which is labor expense, was $1,848.6 million, or 82.8% of net operating revenues, for the six months ended June 30, 2017, compared to $1,839.2 million, or 84.1% of net operating revenues, for the six months ended June 30, 2016. The decrease in our operating expenses relative to our net operating revenues is principally due to the improved operating performance of our start-up specialty hospitals, specialty hospitals closures, and cost reductions achieved by Concentra.  Facility rent expense, a component of cost of services, was $113.8 million for the six months ended June 30, 2017, compared to $109.0 million for the six months ended June 30, 2016. General and administrative expenses were $56.4 million for the six months ended June 30, 2017, compared to $54.1 million for the six months ended June 30, 2016, which includes $3.2 million of Physiotherapy acquisition costs. General and administrative expenses as a percentage of net operating revenues were 2.5% for both the six months ended June 30, 2017 and 2016. Our bad debt expense was $38.8 million, or 1.7% of net operating revenues, for the six months ended June 30, 2017, compared to $33.9 million, or 1.6% of net operating revenues, for the six months ended June 30, 2016. The increase was principally the result of increases in bad debt expense in our specialty hospitals and Concentra segments.

43

Adjusted EBITDA

Specialty Hospitals Segment.  Adjusted EBITDA increased 10.2% to $186.8 million for the six months ended June 30, 2017, compared to $169.5 million for the six months ended June 30, 2016 for our specialty hospitals segment. Our Adjusted EBITDA margin for the segment was 15.6% for the six months ended June 30, 2017, compared to 14.3% for the six months ended June 30, 2016. The increase in Adjusted EBITDA for our specialty hospitals segment was primarily driven by the improved operating performance of our LTCHs, reductions in Adjusted EBITDA losses in our start-up specialty hospitals, and the closure of specialty hospitals which had generated Adjusted EBITDA losses during the six months ended June 30, 2016. Adjusted EBITDA losses in our start-up specialty hospitals were $3.2 million for the six months ended June 30, 2017, compared to $10.5 million for the six months ended June 30, 2016.

Outpatient Rehabilitation Segment.  Adjusted EBITDA increased 9.4% to $73.3 million for the six months ended June 30, 2017, compared to $67.0 million for the six months ended June 30, 2016 for our outpatient rehabilitation segment. The increase in Adjusted EBITDA was principally due to growth in visits, as discussed above under “Net Operating Revenues.” Our Adjusted EBITDA margin for the outpatient rehabilitation segment was 14.3% for the six months ended June 30, 2017, compared to 13.5% for the six months ended June 30, 2016. The increase was principally due to the sale of our contract therapy businesses on March 31, 2016, which operated at lower Adjusted EBITDA margins than our outpatient rehabilitation clinics.

Concentra Segment.  Adjusted EBITDA increased 11.0% to $85.7 million for the six months ended June 30, 2017, compared to $77.2 million for the six months ended June 30, 2016 for our Concentra segment. Our Adjusted EBITDA margin for the Concentra segment was 16.5% for the six months ended June 30, 2017, compared to 15.3% for the six months ended June 30, 2016. The increase in Adjusted EBITDA for our Concentra segment was principally the result of cost reductions we have achieved.

Other.  The Adjusted EBITDA loss was $48.2 million for the six months ended June 30, 2017, compared to an Adjusted EBITDA loss of $43.6 million for the six months ended June 30, 2016.

Depreciation and Amortization

Depreciation and amortization expense was $80.9 million for the six months ended June 30, 2017, compared to $70.7 million for the six months ended June 30, 2016. The increase was principally due to new inpatient rehabilitation facilities operating in our specialty hospitals segment.

Income from Operations

For the six months ended June 30, 2017, we had income from operations of $207.4 million, compared to $187.9 million for the six months ended June 30, 2016. The increase in income from operations resulted principally from the improved operating performance of our specialty hospitals and Concentra segments.

Loss on Early Retirement of Debt

On March 6, 2017, we refinanced Select’s senior secured credit facilities which resulted in losses on early retirement of debt of $19.7 million during the six months ended June 30, 2017.

On March 4, 2016, we refinanced a portion of our term loans under Select’s 2011 senior secured credit facility which resulted in a loss on early retirement of debt of $0.8 million during the six months ended June 30, 2016.

Equity in Earnings of Unconsolidated Subsidiaries

For the six months ended June 30, 2017, we had equity in earnings of unconsolidated subsidiaries of $11.2 million, compared to $9.2 million for the six months ended June 30, 2016. The increase in our equity in earnings of unconsolidated subsidiaries resulted principally from improved performance of the inpatient rehabilitation businesses in which we have a minority interest.

44

Non-Operating Gain

We recognized a non-operating gain of $38.1 million during the six months ended June 30, 2016.  The non-operating gain was principally due to the sale of our contract therapy businesses during the quarter ended March 31, 2016, as well as the sale of nine outpatient rehabilitation clinics and the sale of five specialty hospitals in an exchange transaction during the quarter ended June 30, 2016.

Interest Expense

Interest expense was $78.5 million for the six months ended June 30, 2017, compared to $83.2 million for the six months ended June 30, 2016. The decrease in interest expense was principally the result of decreases in our interest rates associated with the refinancing of the Select credit facilities during the first quarter of 2017 and the Concentra credit facilities during the third quarter of 2016.

Income Taxes

We recorded income tax expense of $45.6 million for the six months ended June 30, 2017, which represented an effective tax rate of 37.9% We recorded income tax expense of $50.5 million for the six months ended June 30, 2016, which represented an effective tax rate of 33.4%.

Our effective income tax rate is derived from our full year estimated effective income tax rate and can be impacted by discrete items specific to a particular quarter and quarterly changes in our full year tax provision estimate. On March 31, 2016, we sold our contract therapy businesses. Our tax basis in our contract therapy businesses exceeded our selling price. As a result, we had no tax expense from the sale. Additionally, during the three months ended June 30, 2016, we exchanged five specialty hospitals. Our tax basis in the five specialty hospitals was less than our book basis, resulting in a tax gain exceeding our book gain. The lower effective tax rate for the six months ended June 30, 2016 resulted from the net effects of the two discrete tax events discussed above.

Net Income Attributable to Non-Controlling Interests

Net income attributable to non-controlling interests was $16.8 million for the six months ended June 30, 2017, compared to $12.0 million for the six months ended June 30, 2016. The increase is principally due the minority interest owners’ share of income from Concentra.

45

Liquidity and Capital Resources

Cash Flows for the Six Months Ended June 30, 2017 and Six Months Ended June 30, 2016

In the following, we discuss cash flows from operating activities, investing activities, and financing activities, which, in each case, are the same for Holdings and Select.

	Six Months Ended June 30,
	2016			2017
	(in thousands)
Cash flows provided by operating activities	$	178,238		$	40,340
Cash flows used in investing activities	(432,001		)	(99,132		)
Cash flows provided by financing activities	317,748			33,562
Net increase (decrease) in cash and cash equivalents	63,985			(25,230		)
Cash and cash equivalents at beginning of period	14,435			99,029
Cash and cash equivalents at end of period	$	78,420		$	73,799

Operating activities provided $40.3 million of cash flows for the six months ended June 30, 2017. The decrease in operating cash flows for the six months ended June 30, 2017 compared to the six months ended June 30, 2016 is principally due to increases in our accounts receivable. Our days sales outstanding was 58 days at June 30, 2017, compared to 51 days at both December 31, 2016 and June 30, 2016. Our days sales outstanding will fluctuate based upon variability in our collection cycles. The increase in our days sales outstanding and related decline in our operating cash flows is primarily related to the current underpayments we are receiving through the periodic interim payment program from Medicare in our LTCHs. These underpayments will be corrected in future months as our periodic interim payments are reconciled and reset by our fiscal intermediaries.

Investing activities used $99.1 million for the six months ended June 30, 2017. The principal use of cash was $105.3 million for purchases of property and equipment and $18.5 million for the acquisition of businesses, offset in part by $34.6 million of proceeds from the sale of assets. Investing activities used $432.0 million of cash flows for the six months ended June 30, 2016, principally due to the acquisition of Physiotherapy.

Financing activities provided $33.6 million of cash flows for the six months ended June 30, 2017. The principal source of cash was $80.0 million of net borrowings under the Select revolving facility, offset in part by $23.1 million of cash used for a principal prepayment associated with the Concentra credit facilities, $2.9 million of cash used for a term loan payment associated with the Select credit facilities, and cash used for the payment of financing costs related to the refinancing of the Select credit facilities.

Financing activities provided $317.7 million of cash flows for the six months ended June 30, 2016. The principal source of cash was the issuance of $625.0 million of series F tranche B term loans, resulting in net proceeds of $600.1 million, offset by $215.7 million of cash used to repay the series D tranche B term loans and $60.0 million of net repayments under the Select revolving facility.

Capital Resources

Working capital.  We had net working capital of $302.4 million at June 30, 2017, compared to $191.3 million at December 31, 2016. The increase in net working capital is primarily due to an increase in our accounts receivable.

Select credit facilities.  On March 6, 2017, Select entered into a new senior secured credit agreement that provides for $1.6 billion in senior secured credit facilities comprising a $1.15 billion, seven-year term loan and a $450.0 million, five-year revolving credit facility, including a $75.0 million sublimit for the issuance of standby letters of credit.  Select used borrowings under the Select credit facilities to: (i) repay the series E tranche B term loans due June 1, 2018, the series F tranche B term loans due March 31, 2021, and the revolving facility maturing March 1, 2018 under its then existing credit facilities; and (ii) pay fees and expenses in connection with the refinancing.

46

Borrowings under the Select credit facilities bear interest at a rate equal to: (i) in the case of the Select term loan, Adjusted LIBO (as defined in the Select credit agreement) plus 3.50% (subject to an Adjusted LIBO floor of 1.00%), or Alternate Base Rate (as defined in the Select credit agreement) plus 2.50% (subject to an Alternate Base Rate floor of 2.00%); and (ii) in the case of the Select revolving facility, Adjusted LIBO plus a percentage ranging from 3.00% to 3.25% or Alternate Base Rate plus a percentage ranging from 2.00% to 2.25%, in each case based on Select’s leverage ratio.

The Select term loan amortizes in equal quarterly installments in amounts equal to 0.25% of the aggregate original principal amount of the Select term loan commencing on June 30, 2017. The balance of the Select term loan will be payable on March 8, 2024; however, if the Select 6.375% senior notes, which are due June 1, 2021, are outstanding on March 1, 2021, the maturity date for the Select term loan will become March 1, 2021. The Select revolving facility will be payable on March 8, 2022; however, if the Select 6.375% senior notes are outstanding on February 1, 2021, the maturity date for the Select revolving facility will become February 1, 2021.

Select will be required to prepay borrowings under the Select credit facilities with (i) 100% of the net cash proceeds received from non-ordinary course asset sales or other dispositions, or as a result of a casualty or condemnation, subject to reinvestment provisions and other customary carveouts and, to the extent required, the payment of certain indebtedness secured by liens having priority over the debt under the Select credit facilities or subject to a first lien intercreditor agreement, (ii) 100% of the net cash proceeds received from the issuance of debt obligations other than certain permitted debt obligations, and (ii) 50% of excess cash flow (as defined in the Select credit agreement) if Select’s leverage ratio is greater than 4.50 to 1.00 and 25% of excess cash flow if Select’s leverage ratio is less than or equal to 4.50 to 1.00 and greater than 4.00 to 1.00, in each case, reduced by the aggregate amount of term loans, revolving loans and certain other debt optionally prepaid during the applicable fiscal year. Select will not be required to prepay borrowings with excess cash flow if Select’s leverage ratio is less than or equal to 4.00 to 1.00.

The Select revolving facility requires Select to maintain a leverage ratio (as defined in the Select credit agreement), which is tested quarterly, not to exceed 6.25 to 1.00. After March 31, 2019, the leverage ratio must not exceed 6.00 to 1.00.  Failure to comply with this covenant would result in an event of default under the Select revolving facility and, absent a waiver or an amendment from the revolving lenders, preclude Select from making further borrowings under the Select revolving facility and permit the revolving lenders to accelerate all outstanding borrowings under the Select revolving facility. The termination of the Select revolving facility commitments and the acceleration of amounts outstanding thereunder would constitute an event of default with respect to the Select term loan. As of June 30, 2017, Select’s leverage ratio was 5.86 to 1.00.

The Select credit facilities also contain a number of other affirmative and restrictive covenants, including limitations on mergers, consolidations and dissolutions; sales of assets; investments and acquisitions; indebtedness; liens; affiliate transactions; and dividends and restricted payments. The Select credit facilities contain events of default for non-payment of principal and interest when due (subject, as to interest, to a grace period), cross-default and cross-acceleration provisions and an event of default that would be triggered by a change of control.

Borrowings under the Select credit facilities are guaranteed by Holdings and substantially all of Select’s current domestic subsidiaries and will be guaranteed by substantially all of Select’s future domestic subsidiaries and secured by substantially all of Select’s existing and future property and assets and by a pledge of Select’s capital stock, the capital stock of Select’s domestic subsidiaries and up to 65% of the capital stock of Select’s foreign subsidiaries held directly by Select or a domestic subsidiary.

At June 30, 2017, Select had outstanding borrowings under the Select credit facilities consisting of a $1,147.1 million Select term loan (excluding unamortized discounts and debt issuance costs of $27.0 million) and borrowings of $300.0 million (excluding letters of credit) under the Select revolving facility. At June 30, 2017, Select had $111.4 million of availability under the Select revolving facility after giving effect to $38.6 million of outstanding letters of credit.

Concentra credit facilities.  Select and Holdings are not parties to the Concentra credit facilities and are not obligors with respect to Concentra’s debt under such agreements. While this debt is non-recourse to Select, it is included in Select’s consolidated financial statements.

On March 1, 2017, Concentra made a principal prepayment of $23.1 million associated with its first lien term loans in accordance with the provision in the Concentra credit facilities that requires mandatory prepayments of term loans as a result of annual excess cash flow, as defined in the Concentra credit facilities.

47

At June 30, 2017, Concentra had outstanding borrowings under the Concentra credit facilities of $619.2 million of first lien term loans (excluding unamortized discounts and debt issuance costs of $14.4 million) and no borrowings under the Concentra revolving facility. At June 30 2017, Concentra had $43.4 million of availability under its revolving facility after giving effect to $6.6 million of outstanding letters of credit.

Stock Repurchase Program.  Holdings’ board of directors has authorized a common stock repurchase program to repurchase up to $500.0 million worth of shares of its common stock. The program has been extended until December 31, 2018, and will remain in effect until then, unless further extended or earlier terminated by the board of directors. Stock repurchases under this program may be made in the open market or through privately negotiated transactions, and at times and in such amounts as Holdings deems appropriate. Holdings funds this program with cash on hand and borrowings under the Select revolving facility. Holdings did not repurchase shares during the three months ended June 30, 2017. Since the inception of the program through June 30, 2017, Holdings has repurchased 35,924,128 shares at a cost of approximately $314.7 million, or $8.76 per share, which includes transaction costs.

Liquidity.  We believe our internally generated cash flows and borrowing capacity under the Select and Concentra credit facilities will be sufficient to finance operations over the next twelve months. We may from time to time seek to retire or purchase our outstanding debt through cash purchases and/or exchanges for equity securities, in open market purchases, privately negotiated transactions, tender offers or otherwise. Such repurchases or exchanges, if any, may be funded from operating cash flows or other sources and will depend on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors. The amounts involved may be material.

Use of Capital Resources.  We may from time to time pursue opportunities to develop new joint venture relationships with significant health systems and other healthcare providers, and from time to time we may also develop new inpatient rehabilitation hospitals and occupational medicine centers. We also intend to open new outpatient rehabilitation clinics in local areas that we currently serve where we can benefit from existing referral relationships and brand awareness to produce incremental growth. In addition to our development activities, we may grow through opportunistic acquisitions.

Recent Accounting Pronouncements

In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805), Clarifying the Definition of a Business, which clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. ASU 2017-01 states that if substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the transaction should be accounted for as an asset acquisition. In addition, the ASU clarifies the requirements for a set of activities to be considered a business and narrows the definition of an output. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill and consolidation. ASU 2017-01 is effective for annual periods beginning after December 15, 2017. Early adoption is permitted.

In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740), Intra-Entity Transfers of Assets Other Than Inventory. Current GAAP prohibits the recognition of current and deferred income taxes for an intra-entity asset transfer until the asset has been sold to an outside party. The ASU requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The standard will be effective for fiscal years beginning after December 15, 2017. The Company plans to adopt the guidance effective January 1, 2018. Adoption of the guidance will be applied on a modified retrospective approach through a cumulative effect adjustment to retained earnings as of the effective date.

In February 2016, the FASB issued ASU 2016-02, Leases. This ASU includes a lessee accounting model that recognizes two types of leases; finance and operating. This ASU requires that a lessee recognize on the balance sheet assets and liabilities for all leases with lease terms of more than twelve months. Lessees will need to recognize almost all leases on the balance sheet as a right-of-use asset and a lease liability. For income statement purposes, the FASB retained the dual model, requiring leases to be classified as either operating or finance. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee will depend on its classification as a finance or operating lease. For short-term leases of twelve months or less, lessees are permitted to make an accounting election by class of underlying asset not to recognize right-of-use assets or lease liabilities. If the alternative is elected, lease expense would be recognized generally on the straight-line basis over the respective lease term.

48

The amendments in ASU 2016-02 will take effect for public companies for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Earlier application is permitted as of the beginning of an interim or annual reporting period. A modified retrospective approach is required for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements.

Upon adoption, the Company will recognize significant assets and liabilities on the consolidated balance sheets as a result of the operating lease obligations of the Company. Operating lease expense will still be recognized as rent expense on a straight-line basis over the respective lease terms in the consolidated statements of operations.

The Company will implement the new standard beginning January 1, 2019. The Company’s implementation efforts are focused on designing accounting processes, disclosure processes, and internal controls in order to account for its leases under the new standard.

In May 2014, March 2016, April 2016, and December 2016, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, ASU 2016-08, Revenue from Contracts with Customers, Principal versus Agent Considerations, ASU 2016-10, Revenue from Contracts with Customers, Identifying Performance Obligations and Licensing, ASU 2016-12, Revenue from Contracts with Customers, Narrow Scope Improvements and Practical Expedients, and ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customer (collectively “the standards”), respectively, which supersede most of the current revenue recognition requirements. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. The standards require the selection of a retrospective or cumulative effect transition method.

The Company will implement the new standard beginning January 1, 2018 using the retrospective transition method.  Adoption of the new standard will result in material changes to the presentation of net operating revenues and bad debt expense in the consolidated statements of operations, but the presentation of the amount of income from operations and net income will be unchanged upon adoption of the new standards. The principal change is how the new standard requires healthcare providers to estimate the amount of variable consideration to be included in the transaction price up to an amount which is probable that a significant reversal will not occur. The most common form of variable consideration the Company experiences are amounts for services provided that are ultimately not realizable from a customer. Under the current standards, the Company’s estimate for unrealizable amounts was recorded to bad debt expense. Under the new standards, the Company’s estimate for unrealizable amounts will be recognized as a constraint to revenue and will be reflected as an allowance. Substantially all of the bad debt expense as of June 30, 2016 and June 30, 2017 will be reclassified as an allowance when the Company retrospectively applies the guidance in the standards on January 1, 2018.

The Company’s remaining implementation efforts are focused principally on refining the accounting processes, disclosure processes, and internal controls.

Recently Adopted Accounting Pronouncements

In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes, which changed the presentation of deferred income taxes. The standard changed the presentation of deferred income taxes through the requirement that all deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The Company adopted the standard on January 1, 2017. The consolidated balance sheet at December 31, 2016 has been retrospectively adjusted. Adoption of the new standard impacted the Company’s previously reported results as follows:

	December 31, 2016
	As Reported		As Adjusted
	(in thousands)
Current deferred tax asset	$	45,165	$	—
Total current assets	808,068		762,903
Other assets	152,548		173,944
Total assets	4,944,395		4,920,626
Non-current deferred tax liability	222,847		199,078
Total liabilities	3,616,335		3,592,566
Total liabilities and equity	4,944,395		4,920,626

49

ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are subject to interest rate risk in connection with our variable rate long-term indebtedness. Our principal interest rate exposure relates to the loans outstanding under the Select credit facilities and Concentra credit facilities.

As of June 30, 2017, Select had a $1,147.1 million term loan (excluding unamortized discounts and debt issuance costs of $27.0 million) outstanding and $300.0 million in revolving borrowings outstanding under the Select credit facilities, which bear interest at variable rates.

As of June 30, 2017, Concentra had $619.2 million of first lien term loans (excluding unamortized discounts and debt issuance costs of $14.4 million) outstanding under the Concentra credit facilities, which bear interest at variable rates. Concentra did not have any outstanding revolving borrowings at June 30, 2017.

At June 30, 2017, the 3-month LIBOR rate was 1.30%. Consequently, each 0.25% increase in market interest rates will impact the interest expense on Select’s and Concentra’s variable rate debt by $5.2 million per annum.

ITEM 4.  CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934) as of the end of the period covered in this report. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures, including the accumulation and communication of disclosure to our principal executive officer and principal financial officer as appropriate to allow timely decisions regarding disclosure, are effective as of June 30, 2017 to provide reasonable assurance that material information required to be included in our periodic SEC reports is recorded, processed, summarized, and reported within the time periods specified in the relevant SEC rules and forms.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Securities Exchange Act of 1934) identified in connection with the evaluation required by Rule 13a-15(d) of the Securities Exchange Act of 1934 that occurred during the second quarter ended June 30, 2017 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system will be met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events. Because of these and other inherent limitations of control systems, there is only reasonable assurance that our controls will succeed in achieving their goals under all potential future conditions.

50

PART IIOTHER INFORMATION

ITEM 1.LEGAL PROCEEDINGS

The Company is a party to various legal actions, proceedings, and claims (some of which are not insured), and regulatory and other governmental audits and investigations in the ordinary course of its business. The Company cannot predict the ultimate outcome of pending litigation, proceedings, and regulatory and other governmental audits and investigations. These matters could potentially subject the Company to sanctions, damages, recoupments, fines, and other penalties. The Department of Justice, CMS, or other federal and state enforcement and regulatory agencies may conduct additional investigations related to the Company’s businesses in the future that may, either individually or in the aggregate, have a material adverse effect on the Company’s business, financial position, results of operations, and liquidity.

To address claims arising out of the Company’s operations, the Company maintains professional malpractice liability insurance and general liability insurance, subject to self-insured retention of $2.0 million per medical incident for professional liability claims and $2.0 million per occurrence for general liability claims. The Company also maintains umbrella liability insurance covering claims which, due to their nature or amount, are not covered by or not fully covered by the Company’s other insurance policies. These insurance policies also do not generally cover punitive damages and are subject to various deductibles and policy limits. Significant legal actions, as well as the cost and possible lack of available insurance, could subject the Company to substantial uninsured liabilities. In the Company’s opinion, the outcome of these actions, individually or in the aggregate, will not have a material adverse effect on its financial position, results of operations or cash flows.

Healthcare providers are subject to lawsuits under the qui tam provisions of the federal False Claims Act. Qui tam lawsuits typically remain under seal (hence, usually unknown to the defendant) for some time while the government decides whether or not to intervene on behalf of a private qui tam plaintiff (known as a relator) and take the lead in the litigation. These lawsuits can involve significant monetary damages and penalties and award bounties to private plaintiffs who successfully bring the suits. The Company is and has been a defendant in these cases in the past, and may be named as a defendant in similar cases from time to time in the future.

Evansville Litigation

On October 19, 2015, the plaintiff-relators filed a Second Amended Complaint in United States of America, ex rel. Tracy Conroy, Pamela Schenk and Lisa Wilson v. Select Medical Corporation, Select Specialty Hospital—Evansville, LLC (“SSH-Evansville”), Select Employment Services, Inc., and Dr. Richard Sloan. The case is a civil action filed in the United States District Court for the Southern District of Indiana by private plaintiff-relators on behalf of the United States under the federal False Claims Act. The plaintiff-relators are the former CEO and two former case managers at SSH-Evansville, and the defendants currently include the Company, SSH-Evansville, a subsidiary of the Company serving as common paymaster for its employees, and a physician who practices at SSH-Evansville. The plaintiff-relators allege that SSH-Evansville discharged patients too early or held patients too long, improperly discharged patients to and readmitted them from short stay hospitals, up-coded diagnoses at admission, and admitted patients for whom long-term acute care was not medically necessary. They also allege that the defendants engaged in retaliation in violation of federal and state law. The Second Amended Complaint replaced a prior complaint that was filed under seal on September 28, 2012 and served on the Company on February 15, 2013, after a federal magistrate judge unsealed it on January 8, 2013. All deadlines in the case had been stayed after the seal was lifted in order to allow the government time to complete its investigation and to decide whether or not to intervene. On June 19, 2015, the United States Department of Justice notified the District Court of its decision not to intervene in the case.

In December 2015, the defendants filed a Motion to Dismiss the Second Amended Complaint on multiple grounds, including that the action is disallowed by the False Claims Act’s public disclosure bar, which disqualifies qui tam actions that are based on fraud already publicly disclosed through enumerated sources, unless the relator is an original source, and that the plaintiff-relators did not plead their claims with sufficient particularity, as required by the Federal Rules of Civil Procedure.

Thereafter, the United States filed a notice asserting a veto of the defendants’ use of the public disclosure bar for claims arising from conduct from and after March 23, 2010, which was based on certain statutory changes to the public disclosure bar language included in the Affordable Care Act. On September 30, 2016, the District Court partially granted and partially denied the defendants’ Motion to Dismiss. It ruled that the plaintiff-relators alleged substantially the same conduct as had been publicly disclosed and that the plaintiff relators are not original sources, so that the public disclosure bar requires dismissal of all non-retaliation claims arising from conduct before March 23, 2010. The District Court also ruled that the statutory changes to the public disclosure bar gave the United States the power to veto its applicability to claims arising from conduct on and after March 23, 2010, and therefore did not dismiss those claims based on the public disclosure bar. However,

51

the District Court ruled that the plaintiff-relators did not plead certain of their claims relating to interrupted stay manipulation and premature discharging of patients with the requisite particularity, and dismissed those claims. The District Court declined to dismiss the plaintiff relators’ claims arising from conduct from and after March 23, 2010 relating to delayed discharging of patients and up-coding and the plaintiff relators’ retaliation claims. The plaintiff-relators then proposed a case management plan seeking nationwide discovery involving all of the Company’s LTCHs for the period from March 23, 2010 through the present, which the defendants have opposed. The Company intends to vigorously defend this action, but at this time the Company is unable to predict the timing and outcome of this matter.

Knoxville Litigation

On July 13, 2015, the United States District Court for the Eastern District of Tennessee unsealed a qui tam Complaint in Armes v. Garman, et al, No. 3:14-cv-00172-TAV-CCS, which named as defendants Select, Select Specialty Hospital—Knoxville, Inc. (“SSH-Knoxville”), Select Specialty Hospital—North Knoxville, Inc. and ten current or former employees of these facilities. The Complaint was unsealed after the United States and the State of Tennessee notified the court on July 13, 2015 that each had decided not to intervene in the case. The Complaint is a civil action that was filed under seal on April 29, 2014 by a respiratory therapist formerly employed at SSH-Knoxville. The Complaint alleges violations of the federal False Claims Act and the Tennessee Medicaid False Claims Act based on extending patient stays to increase reimbursement and to increase average length of stay; artificially prolonging the lives of patients to increase Medicare reimbursements and decrease inspections; admitting patients who do not require medically necessary care; performing unnecessary procedures and services; and delaying performance of procedures to increase billing. The Complaint was served on some of the defendants during October 2015.

In November 2015, the defendants filed a Motion to Dismiss the Complaint on multiple grounds. The defendants first argued that False Claims Act’s first-to-file bar required dismissal of plaintiff-relator’s claims. Under the first-to-file bar, if a qui tam case is pending, no person may bring a related action based on the facts underlying the first action. The defendants asserted that the plaintiff-relator’s claims were based on the same underlying facts as were asserted in the Evansville litigation, discussed above. The defendants also argued that the plaintiff-relator’s claims must be dismissed under the public disclosure bar, and because the plaintiff-relator did not plead his claims with sufficient particularity.

In June 2016, the District Court granted the defendants’ Motion to Dismiss and dismissed with prejudice the plaintiff-relator’s lawsuit in its entirety. The District Court ruled that the first-to-file bar precludes all but one of the plaintiff-relator’s claims, and that the remaining claim must also be dismissed because the plaintiff-relator failed to plead it with sufficient particularity. In July 2016, the plaintiff-relator filed a Notice of Appeal to the United States Court of Appeals for the Sixth Circuit. Then, on October 11, 2016, the plaintiff-relator filed a Motion to Remand the case to the District Court for further proceedings, arguing that the September 30, 2016 decision in the Evansville litigation, discussed above, undermines the basis for the District Court’s dismissal. After the Court of Appeals denied the Motion to Remand, the plaintiff-relator then sought an indicative ruling from the District Court that it would vacate its prior dismissal ruling and allow plaintiff-relator to supplement his Complaint, which the defendants have opposed. The case has been fully briefed in the Court of Appeals. The Company intends to vigorously defend this action, but at this time the Company is unable to predict the timing and outcome of this matter.

Wilmington Litigation

On January 19, 2017, the United States District Court for the District of Delaware unsealed a qui tam Complaint in United States of America and State of Delaware ex rel. Theresa Kelly v. Select Specialty Hospital—Wilmington, Inc. (“SSH-Wilmington”), Select Specialty Hospitals, Inc., Select Employment Services, Inc., Select Medical Corporation, and Crystal Cheek, No. 16-347-LPS. The Complaint was initially filed under seal on May 12, 2016 by a former chief nursing officer at SSH-Wilmington and was unsealed after the United States filed a Notice of Election to Decline Intervention on January 13, 2017. The corporate defendants were served on March 6, 2017. In the complaint, the plaintiff-relator alleges that the Select defendants and an individual defendant, who is a former health information manager at SSH-Wilmington, violated the False Claims Act and the Delaware False Claims and Reporting Act based on allegedly falsifying medical practitioner signatures on medical records and failing to properly examine the credentials of medical practitioners at SSH-Wilmington. In response to the Select defendants’ motion to dismiss the Complaint, on May 17, 2017 the plaintiff-relator filed an Amended Complaint asserting the same causes of action. The Select defendants filed a Motion to Dismiss the Amended Complaint, which is now pending, based on numerous grounds, including that the Amended Complaint did not plead any alleged fraud with sufficient particularity, failed to plead that the alleged fraud was material to the government’s payment decision, failed to plead sufficient facts to establish that the Select defendants knowingly submitted false claims or records, and failed to allege any reverse false claim.

52

On March 24, 2017, the plaintiff-relator initiated a second action by filing a Complaint in the Superior Court of the State of Delaware in Theresa Kelly v. Select Medical Corporation, Select Employment Services, Inc., and SSH-Wilmington, C.A. No. N17C-03-293 CLS. The Delaware Complaint alleges that the defendants retaliated against her in violation of the Delaware Whistleblowers’ Protection Act for reporting the same alleged violations that are the subject of the federal Amended Complaint. The defendants filed a motion to dismiss, or alternatively to stay, the Delaware Complaint based on the pending federal Amended Complaint and the failure to allege facts to support a violation of the Delaware Whistleblowers’ Protection Act.  The motion is currently pending.

The Company intends to vigorously defend these actions, but at this time the Company is unable to predict the timing and outcome of this matter.

Contract Therapy Subpoena

On May 18, 2017, the Company received a subpoena from the U.S. Attorney’s Office for the District of New Jersey seeking various documents principally relating to the Company’s contract therapy division, which contracted to furnish rehabilitation therapy services to residents of skilled nursing facilities (“SNFs”) and other providers. The Company operated its contract therapy division through a subsidiary until March 31, 2016, when the Company sold the stock of the subsidiary. The subpoena seeks documents that appear to be aimed at assessing whether therapy services were furnished and billed in compliance with Medicare SNF billing requirements, including whether therapy services were coded at inappropriate levels and whether excessive or unnecessary therapy was furnished to justify coding at higher paying levels. The Company does not know whether the subpoena has been issued in connection with a qui tam lawsuit or in connection with possible civil, criminal or administrative proceedings by the government. The Company is producing documents in response to the subpoena and intends to fully cooperate with this investigation. At this time, the Company is unable to predict the timing and outcome of this matter.

ITEM 1A. RISK FACTORS

There have been no material changes from our risk factors as previously reported in our Annual Report on Form 10-K for the year ended December 31, 2016.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Purchases of Equity Securities by the Issuer

Holdings’ board of directors has authorized a common stock repurchase program to repurchase up to $500.0 million worth of shares of its common stock. The program has been extended until December 31, 2018 and will remain in effect until then, unless further extended or earlier terminated by the board of directors. Stock repurchases under this program may be made in the open market or through privately negotiated transactions, and at times and in such amounts as Holdings deems appropriate. Holdings did not repurchase shares during the three months ended June 30, 2017 under the authorized common stock repurchase program.

The following table provides information regarding repurchases of our common stock during the three months ended June 30, 2017. The shares repurchased during the three months ended June 30, 2017 relate entirely to shares of common stock surrendered to us to satisfy tax withholding obligations associated with the vesting of restricted shares issued to employees, pursuant to the provisions of our equity incentive plans.

	Total Number of Shares Purchased	Average Price Paid Per Share		Total Number of Shares Purchased as Part of Publically Announced Plans or Programs	Approximate Dollar Value of Shares that May Yet Be Purchased Under Plans or Programs
April 1 - April 30, 2017	3,209	$	13.75	—	$	185,249,408
May 1 - May 31, 2017	29,165	13.70		—	185,249,408
June 1 - June 30, 2017	—	—		—	185,249,408
Total	32,374	$	13.70	—	$	185,249,408

53

ITEM 3.DEFAULTS UPON SENIOR SECURITIES

Not applicable

ITEM 4.MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5.OTHER INFORMATION

In light of the results of the advisory vote on the frequency of Say-On-Pay votes at our annual meeting of stockholders on May 2, 2017, our Board of Directors determined that the Company will continue to hold an advisory Say-on-Pay vote annually. Our Board of Directors will re-evaluate this determination no later than the next stockholder vote on the frequency of Say-on-Pay votes.

ITEM 6.EXHIBITS

The exhibits to this report are listed in the Exhibit Index appearing on page 56 hereof.

54

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrants have duly caused this Report to be signed on their behalf by the undersigned, thereunto duly authorized.

	SELECT MEDICAL CORPORATION
	By:	/s/	Martin F. Jackson
			Martin F. Jackson
		Executive Vice President and Chief Financial Officer
		(Duly Authorized Officer)
	By:	/s/	Scott A. Romberger
			Scott A. Romberger
		Senior Vice President, Chief Accounting Officer and Controller
		(Principal Accounting Officer)
Dated: August 3, 2017
	SELECT MEDICAL HOLDINGS CORPORATION
	By:	/s/	Martin F. Jackson
			Martin F. Jackson
		Executive Vice President and Chief Financial Officer
		(Duly Authorized Officer)
	By:	/s/	Scott A. Romberger
			Scott A. Romberger
		Senior Vice President, Chief Accounting Officer and Controller
		(Principal Accounting Officer)
Dated: August 3, 2017

55

EXHIBIT INDEX

Number	Description
10.1	Second Amendment to Lease Agreement, dated as of May 30, 2017, between Old Gettysburg Associates and Select Medical Corporation (Reg. Nos. 001-34465 and 001-31441).
31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Executive Vice President and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Chief Executive Officer, and Executive Vice President and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101	The following financial information from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2017 formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2016 and 2017, (ii) Condensed Consolidated Balance Sheets as of June 30, 2017 and December 31, 2016, (iii) Condensed Consolidated Statements of Cash Flows for the three and six months ended June 30, 2016 and 2017, (iv) Condensed Consolidated Statements of Changes in Equity and Income for the six months ended June 30, 2017 and (v) Notes to Condensed Consolidated Financial Statements.

56

EX-10.1

Exhibit 10.1

Executive Park West I

4718 Gettysburg Road

Mechanicsburg, PA 17055

Second Amendment to Lease Agreement

This Second Amendment is made as of this 30th day of May, 2017 by and between OLD GETTYSBURG ASSOCIATES, a Pennsylvania general partnership (“Landlord”), and SELECT MEDICAL CORPORATION, a Delaware corporation (“Tenant”).

BACKGROUND:

A.Landlord and Tenant are parties to that certain Office Lease Agreement dated November 1, 2012 with an effective Commencement date of January 1, 2013 thereto, pursuant to which Landlord leased to Tenant, and Tenant leased from Landlord, approximately 30,225 rentable square feet (“RSF”) of space consisting of the entire third floor, and Suites 101, 102, 103, 104, 201, 202, 203, 204 and 402, in the building located at 4718 Gettysburg Road, Mechanicsburg, Pennsylvania (the “Building”).  All capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Lease.

B.Landlord and Tenant are parties to that certain First Amendment to Lease Agreement dated as of November 15, 2016, pursuant to which Landlord leased to Tenant, and Tenant leased from Landlord, approximately 3,839 RSF of space on the fourth floor of the Building known as Suite 405.

C.Landlord and Tenant now desire to amend the Lease as hereinafter set forth.

NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein, and intending to be legally bound hereby, Landlord and Tenant agree as follows:

Effective on May 8, 2017, the following terms contained in the Basic Lease shall be amended as follows:

1.Landlord and Tenant hereby agree that Tenant shall add to the Master Lease and occupy an additional 2,562 RSF of space known as Suite 401.

2.The first month’s rent for this space will commence as of May 8, 2017 and will expire on December 31, 2022.

3.The rental rate for Suite 401 shall be the same as the rental rate for the Master Lease.

4.All of the Lease terms and conditions of the existing Master Lease shall be applicable to Suite 401.

All other terms and conditions contained in the Lease and not amended hereby remain in full force and effect.

Landlord and Tenant have caused this Second Amendment to be duly executed.

Landlord: OLD GETTYSBURG ASSOCIATES
By:	/s/ John M. Ortenzio
		John M. Ortenzio, President, Select Capital Commercial Properties, Inc. as Property Manager
Tenant: SELECT MEDICAL CORPORATION
By:	/s/ Michael E. Tarvin
		Michael E. Tarvin, Executive Vice President, General Counsel & Secretary

EX-31.1

EXHIBIT 31.1

SELECT MEDICAL HOLDINGS CORPORATION AND
SELECT MEDICAL CORPORATION
CERTIFICATIONS PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002

CERTIFICATION

I, David S. Chernow, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Select Medical Holdings Corporation and Select Medical Corporation;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 3, 2017	/s/ David S. Chernow
	David S. Chernow
	President and Chief Executive Officer

EX-31.2

EXHIBIT 31.2

SELECT MEDICAL HOLDINGS CORPORATION AND
SELECT MEDICAL CORPORATION
CERTIFICATIONS PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002

CERTIFICATION

I, Martin F. Jackson, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Select Medical Holdings Corporation and Select Medical Corporation;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 3, 2017	/s/ Martin F. Jackson
	Martin F. Jackson
	Executive Vice President and Chief Financial Officer

EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Select Medical Holdings Corporation and Select Medical Corporation (the “Company”) for the period ended June 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, David S. Chernow and Martin F. Jackson, Chief Executive Officer and Chief Financial Officer, respectively, of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to our knowledge:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.

August 3, 2017

/s/ David S. Chernow

David S. Chernow

President and Chief Executive Officer

/s/ Martin F. Jackson

Martin F. Jackson

Executive Vice President and Chief Financial Officer

XML

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Jul. 31, 2017
Document and Entity Information
Entity Registrant Name	SELECT MEDICAL HOLDINGS CORP
Entity Central Index Key	0001320414
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		132,936,770
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q2

XML

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current Assets:
Cash and cash equivalents	$ 73,799	$ 99,029
Accounts receivable, net of allowance for doubtful accounts of $63,787 and $67,769 at 2016 and 2017, respectively	714,236	573,752
Prepaid income taxes		12,423
Other current assets	83,211	77,699
Total Current Assets	871,246	762,903
Property and equipment, net	911,532	892,217
Goodwill	2,766,296	2,751,000
Identifiable intangible assets, net	335,704	340,562
Other assets	169,433	173,944
Total Assets	5,054,211	4,920,626
Current Liabilities:
Bank overdrafts	34,134	39,362
Current portion of long-term debt and notes payable	26,577	13,656
Accounts payable	123,631	126,558
Accrued payroll	119,187	146,397
Accrued vacation	92,250	83,261
Accrued interest	19,277	22,325
Accrued other	146,853	140,076
Income taxes payable	6,976
Total Current Liabilities	568,885	571,635
Long-term debt, net of current portion	2,734,132	2,685,333
Non-current deferred tax liability	197,411	199,078
Other non-current liabilities	141,279	136,520
Total Liabilities	3,641,707	3,592,566
Commitments and contingencies (Note 8)
Redeemable non-controlling interests	468,850	422,159
Stockholders' Equity:
Common stock	133	132
Capital in excess of par	454,892	443,908
Retained earnings (accumulated deficit)	393,294	371,685
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	848,319	815,725
Non-controlling interest	95,335	90,176
Total Equity	943,654	905,901
Total Liabilities and Equity	5,054,211	4,920,626
Select Medical Corporation
Current Assets:
Cash and cash equivalents	73,799	99,029
Accounts receivable, net of allowance for doubtful accounts of $63,787 and $67,769 at 2016 and 2017, respectively	714,236	573,752
Prepaid income taxes		12,423
Other current assets	83,211	77,699
Total Current Assets	871,246	762,903
Property and equipment, net	911,532	892,217
Goodwill	2,766,296	2,751,000
Identifiable intangible assets, net	335,704	340,562
Other assets	169,433	173,944
Total Assets	5,054,211	4,920,626
Current Liabilities:
Bank overdrafts	34,134	39,362
Current portion of long-term debt and notes payable	26,577	13,656
Accounts payable	123,631	126,558
Accrued payroll	119,187	146,397
Accrued vacation	92,250	83,261
Accrued interest	19,277	22,325
Accrued other	146,853	140,076
Income taxes payable	6,976
Total Current Liabilities	568,885	571,635
Long-term debt, net of current portion	2,734,132	2,685,333
Non-current deferred tax liability	197,411	199,078
Other non-current liabilities	141,279	136,520
Total Liabilities	3,641,707	3,592,566
Commitments and contingencies (Note 8)
Redeemable non-controlling interests	468,850	422,159
Stockholders' Equity:
Common stock	0	0
Capital in excess of par	936,428	925,111
Retained earnings (accumulated deficit)	(88,109)	(109,386)
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	848,319	815,725
Non-controlling interest	95,335	90,176
Total Equity	943,654	905,901
Total Liabilities and Equity	$ 5,054,211	$ 4,920,626

XML

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Accounts receivable, allowance for doubtful accounts (in dollars)	$ 67,769	$ 63,787
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	700,000,000	700,000,000
Common stock, shares issued	132,929,545	132,596,758
Common stock, shares outstanding	132,929,545	132,596,758
Select Medical Corporation
Accounts receivable, allowance for doubtful accounts (in dollars)	$ 67,769	$ 63,787
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares issued	100	100
Common stock, shares outstanding	100	100

XML

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Net operating revenues	$ 1,120,675	$ 1,097,631	$ 2,232,036	$ 2,185,961
Costs and expenses:
Cost of services	920,230	916,985	1,848,587	1,839,247
General and administrative	28,275	25,870	56,350	54,138
Bad debt expense	18,174	17,517	38,799	33,914
Depreciation and amortization	38,333	36,205	80,872	70,722
Total costs and expenses	1,005,012	996,577	2,024,608	1,998,021
Income from operations	115,663	101,054	207,428	187,940
Other income and expense:
Loss on early retirement of debt			(19,719)	(773)
Equity in earnings of unconsolidated subsidiaries	5,666	4,546	11,187	9,198
Non-operating gain (loss)		13,035	(49)	38,122
Interest expense	(37,655)	(44,332)	(78,508)	(83,180)
Income before income taxes	83,674	74,303	120,339	151,307
Income tax expense	32,374	33,450	45,576	50,510
Net income	51,300	40,853	74,763	100,797
Less: Net income attributable to non-controlling interests	9,245	6,918	16,838	12,029
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	$ 42,055	$ 33,935	$ 57,925	$ 88,768
Basic (in dollars per share)	$ 0.32	$ 0.26	$ 0.44	$ 0.68
Diluted (in dollars per share)	$ 0.32	$ 0.26	$ 0.44	$ 0.68
Weighted average shares outstanding:
Basic (in shares)	128,624	127,626	128,544	127,563
Diluted (in shares)	128,777	127,820	128,703	127,709
Select Medical Corporation
Net operating revenues	$ 1,120,675	$ 1,097,631	$ 2,232,036	$ 2,185,961
Costs and expenses:
Cost of services	920,230	916,985	1,848,587	1,839,247
General and administrative	28,275	25,870	56,350	54,138
Bad debt expense	18,174	17,517	38,799	33,914
Depreciation and amortization	38,333	36,205	80,872	70,722
Total costs and expenses	1,005,012	996,577	2,024,608	1,998,021
Income from operations	115,663	101,054	207,428	187,940
Other income and expense:
Loss on early retirement of debt			(19,719)	(773)
Equity in earnings of unconsolidated subsidiaries	5,666	4,546	11,187	9,198
Non-operating gain (loss)		13,035	(49)	38,122
Interest expense	(37,655)	(44,332)	(78,508)	(83,180)
Income before income taxes	83,674	74,303	120,339	151,307
Income tax expense	32,374	33,450	45,576	50,510
Net income	51,300	40,853	74,763	100,797
Less: Net income attributable to non-controlling interests	9,245	6,918	16,838	12,029
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	$ 42,055	$ 33,935	$ 57,925	$ 88,768

XML

Condensed Consolidated Statements of Changes in Equity and Income - 6 months ended Jun. 30, 2017 - USD ($) $ in Thousands	Total Stockholders' Equity Select Medical Corporation	Total Stockholders' Equity	Common Stock Select Medical Corporation	Common Stock	Capital in Excess of Par Select Medical Corporation	Capital in Excess of Par	Retained Earnings Select Medical Corporation	Retained Earnings	Non-controlling Interests Select Medical Corporation	Non-controlling Interests	Select Medical Corporation	Total
Balance at Dec. 31, 2016	$ 815,725	$ 815,725	$ 0	$ 132	$ 925,111	$ 443,908	$ (109,386)	$ 371,685	$ 90,176	$ 90,176	$ 905,901	$ 905,901
Balance (in shares) at Dec. 31, 2016			0	132,597,000							100	132,596,758
Increase (Decrease) in Stockholders' Equity
Net income attributable to Select Medical Holdings Corporation	57,925	57,925					57,925	57,925			$ 57,925	$ 57,925
Net income attributable to non-controlling interests									3,698	3,698	3,698	3,698
Issuance and vesting of restricted stock		8,701		$ 1		8,700						8,701
Issuance and vesting of restricted stock (in shares)				268,000
Additional investment by Holdings	963				963						963
Repurchase of common shares		(600)		$ 0		(332)		(268)				(600)
Repurchase of common shares (in shares)				(45,000)
Dividends declared and paid to Holdings	(600)						(600)				(600)
Contribution related to restricted stock awards and stock option issuances by Holdings	8,701				8,701						8,701
Exercise of stock options		963		$ 0		963						963
Exercise of stock options (in shares)				109,000
Issuance of non-controlling interests	1,653	1,653			1,653	1,653			3,634	3,634	5,287	5,287
Purchase of non-controlling interests	7	7					7	7			7	7
Distributions to non-controlling interests									(2,303)	(2,303)	(2,303)	(2,303)
Redemption adjustment on non-controlling interests	(36,292)	(36,292)					(36,292)	(36,292)			(36,292)	(36,292)
Other	237	237					237	237	130	130	367	367
Balance at Jun. 30, 2017	$ 848,319	$ 848,319	$ 0	$ 133	$ 936,428	$ 454,892	$ (88,109)	$ 393,294	$ 95,335	$ 95,335	$ 943,654	$ 943,654
Balance (in shares) at Jun. 30, 2017			0	132,929,000							100	132,929,545
Balance - Redeemable Non-controlling Interests at Dec. 31, 2016											$ 422,159	$ 422,159
Redeemable Non-controlling interests
Net income attributable to redeemable non-controlling interests											13,140	13,140
Purchase of non-controlling interests											(127)	(127)
Distributions to non-controlling interests											(3,113)	(3,113)
Redemption adjustment on non-controlling interests											36,292	36,292
Other											499	499
Balance - Redeemable Non-controlling Interests at Jun. 30, 2017											$ 468,850	$ 468,850

XML

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Operating activities
Net income	$ 74,763	$ 100,797
Adjustments to reconcile net income to net cash provided by operating activities:
Distributions from unconsolidated subsidiaries	10,933	12,039
Depreciation and amortization	80,872	70,722
Provision for bad debts	38,799	33,914
Equity in earnings of unconsolidated subsidiaries	(11,187)	(9,198)
Loss on extinguishment of debt	6,527	773
Gain on sale of assets and businesses	(9,523)	(43,461)
Loss on disposal of assets		55
Impairment of equity investment		5,339
Stock compensation expense	9,270	8,174
Amortization of debt discount, premium and issuance costs	5,974	7,077
Deferred income taxes	(1,474)	(13,286)
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	(179,003)	(44,096)
Other current assets	(5,557)	11,011
Other assets	4,621	4,508
Accounts payable	759	(15,852)
Accrued expenses	(4,833)	20,632
Income taxes	19,399	29,090
Net cash provided by operating activities	40,340	178,238
Investing activities
Acquisition of businesses, net of cash acquired	(18,508)	(421,519)
Purchases of property and equipment	(105,302)	(80,258)
Investment in businesses	(9,874)	(1,590)
Proceeds from sale of assets and businesses	34,552	71,366
Net cash used in investing activities	(99,132)	(432,001)
Financing activities
Borrowings on revolving facilities	630,000	320,000
Payments on revolving facilities	(550,000)	(380,000)
Proceeds from term loans	1,139,487	600,127
Payments on term loans	(1,173,692)	(229,649)
Revolving facility debt issuance costs	(4,392)
Borrowings of other debt	9,444	22,082
Principal payments on other debt	(10,437)	(9,926)
Repayments of bank overdrafts	(5,228)	(2,138)
Repurchase of common stock	(600)	(506)
Proceeds from exercise of stock options	963	657
Proceeds from issuance of non-controlling interests	3,553	3,103
Purchase of non-controlling interests	(120)	(1,294)
Distributions to non-controlling interests	(5,416)	(4,708)
Net cash provided by financing activities	33,562	317,748
Net increase (decrease) in cash and cash equivalents	(25,230)	63,985
Cash and cash equivalents at beginning of period	99,029	14,435
Cash and cash equivalents at end of period	73,799	78,420
Supplemental Information
Cash paid for interest	76,650	69,315
Cash paid for taxes	27,626	35,518
Select Medical Corporation
Operating activities
Net income	74,763	100,797
Adjustments to reconcile net income to net cash provided by operating activities:
Distributions from unconsolidated subsidiaries	10,933	12,039
Depreciation and amortization	80,872	70,722
Provision for bad debts	38,799	33,914
Equity in earnings of unconsolidated subsidiaries	(11,187)	(9,198)
Loss on extinguishment of debt	6,527	773
Gain on sale of assets and businesses	(9,523)	(43,461)
Loss on disposal of assets		55
Impairment of equity investment		5,339
Stock compensation expense	9,270	8,174
Amortization of debt discount, premium and issuance costs	5,974	7,077
Deferred income taxes	(1,474)	(13,286)
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	(179,003)	(44,096)
Other current assets	(5,557)	11,011
Other assets	4,621	4,508
Accounts payable	759	(15,852)
Accrued expenses	(4,833)	20,632
Income taxes	19,399	29,090
Net cash provided by operating activities	40,340	178,238
Investing activities
Acquisition of businesses, net of cash acquired	(18,508)	(421,519)
Purchases of property and equipment	(105,302)	(80,258)
Investment in businesses	(9,874)	(1,590)
Proceeds from sale of assets and businesses	34,552	71,366
Net cash used in investing activities	(99,132)	(432,001)
Financing activities
Borrowings on revolving facilities	630,000	320,000
Payments on revolving facilities	(550,000)	(380,000)
Proceeds from term loans	1,139,487	600,127
Payments on term loans	(1,173,692)	(229,649)
Revolving facility debt issuance costs	(4,392)
Borrowings of other debt	9,444	22,082
Principal payments on other debt	(10,437)	(9,926)
Repayments of bank overdrafts	(5,228)	(2,138)
Dividends paid to Holdings	(600)	(506)
Equity investment by Holdings	963	657
Proceeds from issuance of non-controlling interests	3,553	3,103
Purchase of non-controlling interests	(120)	(1,294)
Distributions to non-controlling interests	(5,416)	(4,708)
Net cash provided by financing activities	33,562	317,748
Net increase (decrease) in cash and cash equivalents	(25,230)	63,985
Cash and cash equivalents at beginning of period	99,029	14,435
Cash and cash equivalents at end of period	73,799	78,420
Supplemental Information
Cash paid for interest	76,650	69,315
Cash paid for taxes	$ 27,626	$ 35,518

XML

Basis of Presentation

6 Months Ended

Jun. 30, 2017

Basis of Presentation

Basis of Presentation

1. Basis of Presentation

The unaudited condensed consolidated financial statements of Select Medical Holdings Corporation (“Holdings”) include the accounts of its wholly owned subsidiary, Select Medical Corporation (“Select”). Holdings conducts substantially all of its business through Select and its subsidiaries. Holdings and Select and its subsidiaries are collectively referred to as the “Company.” The unaudited condensed consolidated financial statements of the Company as of June 30, 2017, and for the three and six month periods ended June 30, 2016 and 2017, have been prepared pursuant to the rules and regulations of the Securities Exchange Commission (the “SEC”) for interim reporting and accounting principles generally accepted in the United States of America (“GAAP”). Accordingly, certain information and disclosures required by GAAP, which are normally included in the notes to consolidated financial statements, have been condensed or omitted pursuant to those rules and regulations, although the Company believes the disclosure is adequate to make the information presented not misleading. In the opinion of management, such information contains all adjustments, which are normal and recurring in nature, necessary for a fair statement of the financial position, results of operations and cash flow for such periods. All significant intercompany transactions and balances have been eliminated.

The results of operations for the three and six months ended June 30, 2017 are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2017. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2016 contained in the Company’s Annual Report on Form 10-K filed with the SEC on February 23, 2017.

XML

Accounting Policies

6 Months Ended

Jun. 30, 2017

Accounting Policies

Accounting Policies

2. Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingencies, at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Recent Accounting Pronouncements

In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-01, Business Combinations (Topic 805), Clarifying the Definition of a Business, which clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. ASU 2017-01 states that if substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the transaction should be accounted for as an asset acquisition. In addition, the ASU clarifies the requirements for a set of activities to be considered a business and narrows the definition of an output. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill and consolidation. ASU 2017-01 is effective for annual periods beginning after December 15, 2017. Early adoption is permitted.

In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740), Intra-Entity Transfers of Assets Other Than Inventory. Current GAAP prohibits the recognition of current and deferred income taxes for an intra-entity asset transfer until the asset has been sold to an outside party. The ASU requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The standard will be effective for fiscal years beginning after December 15, 2017. The Company plans to adopt the guidance effective January 1, 2018. Adoption of the guidance will be applied on a modified retrospective approach through a cumulative effect adjustment to retained earnings as of the effective date.

In February 2016, the FASB issued ASU 2016-02, Leases. This ASU includes a lessee accounting model that recognizes two types of leases; finance and operating. This ASU requires that a lessee recognize on the balance sheet assets and liabilities for all leases with lease terms of more than twelve months. Lessees will need to recognize almost all leases on the balance sheet as a right-of-use asset and a lease liability. For income statement purposes, the FASB retained the dual model, requiring leases to be classified as either operating or finance. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee will depend on its classification as a finance or operating lease. For short-term leases of twelve months or less, lessees are permitted to make an accounting election by class of underlying asset not to recognize right-of-use assets or lease liabilities. If the alternative is elected, lease expense would be recognized generally on the straight-line basis over the respective lease term.

The amendments in ASU 2016-02 will take effect for public companies for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Earlier application is permitted as of the beginning of an interim or annual reporting period. A modified retrospective approach is required for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements.

Upon adoption, the Company will recognize significant assets and liabilities on the consolidated balance sheets as a result of the operating lease obligations of the Company. Operating lease expense will still be recognized as rent expense on a straight-line basis over the respective lease terms in the consolidated statements of operations.

The Company will implement the new standard beginning January 1, 2019. The Company’s implementation efforts are focused on designing accounting processes, disclosure processes, and internal controls in order to account for its leases under the new standard.

In May 2014, March 2016, April 2016, and December 2016, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, ASU 2016-08, Revenue from Contracts with Customers, Principal versus Agent Considerations, ASU 2016-10, Revenue from Contracts with Customers, Identifying Performance Obligations and Licensing, ASU 2016-12, Revenue from Contracts with Customers, Narrow Scope Improvements and Practical Expedients, and ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customer (collectively “the standards”), respectively, which supersede most of the current revenue recognition requirements. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. The standards require the selection of a retrospective or cumulative effect transition method.

The Company will implement the new standard beginning January 1, 2018 using the retrospective transition method.  Adoption of the new standard will result in material changes to the presentation of net operating revenues and bad debt expense in the consolidated statements of operations, but the presentation of the amount of income from operations and net income will be unchanged upon adoption of the new standards. The principal change is how the new standard requires healthcare providers to estimate the amount of variable consideration to be included in the transaction price up to an amount which is probable that a significant reversal will not occur. The most common form of variable consideration the Company experiences are amounts for services provided that are ultimately not realizable from a customer. Under the current standards, the Company’s estimate for unrealizable amounts was recorded to bad debt expense. Under the new standards, the Company’s estimate for unrealizable amounts will be recognized as a constraint to revenue and will be reflected as an allowance. Substantially all of the bad debt expense as of June 30, 2016 and June 30, 2017 will be reclassified as an allowance when the Company retrospectively applies the guidance in the standards on January 1, 2018.

The Company’s remaining implementation efforts are focused principally on refining the accounting processes, disclosure processes, and internal controls.

Recently Adopted Accounting Pronouncements

In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes, which changed the presentation of deferred income taxes. The standard changed the presentation of deferred income taxes through the requirement that all deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The Company adopted the standard on January 1, 2017. The consolidated balance sheet at December 31, 2016 has been retrospectively adjusted. Adoption of the new standard impacted the Company’s previously reported results as follows:

	December 31, 2016
	As Reported		As Adjusted
	(in thousands)
Current deferred tax asset	$	45,165	$	—
Total current assets	808,068		762,903
Other assets	152,548		173,944
Total assets	4,944,395		4,920,626
Non-current deferred tax liability	222,847		199,078
Total liabilities	3,616,335		3,592,566
Total liabilities and equity	4,944,395		4,920,626

Reclassifications

Certain reclassifications have been made to prior year amounts in order to conform to current year presentation. As discussed above, the condensed consolidated balance sheet at December 31, 2016 has been changed in order to conform to the current year balance sheet presentation for the adoption of ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes.

XML

Acquisitions

6 Months Ended

Jun. 30, 2017

Acquisitions

Acquisitions

3.  Acquisitions

Physiotherapy Acquisition

On March 4, 2016, Select acquired 100% of the issued and outstanding equity securities of Physiotherapy Associates Holdings, Inc. (“Physiotherapy”) for $406.3 million, net of $12.3 million of cash acquired.

For the Physiotherapy acquisition, the Company allocated the purchase price to tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair value in accordance with the provisions of Accounting Standards Codification (“ASC”) 805, Business Combinations. During the quarter ended March 31, 2017, the Company finalized the purchase price allocation.

The following table reconciles the allocation of the consideration given for identifiable net assets and goodwill acquired to the net cash paid for the acquired business (in thousands):

Cash and cash equivalents	$	12,340
Identifiable tangible assets, excluding cash and cash equivalents	87,832
Identifiable intangible assets	32,484
Goodwill	343,187
Total assets	475,843
Total liabilities	54,685
Acquired non-controlling interests	2,514
Net assets acquired	418,644
Less: Cash and cash equivalents acquired	(12,340		)
Net cash paid	$	406,304

Goodwill of $343.2 million has been recognized in the business combination, representing the excess of the consideration given over the fair value of identifiable net assets acquired. The value of goodwill is derived from Physiotherapy’s future earnings potential and its assembled workforce. Goodwill has been assigned to the outpatient rehabilitation reporting unit and is not deductible for tax purposes. However, prior to its acquisition by the Company, Physiotherapy completed certain acquisitions that resulted in tax deductible goodwill with an estimated value of $8.8 million, which the Company will deduct through 2030.

Due to the integration of Physiotherapy into our outpatient rehabilitation operations, it is not practicable to separately identify net revenue and earnings of Physiotherapy on a stand-alone basis.

The following pro forma unaudited results of operations have been prepared assuming the acquisition of Physiotherapy occurred on January 1, 2015. These results are not necessarily indicative of results of future operations nor of the results that would have actually occurred had the acquisition been consummated on the aforementioned date. The Company’s results of operations for the three months ended June 30, 2016 and for the three and six months ended June 30, 2017 include Physiotherapy for the entire period. There were no pro forma adjustments during these periods; therefore, no pro forma information is presented for the periods.

	For the Six Months Ended June 30, 2016
	(in thousands, except per share amounts)
Net revenue	$	2,239,491
Net income attributable to Holdings	86,948
Income per common share:
Basic	$	0.66
Diluted	$	0.66

The net income tax impact was calculated at a statutory rate, as if Physiotherapy had been a subsidiary of the Company as of January 1, 2015. Pro forma results for the six months ended June 30, 2016 were adjusted to exclude approximately $3.2 million of Physiotherapy acquisition costs.

Other Acquisitions

The Company completed acquisitions within our specialty hospitals, outpatient rehabilitation, and Concentra segments during the six months ended June 30, 2017. The Company provided total consideration of $20.2 million, consisting principally of $18.5 million of cash, net of cash received, and the issuance of non-controlling interests. The assets received in these acquisitions consisted principally of accounts receivable, property and equipment, identifiable intangible assets, and goodwill, of which $0.7 million, $0.3 million, and $14.5 million of goodwill was recognized in our specialty hospitals, outpatient rehabilitation, and Concentra reporting units, respectively.

XML

Intangible Assets and Liabilities

6 Months Ended

Jun. 30, 2017

Intangible Assets and Liabilities

Intangible Assets and Liabilities

4. Intangible Assets and Liabilities

Goodwill

The following table shows changes in the carrying amount of goodwill by reporting unit for the six months ended June 30, 2017:

	Specialty Hospitals			Outpatient Rehabilitation		Concentra		Total
	(in thousands)
Balance as of December 31, 2016	$	1,447,406		$	643,557	$	660,037	$	2,751,000
Acquired	654			311		14,505		15,470
Measurement period adjustment	(342		)	168		—		(174		)
Balance as of June 30, 2017	$	1,447,718		$	644,036	$	674,542	$	2,766,296

See Note 3 for details of the goodwill acquired during the period.

Identifiable Intangible Assets and Liabilities

The following table provides the gross carrying amounts, accumulated amortization, and net carrying amounts for the Company’s identifiable intangible assets and liabilities:

	December 31, 2016							June 30, 2017
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
	(in thousands)
Indefinite-lived assets:
Trademarks	$	166,698	$	—		$	166,698	$	166,698	$	—		$	166,698
Certificates of need	17,026		—			17,026		19,207		—			19,207
Accreditations	2,235		—			2,235		2,074		—			2,074
Finite-lived assets:
Customer relationships	142,198		(23,185		)	119,013		143,953		(30,681		)	113,272
Favorable leasehold interests	13,089		(2,317		)	10,772		13,295		(3,255		)	10,040
Non-compete agreements	26,655		(1,837		)	24,818		27,267		(2,854		)	24,413
Total identifiable intangible assets	$	367,901	$	(27,339	)	$	340,562	$	372,494	$	(36,790	)	$	335,704
Finite-lived liabilities:
Unfavorable leasehold interests	$	5,139	$	(1,410	)	$	3,729	$	5,343	$	(1,957	)	$	3,386

The Company’s customer relationships and non-compete agreements amortize over their estimated useful lives. Amortization expense was $4.3 million for both the three months ended June 30, 2016 and 2017. Amortization expense was $8.1 million and $8.7 million for the six months ended June 30, 2016 and 2017, respectively.

The Company’s favorable and unfavorable leasehold interests are amortized to rent expense over the remaining term of their respective leases to reflect a market rent per period based upon the market conditions present at the acquisition date. The Company’s unfavorable leasehold interests are not separately presented on the condensed consolidated balance sheets but are included as a component of accrued other and other non-current liabilities.

The Company’s accreditations and trademarks have renewal terms and the costs to renew these intangible assets are expensed as incurred. At June 30, 2017, the accreditations and trademarks have a weighted average time until next renewal of 1.5 years and 2.4 years, respectively.

XML

Long-Term Debt and Notes Payable

6 Months Ended

Jun. 30, 2017

Long-Term Debt and Notes Payable

Long-Term Debt and Notes Payable

5. Long-Term Debt and Notes Payable

For purposes of this indebtedness footnote, references to Select exclude Concentra because the Concentra credit facilities are non-recourse to Holdings and Select.

The Company’s long-term debt and notes payable as of June 30, 2017 are as follows (in thousands):

	Principal Outstanding		Unamortized Premium (Discount)			Unamortized Issuance Costs			Carrying Value		Fair Value
Select:
6.375% senior notes	$	710,000	$	892		$	(7,510	)	$	703,382	$	732,152
Credit facilities:
Revolving facility	300,000		—			—			300,000		276,000
Term loan	1,147,125		(13,480		)	(13,540		)	1,120,105		1,158,596
Other	25,700		—			—			25,700		25,700
Total Select debt	$	2,182,825	$	(12,588	)	$	(21,050	)	$	2,149,187	$	2,192,448
Concentra:
Credit facilities:
Term loan	$	619,175	$	(2,513	)	$	(11,867	)	$	604,795	$	617,434
Other	6,727		—			—			6,727		6,727
Total Concentra debt	$	625,902	$	(2,513	)	$	(11,867	)	$	611,522	$	624,161
Total debt	$	2,808,727	$	(15,101	)	$	(32,917	)	$	2,760,709	$	2,816,609

Principal maturities of the Company’s long-term debt and notes payable are approximately as follows (in thousands):

	2017		2018		2019		2020		2021		Thereafter		Total
Select:
6.375% senior notes	$	—	$	—	$	—	$	—	$	710,000	$	—	$	710,000
Credit facilities:
Revolving facility	—		—		—		—		—		300,000		300,000
Term loan	5,750		11,500		11,500		11,500		11,500		1,095,375		1,147,125
Other	10,251		3,530		11,827		68		14		10		25,700
Total Select debt	$	16,001	$	15,030	$	23,327	$	11,568	$	721,514	$	1,395,385	$	2,182,825
Concentra:
Credit facilities:
Term loan	$	—	$	—	$	—	$	3,016	$	6,520	$	609,639	$	619,175
Other	1,309		1,394		144		161		160		3,559		6,727
Total Concentra debt	$	1,309	$	1,394	$	144	$	3,177	$	6,680	$	613,198	$	625,902
Total debt	$	17,310	$	16,424	$	23,471	$	14,745	$	728,194	$	2,008,583	$	2,808,727

The Company’s long-term debt and notes payable as of December 31, 2016 are as follows (in thousands):

	Principal Outstanding		Unamortized Premium (Discount)			Unamortized Issuance Costs			Carrying Value		Fair Value
Select:
6.375% senior notes	$	710,000	$	1,006		$	(8,461	)	$	702,545	$	710,000
Credit facilities:
Revolving facility	220,000		—			—			220,000		204,600
Term loans	1,147,751		(11,967		)	(13,581		)	1,122,203		1,165,860
Other	22,688		—			—			22,688		22,688
Total Select debt	$	2,100,439	$	(10,961	)	$	(22,042	)	$	2,067,436	$	2,103,148
Concentra:
Credit facilities:
Term loan	$	642,239	$	(2,773	)	$	(13,091	)	$	626,375	$	644,648
Other	5,178		—			—			5,178		5,178
Total Concentra debt	$	647,417	$	(2,773	)	$	(13,091	)	$	631,553	$	649,826
Total debt	$	2,747,856	$	(13,734	)	$	(35,133	)	$	2,698,989	$	2,752,974

Select Credit Facilities

On March 6, 2017, Select entered into a new senior secured credit agreement (the “Select credit agreement”) that provides for $1.6 billion in senior secured credit facilities comprising a $1.15 billion, seven-year term loan (the “Select term loan”) and a $450.0 million, five-year revolving credit facility (the “Select revolving facility” and together with the Select term loan, the “Select credit facilities”), including a $75.0 million sublimit for the issuance of standby letters of credit.

Select used borrowings under the Select credit facilities to: (i) repay in full the series E tranche B term loans due June 1, 2018, the series F tranche B term loans due March 31, 2021, and the revolving facility maturing March 1, 2018 under its then existing credit facilities; and (ii) pay fees and expenses in connection with the refinancing, which resulted in $6.5 million of debt extinguishment losses and $13.2 million of debt modification losses during the first quarter of 2017.

Borrowings under the Select credit facilities bear interest at a rate equal to: (i) in the case of the Select term loan, Adjusted LIBO (as defined in the Select credit agreement) plus 3.50% (subject to an Adjusted LIBO floor of 1.00%), or Alternate Base Rate (as defined in the Select credit agreement) plus 2.50% (subject to an Alternate Base Rate floor of 2.00%); and (ii) in the case of the Select revolving facility, Adjusted LIBO plus a percentage ranging from 3.00% to 3.25% or Alternate Base Rate plus a percentage ranging from 2.00% to 2.25%, in each case based on Select’s leverage ratio.

The Select term loan amortizes in equal quarterly installments in amounts equal to 0.25% of the aggregate original principal amount of the Select term loan commencing on June 30, 2017.  The balance of the Select term loan will be payable on March 8, 2024; however, if the Select 6.375% senior notes, which are due June 1, 2021, are outstanding on March 1, 2021, the maturity date for the Select term loan will become March 1, 2021. The Select revolving facility will be payable on March 8, 2022; however, if the Select 6.375% senior notes are outstanding on February 1, 2021, the maturity date for the Select revolving facility will become February 1, 2021.

Select will be required to prepay borrowings under the Select credit facilities with (i) 100% of the net cash proceeds received from non-ordinary course asset sales or other dispositions, or as a result of a casualty or condemnation, subject to reinvestment provisions and other customary carveouts and, to the extent required, the payment of certain indebtedness secured by liens having priority over the debt under the Select credit facilities or subject to a first lien intercreditor agreement, (ii) 100% of the net cash proceeds received from the issuance of debt obligations other than certain permitted debt obligations, and (ii) 50% of excess cash flow (as defined in the Select credit agreement) if Select’s leverage ratio is greater than 4.50 to 1.00 and 25% of excess cash flow if Select’s leverage ratio is less than or equal to 4.50 to 1.00 and greater than 4.00 to 1.00, in each case, reduced by the aggregate amount of term loans, revolving loans and certain other debt optionally prepaid during the applicable fiscal year.  Select will not be required to prepay borrowings with excess cash flow if Select’s leverage ratio is less than or equal to 4.00 to 1.00.

The Select revolving facility requires Select to maintain a leverage ratio (as defined in the Select credit agreement), which is tested quarterly, not to exceed 6.25 to 1.00. After March 31, 2019, the leverage ratio must not exceed 6.00 to 1.00.  Failure to comply with this covenant would result in an event of default under the Select revolving facility and, absent a waiver or an amendment from the revolving lenders, preclude Select from making further borrowings under the Select revolving facility and permit the revolving lenders to accelerate all outstanding borrowings under the Select revolving facility. The termination of the Select revolving facility commitments and the acceleration of amounts outstanding thereunder would constitute an event of default with respect to the Select term loan. As of June 30, 2017, Select’s leverage ratio was 5.86 to 1.00.

The Select credit facilities also contain a number of other affirmative and restrictive covenants, including limitations on mergers, consolidations and dissolutions; sales of assets; investments and acquisitions; indebtedness; liens; affiliate transactions; and dividends and restricted payments. The Select credit facilities contain events of default for non-payment of principal and interest when due (subject, as to interest, to a grace period), cross-default and cross-acceleration provisions and an event of default that would be triggered by a change of control.

Borrowings under the Select credit facilities are guaranteed by Holdings and substantially all of Select’s current domestic subsidiaries and will be guaranteed by substantially all of Select’s future domestic subsidiaries and secured by substantially all of Select’s existing and future property and assets and by a pledge of Select’s capital stock, the capital stock of Select’s domestic subsidiaries and up to 65% of the capital stock of Select’s foreign subsidiaries held directly by Select or a domestic subsidiary.

Excess Cash Flow Payment

On March 1, 2017, Concentra made a principal prepayment of $23.1 million associated with the Concentra first lien term loans in accordance with the provision in the Concentra credit facilities that requires mandatory prepayments of term loans as a result of annual excess cash flow, as defined in the Concentra credit facilities.

Fair Value

The Company considers the inputs in the valuation process to be Level 2 in the fair value hierarchy for Select’s 6.375% senior notes and for its credit facilities. Level 2 in the fair value hierarchy is defined as inputs that are observable for the asset or liability, either directly or indirectly, which includes quoted prices for identical assets or liabilities in markets that are not active.

The fair values of the Select credit facilities and the Concentra credit facilities were based on quoted market prices for this debt in the syndicated loan market. The fair value of Select’s 6.375% senior notes was based on quoted market prices. The carrying amount of other debt, principally short-term notes payable, approximates fair value.

XML

Segment Information

6 Months Ended

Jun. 30, 2017

Segment Information

Segment Information

6.  Segment Information

The Company’s reportable segments consist of: specialty hospitals, outpatient rehabilitation, and Concentra. Other activities include the Company’s corporate shared services and certain other non-consolidating joint ventures and minority investments in other healthcare related businesses. The Company evaluates performance of the segments based on Adjusted EBITDA. Adjusted EBITDA is defined as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, Physiotherapy acquisition costs, non-operating gain (loss), and equity in earnings (losses) of unconsolidated subsidiaries.

The following tables summarize selected financial data for the Company’s reportable segments. The segment results of Holdings are identical to those of Select.

	Three Months Ended June 30,						Six Months Ended June 30,
	2016			2017			2016			2017
	(in thousands)
Net operating revenues:
Specialty hospitals	$	585,816		$	600,960		$	1,184,770		$	1,199,747
Outpatient rehabilitation(1)	256,928			258,106			495,010			513,923
Concentra	254,868			261,586			505,745			517,735
Other	19			23			436			631
Total Company	$	1,097,631		$	1,120,675		$	2,185,961		$	2,232,036
Adjusted EBITDA:
Specialty hospitals	$	82,739		$	98,172		$	169,495		$	186,837
Outpatient rehabilitation(1)	38,132			41,926			67,011			73,277
Concentra	43,039			43,061			77,192			85,653
Other	(22,453		)	(24,479		)	(43,626		)	(48,197		)
Total Company	$	141,457		$	158,680		$	270,072		$	297,570
Total assets:(2)
Specialty hospitals	$	2,457,948		$	2,655,617		$	2,457,948		$	2,655,617
Outpatient rehabilitation	959,748			982,811			959,748			982,811
Concentra	1,328,243			1,310,483			1,328,243			1,310,483
Other	73,950			105,300			73,950			105,300
Total Company	$	4,819,889		$	5,054,211		$	4,819,889		$	5,054,211
Purchases of property and equipment, net:
Specialty hospitals	$	21,313		$	36,691		$	54,988		$	69,048
Outpatient rehabilitation(1)	3,825			6,201			8,798			12,874
Concentra	4,716			7,601			7,927			16,287
Other	3,636			4,156			8,545			7,093
Total Company	$	33,490		$	54,649		$	80,258		$	105,302

A reconciliation of Adjusted EBITDA to income before income taxes is as follows:

	Three Months Ended June 30, 2016
	Specialty Hospitals			Outpatient Rehabilitation(1)			Concentra			Other			Total
	(in thousands)
Adjusted EBITDA	$	82,739		$	38,132		$	43,039		$	(22,453	)
Depreciation and amortization	(13,812		)	(6,202		)	(14,916		)	(1,275		)
Stock compensation expense	—			—			(192		)	(4,006		)
Income (loss) from operations	$	68,927		$	31,930		$	27,931		$	(27,734	)	$	101,054
Equity in earnings of unconsolidated subsidiaries													4,546
Non-operating gain													13,035
Interest expense													(44,332		)
Income before income taxes													$	74,303

	Three Months Ended June 30, 2017
	Specialty Hospitals			Outpatient Rehabilitation			Concentra			Other			Total
	(in thousands)
Adjusted EBITDA	$	98,172		$	41,926		$	43,061		$	(24,479	)
Depreciation and amortization	(15,454		)	(5,878		)	(15,429		)	(1,572		)
Stock compensation expense	—			—			(264		)	(4,420		)
Income (loss) from operations	$	82,718		$	36,048		$	27,368		$	(30,471	)	$	115,663
Equity in earnings of unconsolidated subsidiaries													5,666
Interest expense													(37,655		)
Income before income taxes													$	83,674

	Six Months Ended June 30, 2016
	Specialty Hospitals			Outpatient Rehabilitation(1)			Concentra			Other			Total
	(in thousands)
Adjusted EBITDA	$	169,495		$	67,011		$	77,192		$	(43,626	)
Depreciation and amortization	(27,705		)	(10,238		)	(30,292		)	(2,487		)
Stock compensation expense	—			—			(384		)	(7,790		)
Physiotherapy acquisition costs	—			—			—			(3,236		)
Income (loss) from operations	$	141,790		$	56,773		$	46,516		$	(57,139	)	$	187,940
Loss on early retirement of debt													(773		)
Equity in earnings of unconsolidated subsidiaries													9,198
Non-operating gain													38,122
Interest expense													(83,180		)
Income before income taxes													$	151,307

	Six Months Ended June 30, 2017
	Specialty Hospitals			Outpatient Rehabilitation			Concentra			Other			Total
	(in thousands)
Adjusted EBITDA	$	186,837		$	73,277		$	85,653		$	(48,197	)
Depreciation and amortization	(33,954		)	(12,218		)	(31,552		)	(3,148		)
Stock compensation expense	—			—			(570		)	(8,700		)
Income (loss) from operations	$	152,883		$	61,059		$	53,531		$	(60,045	)	$	207,428
Loss on early retirement of debt													(19,719		)
Equity in earnings of unconsolidated subsidiaries													11,187
Non-operating loss													(49		)
Interest expense													(78,508		)
Income before income taxes													$	120,339

(1) The outpatient rehabilitation segment includes the operating results of the Company’s contract therapy businesses through March 31, 2016 and Physiotherapy beginning March 4, 2016.

(2) Reflects the retrospective adoption of ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. Total assets as of June 30, 2016 were retrospectively conformed to reflect the adoption of the standard, resulting in a reduction to total assets of $18.5 million.

XML

Income per Common Share

6 Months Ended

Jun. 30, 2017

Income per Common Share

Income per Common Share

7.  Income per Common Share

Holdings applies the two-class method for calculating and presenting income per common share. The two-class method is an earnings allocation formula that determines earnings per share for each class of stock participation rights in undistributed earnings.

The following table sets forth the calculation of income per share in Holdings’ condensed consolidated statements of operations and the differences between basic weighted average shares outstanding and diluted weighted average shares outstanding used to compute basic and diluted earnings per share, respectively.

	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2017		2016		2017
	(in thousands, except per share amounts)
Numerator:
Net income attributable to Select Medical Holdings Corporation	$	33,935	$	42,055	$	88,768	$	57,925
Less: Earnings allocated to unvested restricted stockholders	972		1,341		2,552		1,849
Net income available to common stockholders	$	32,963	$	40,714	$	86,216	$	56,076
Denominator:
Weighted average shares—basic	127,626		128,624		127,563		128,544
Effect of dilutive securities:
Stock options	194		153		146		159
Weighted average shares—diluted	127,820		128,777		127,709		128,703
Basic income per common share:	$	0.26	$	0.32	$	0.68	$	0.44
Diluted income per common share:	$	0.26	$	0.32	$	0.68	$	0.44

XML

Commitments and Contingencies

6 Months Ended

Jun. 30, 2017

Commitments and Contingencies

Commitments and Contingencies

8.  Commitments and Contingencies

Litigation

The Company is a party to various legal actions, proceedings, and claims (some of which are not insured), and regulatory and other governmental audits and investigations in the ordinary course of its business. The Company cannot predict the ultimate outcome of pending litigation, proceedings, and regulatory and other governmental audits and investigations. These matters could potentially subject the Company to sanctions, damages, recoupments, fines, and other penalties. The Department of Justice, Centers for Medicare & Medicaid Services (“CMS”), or other federal and state enforcement and regulatory agencies may conduct additional investigations related to the Company’s businesses in the future that may, either individually or in the aggregate, have a material adverse effect on the Company’s business, financial position, results of operations, and liquidity.

To address claims arising out of the Company’s operations, the Company maintains professional malpractice liability insurance and general liability insurance, subject to self-insured retention of $2.0 million per medical incident for professional liability claims and $2.0 million per occurrence for general liability claims. The Company also maintains umbrella liability insurance covering claims which, due to their nature or amount, are not covered by or not fully covered by the Company’s other insurance policies. These insurance policies also do not generally cover punitive damages and are subject to various deductibles and policy limits. Significant legal actions, as well as the cost and possible lack of available insurance, could subject the Company to substantial uninsured liabilities. In the Company’s opinion, the outcome of these actions, individually or in the aggregate, will not have a material adverse effect on its financial position, results of operations or cash flows.

Healthcare providers are subject to lawsuits under the qui tam provisions of the federal False Claims Act. Qui tam lawsuits typically remain under seal (hence, usually unknown to the defendant) for some time while the government decides whether or not to intervene on behalf of a private qui tam plaintiff (known as a relator) and take the lead in the litigation. These lawsuits can involve significant monetary damages and penalties and award bounties to private plaintiffs who successfully bring the suits. The Company is and has been a defendant in these cases in the past, and may be named as a defendant in similar cases from time to time in the future.

Evansville Litigation

On October 19, 2015, the plaintiff-relators filed a Second Amended Complaint in United States of America, ex rel. Tracy Conroy, Pamela Schenk and Lisa Wilson v. Select Medical Corporation, Select Specialty Hospital—Evansville, LLC (“SSH-Evansville”), Select Employment Services, Inc., and Dr. Richard Sloan. The case is a civil action filed in the United States District Court for the Southern District of Indiana by private plaintiff-relators on behalf of the United States under the federal False Claims Act. The plaintiff-relators are the former CEO and two former case managers at SSH-Evansville, and the defendants currently include the Company, SSH-Evansville, a subsidiary of the Company serving as common paymaster for its employees, and a physician who practices at SSH-Evansville. The plaintiff-relators allege that SSH-Evansville discharged patients too early or held patients too long, improperly discharged patients to and readmitted them from short stay hospitals, up-coded diagnoses at admission, and admitted patients for whom long-term acute care was not medically necessary. They also allege that the defendants engaged in retaliation in violation of federal and state law. The Second Amended Complaint replaced a prior complaint that was filed under seal on September 28, 2012 and served on the Company on February 15, 2013, after a federal magistrate judge unsealed it on January 8, 2013. All deadlines in the case had been stayed after the seal was lifted in order to allow the government time to complete its investigation and to decide whether or not to intervene. On June 19, 2015, the United States Department of Justice notified the District Court of its decision not to intervene in the case.

In December 2015, the defendants filed a Motion to Dismiss the Second Amended Complaint on multiple grounds, including that the action is disallowed by the False Claims Act’s public disclosure bar, which disqualifies qui tam actions that are based on fraud already publicly disclosed through enumerated sources, unless the relator is an original source, and that the plaintiff-relators did not plead their claims with sufficient particularity, as required by the Federal Rules of Civil Procedure.

Thereafter, the United States filed a notice asserting a veto of the defendants’ use of the public disclosure bar for claims arising from conduct from and after March 23, 2010, which was based on certain statutory changes to the public disclosure bar language included in the Affordable Care Act. On September 30, 2016, the District Court partially granted and partially denied the defendants’ Motion to Dismiss. It ruled that the plaintiff-relators alleged substantially the same conduct as had been publicly disclosed and that the plaintiff relators are not original sources, so that the public disclosure bar requires dismissal of all non-retaliation claims arising from conduct before March 23, 2010. The District Court also ruled that the statutory changes to the public disclosure bar gave the United States the power to veto its applicability to claims arising from conduct on and after March 23, 2010, and therefore did not dismiss those claims based on the public disclosure bar. However, the District Court ruled that the plaintiff-relators did not plead certain of their claims relating to interrupted stay manipulation and premature discharging of patients with the requisite particularity, and dismissed those claims. The District Court declined to dismiss the plaintiff relators’ claims arising from conduct from and after March 23, 2010 relating to delayed discharging of patients and up-coding and the plaintiff relators’ retaliation claims. The plaintiff-relators then proposed a case management plan seeking nationwide discovery involving all of the Company’s LTCHs for the period from March 23, 2010 through the present, which the defendants have opposed. The Company intends to vigorously defend this action, but at this time the Company is unable to predict the timing and outcome of this matter.

Knoxville Litigation

On July 13, 2015, the United States District Court for the Eastern District of Tennessee unsealed a qui tam Complaint in Armes v. Garman, et al, No. 3:14-cv-00172-TAV-CCS, which named as defendants Select, Select Specialty Hospital—Knoxville, Inc. (“SSH-Knoxville”), Select Specialty Hospital—North Knoxville, Inc. and ten current or former employees of these facilities. The Complaint was unsealed after the United States and the State of Tennessee notified the court on July 13, 2015 that each had decided not to intervene in the case. The Complaint is a civil action that was filed under seal on April 29, 2014 by a respiratory therapist formerly employed at SSH-Knoxville. The Complaint alleges violations of the federal False Claims Act and the Tennessee Medicaid False Claims Act based on extending patient stays to increase reimbursement and to increase average length of stay; artificially prolonging the lives of patients to increase Medicare reimbursements and decrease inspections; admitting patients who do not require medically necessary care; performing unnecessary procedures and services; and delaying performance of procedures to increase billing. The Complaint was served on some of the defendants during October 2015.

In November 2015, the defendants filed a Motion to Dismiss the Complaint on multiple grounds. The defendants first argued that False Claims Act’s first-to-file bar required dismissal of plaintiff-relator’s claims. Under the first-to-file bar, if a qui tam case is pending, no person may bring a related action based on the facts underlying the first action. The defendants asserted that the plaintiff-relator’s claims were based on the same underlying facts as were asserted in the Evansville litigation, discussed above. The defendants also argued that the plaintiff-relator’s claims must be dismissed under the public disclosure bar, and because the plaintiff-relator did not plead his claims with sufficient particularity.

In June 2016, the District Court granted the defendants’ Motion to Dismiss and dismissed with prejudice the plaintiff-relator’s lawsuit in its entirety. The District Court ruled that the first-to-file bar precludes all but one of the plaintiff-relator’s claims, and that the remaining claim must also be dismissed because the plaintiff-relator failed to plead it with sufficient particularity. In July 2016, the plaintiff-relator filed a Notice of Appeal to the United States Court of Appeals for the Sixth Circuit. Then, on October 11, 2016, the plaintiff-relator filed a Motion to Remand the case to the District Court for further proceedings, arguing that the September 30, 2016 decision in the Evansville litigation, discussed above, undermines the basis for the District Court’s dismissal. After the Court of Appeals denied the Motion to Remand, the plaintiff-relator then sought an indicative ruling from the District Court that it would vacate its prior dismissal ruling and allow plaintiff-relator to supplement his Complaint, which the defendants have opposed. The case has been fully briefed in the Court of Appeals. The Company intends to vigorously defend this action, but at this time the Company is unable to predict the timing and outcome of this matter.

Wilmington Litigation

On January 19, 2017, the United States District Court for the District of Delaware unsealed a qui tam Complaint in United States of America and State of Delaware ex rel. Theresa Kelly v. Select Specialty Hospital—Wilmington, Inc. (“SSH-Wilmington”), Select Specialty Hospitals, Inc., Select Employment Services, Inc., Select Medical Corporation, and Crystal Cheek, No. 16-347-LPS. The Complaint was initially filed under seal on May 12, 2016 by a former chief nursing officer at SSH-Wilmington and was unsealed after the United States filed a Notice of Election to Decline Intervention on January 13, 2017. The corporate defendants were served on March 6, 2017. In the complaint, the plaintiff-relator alleges that the Select defendants and an individual defendant, who is a former health information manager at SSH-Wilmington, violated the False Claims Act and the Delaware False Claims and Reporting Act based on allegedly falsifying medical practitioner signatures on medical records and failing to properly examine the credentials of medical practitioners at SSH-Wilmington. In response to the Select defendants’ motion to dismiss the Complaint, on May 17, 2017 the plaintiff-relator filed an Amended Complaint asserting the same causes of action. The Select defendants filed a Motion to Dismiss the Amended Complaint, which is now pending, based on numerous grounds, including that the Amended Complaint did not plead any alleged fraud with sufficient particularity, failed to plead that the alleged fraud was material to the government’s payment decision, failed to plead sufficient facts to establish that the Select defendants knowingly submitted false claims or records, and failed to allege any reverse false claim.

On March 24, 2017, the plaintiff-relator initiated a second action by filing a Complaint in the Superior Court of the State of Delaware in Theresa Kelly v. Select Medical Corporation, Select Employment Services, Inc., and SSH-Wilmington, C.A. No. N17C-03-293 CLS. The Delaware Complaint alleges that the defendants retaliated against her in violation of the Delaware Whistleblowers’ Protection Act for reporting the same alleged violations that are the subject of the federal Amended Complaint. The defendants filed a motion to dismiss, or alternatively to stay, the Delaware Complaint based on the pending federal Amended Complaint and the failure to allege facts to support a violation of the Delaware Whistleblowers’ Protection Act.  The motion is currently pending.

The Company intends to vigorously defend these actions, but at this time the Company is unable to predict the timing and outcome of this matter.

Contract Therapy Subpoena

On May 18, 2017, the Company received a subpoena from the U.S. Attorney’s Office for the District of New Jersey seeking various documents principally relating to the Company’s contract therapy division, which contracted to furnish rehabilitation therapy services to residents of skilled nursing facilities (“SNFs”) and other providers. The Company operated its contract therapy division through a subsidiary until March 31, 2016, when the Company sold the stock of the subsidiary. The subpoena seeks documents that appear to be aimed at assessing whether therapy services were furnished and billed in compliance with Medicare SNF billing requirements, including whether therapy services were coded at inappropriate levels and whether excessive or unnecessary therapy was furnished to justify coding at higher paying levels. The Company does not know whether the subpoena has been issued in connection with a qui tam lawsuit or in connection with possible civil, criminal or administrative proceedings by the government. The Company is producing documents in response to the subpoena and intends to fully cooperate with this investigation. At this time, the Company is unable to predict the timing and outcome of this matter.

XML

Condensed Consolidating Financial Information

6 Months Ended

Jun. 30, 2017

Condensed Consolidating Financial Information

Condensed Consolidating Financial Information

9.  Condensed Consolidating Financial Information

Select’s 6.375% senior notes are fully and unconditionally and jointly and severally guaranteed, except for customary limitations, on a senior basis by all of Select’s wholly owned subsidiaries (the “Subsidiary Guarantors”). The Subsidiary Guarantors are defined as subsidiaries where Select, or a subsidiary of Select, holds all of the outstanding ownership interests. Certain of Select’s subsidiaries did not guarantee the 6.375% senior notes (the “Non-Guarantor Subsidiaries” and Concentra Group Holdings and its subsidiaries, the “Non-Guarantor Concentra”).

Select conducts a significant portion of its business through its subsidiaries. Presented below is condensed consolidating financial information for Select, the Subsidiary Guarantors, the Non-Guarantor Subsidiaries, and Non-Guarantor Concentra at December 31, 2016 and June 30, 2017 and for the three and six months ended June 30, 2016 and 2017.

The equity method has been used by Select with respect to investments in subsidiaries. The equity method has been used by Subsidiary Guarantors with respect to investments in Non-Guarantor Subsidiaries. Separate financial statements for Subsidiary Guarantors are not presented.

Certain reclassifications have been made to prior reported amounts in order to conform to the current year guarantor structure.

Select Medical Corporation

Condensed Consolidating Balance Sheet

June 30, 2017

(unaudited)

	Select (Parent Company Only)			Subsidiary Guarantors		Non-Guarantor Subsidiaries			Non-Guarantor Concentra		Eliminations			Consolidated Select Medical Corporation
	(in thousands)
Assets
Current Assets:
Cash and cash equivalents	$	72		$	5,533	$	4,946		$	63,248	$	—		$	73,799
Accounts receivable, net	—			467,412		120,272			126,552		—			714,236
Intercompany receivables	—			1,489,631		58,333			—		(1,547,964		) (a)	—
Other current assets	17,584			28,326		12,786			24,515		—			83,211
Total Current Assets	17,656			1,990,902		196,337			214,315		(1,547,964		)	871,246
Property and equipment, net	56,568			620,364		54,964			179,636		—			911,532
Investment in affiliates	4,523,727			118,248		—			—		(4,641,975		) (b) (c)	—
Goodwill	—			2,091,754		—			674,542		—			2,766,296
Identifiable intangible assets, net	—			109,913		—			225,791		—			335,704
Other assets	42,452			98,649		36,528			16,199		(24,395		) (d)	169,433
Total Assets	$	4,640,403		$	5,029,830	$	287,829		$	1,310,483	$	(6,214,334	)	$	5,054,211
Liabilities and Equity
Current Liabilities:
Bank overdrafts	$	34,134		$	—	$	—		$	—	$	—		$	34,134
Current portion of long-term debt and notes payable	23,052			644		244			2,637		—			26,577
Accounts payable	10,362			75,105		22,387			15,777		—			123,631
Intercompany payables	1,489,631			58,333		—			—		(1,547,964		) (a)	—
Accrued payroll	7,526			80,245		3,545			27,871		—			119,187
Accrued vacation	3,927			58,895		12,214			17,214		—			92,250
Accrued interest	17,096			5		4			2,172		—			19,277
Accrued other	44,032			60,078		10,533			32,210		—			146,853
Income taxes payable	2,709			—		—			4,267		—			6,976
Total Current Liabilities	1,632,469			333,305		48,927			102,148		(1,547,964		)	568,885
Long-term debt, net of current portion	2,115,318			266		9,663			608,885		—			2,734,132
Non-current deferred tax liability	—			136,920		736			84,150		(24,395		) (d)	197,411
Other non-current liabilities	44,297			54,100		7,688			35,194		—			141,279
Total Liabilities	3,792,084			524,591		67,014			830,377		(1,572,359		)	3,641,707
Redeemable non-controlling interests	—			—		10,079			458,771		—			468,850
Stockholder’s Equity:
Common stock	0			—		—			—		—			0
Capital in excess of par	936,428			—		—			—		—			936,428
Retained earnings (accumulated deficit)	(88,109		)	1,314,773		(37,110		)	12,447		(1,290,110		) (c)	(88,109		)
Subsidiary investment	—			3,190,466		156,262			5,137		(3,351,865		) (b)	—
Total Select Medical Corporation Stockholder’s Equity	848,319			4,505,239		119,152			17,584		(4,641,975		)	848,319
Non-controlling interests	—			—		91,584			3,751		—			95,335
Total Equity	848,319			4,505,239		210,736			21,335		(4,641,975		)	943,654
Total Liabilities and Equity	$	4,640,403		$	5,029,830	$	287,829		$	1,310,483	$	(6,214,334	)	$	5,054,211

(a) Elimination of intercompany balances.

(b) Elimination of investments in consolidated subsidiaries.

(c) Elimination of investments in consolidated subsidiaries’ earnings.

(d) Reclass of non-current deferred tax asset to report net non-current deferred tax liability in consolidation.

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Three Months Ended June 30, 2017

(unaudited)

	Select (Parent Company Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Eliminations			Consolidated Select Medical Corporation
	(in thousands)
Net operating revenues	$	23		$	687,886		$	171,180		$	261,586		$	—		$	1,120,675
Costs and expenses:
Cost of services	644			561,304			144,211			214,071			—			920,230
General and administrative	28,227			48			—			—			—			28,275
Bad debt expense	—			9,829			3,627			4,718			—			18,174
Depreciation and amortization	1,573			18,149			3,182			15,429			—			38,333
Total costs and expenses	30,444			589,330			151,020			234,218			—			1,005,012
Income (loss) from operations	(30,421		)	98,556			20,160			27,368			—			115,663
Other income and expense:
Intercompany interest and royalty fees	(2,263		)	3,596			(1,333		)	—			—			—
Intercompany management fees	63,504			(53,435		)	(10,069		)	—			—			—
Equity in earnings of unconsolidated subsidiaries	—			5,646			20			—			—			5,666
Interest expense	(19,623		)	(8,234		)	(2,360		)	(7,438		)	—			(37,655		)
Income before income taxes	11,197			46,129			6,418			19,930			—			83,674
Income tax expense (benefit)	(2,324		)	27,307			309			7,082			—			32,374
Equity in earnings of consolidated subsidiaries	28,534			4,200			—			—			(32,734		) (a)	—
Net income	42,055			23,022			6,109			12,848			(32,734		)	51,300
Less: Net income attributable to non-controlling interests	—			—			2,175			7,070			—			9,245
Net income attributable to Select Medical Corporation	$	42,055		$	23,022		$	3,934		$	5,778		$	(32,734	)	$	42,055

(a) Elimination of equity in earnings of subsidiaries.

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Six Months Ended June 30, 2017

(unaudited)

	Select (Parent Company Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Eliminations			Consolidated Select Medical Corporation
	(in thousands)
Net operating revenues	$	631		$	1,377,279		$	336,391		$	517,735		$	—		$	2,232,036
Costs and expenses:
Cost of services	1,176			1,142,527			282,521			422,363			—			1,848,587
General and administrative	56,263			87			—			—			—			56,350
Bad debt expense	—			21,577			6,933			10,289			—			38,799
Depreciation and amortization	3,148			39,489			6,683			31,552			—			80,872
Total costs and expenses	60,587			1,203,680			296,137			464,204			—			2,024,608
Income (loss) from operations	(59,956		)	173,599			40,254			53,531			—			207,428
Other income and expense:
Intercompany interest and royalty fees	(4,159		)	6,914			(2,755		)	—			—			—
Intercompany management fees	125,202			(106,069		)	(19,133		)	—			—			—
Loss on early retirement of debt	(19,719		)	—			—			—			—			(19,719		)
Equity in earnings of unconsolidated subsidiaries	—			11,139			48			—			—			11,187
Non-operating loss	—			(49		)	—			—			—			(49		)
Interest expense	(42,431		)	(16,307		)	(4,833		)	(14,937		)	—			(78,508		)
Income (loss) before income taxes	(1,063		)	69,227			13,581			38,594			—			120,339
Income tax expense (benefit)	(2,198		)	33,243			613			13,918			—			45,576
Equity in earnings of consolidated subsidiaries	56,790			9,775			—			—			(66,565		) (a)	—
Net income	57,925			45,759			12,968			24,676			(66,565		)	74,763
Less: Net income attributable to non-controlling interests	—			—			3,244			13,594			—			16,838
Net income attributable to Select Medical Corporation	$	57,925		$	45,759		$	9,724		$	11,082		$	(66,565	)	$	57,925

(a) Elimination of equity in earnings of subsidiaries.

Select Medical Corporation

Condensed Consolidating Statement of Cash Flows

For the Six Months Ended June 30, 2017

(unaudited)

	Select (Parent Company Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Eliminations			Consolidated Select Medical Corporation
	(in thousands)
Operating activities
Net income	$	57,925		$	45,759		$	12,968		$	24,676		$	(66,565	) (a)	$	74,763
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries	—			10,902			31			—			—			10,933
Depreciation and amortization	3,148			39,489			6,683			31,552			—			80,872
Provision for bad debts	—			21,577			6,933			10,289			—			38,799
Equity in earnings of unconsolidated subsidiaries	—			(11,139		)	(48		)	—			—			(11,187		)
Equity in earnings of consolidated subsidiaries	(56,790		)	(9,775		)	—			—			66,565		(a)	—
Loss on extinguishment of debt	6,527			—			—			—			—			6,527
Gain on sale of assets and businesses	(8		)	(4,828		)	(4,687		)	—			—			(9,523		)
Stock compensation expense	8,700			—			—			570			—			9,270
Amortization of debt discount, premium and issuance costs	4,342			—			—			1,632			—			5,974
Deferred income taxes	5,987			—			—			(7,461		)	—			(1,474		)
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	—			(125,418		)	(29,435		)	(24,150		)	—			(179,003		)
Other current assets	(5,631		)	5,452			(2,517		)	(2,861		)	—			(5,557		)
Other assets	3,184			(16,925		)	17,426			936			—			4,621
Accounts payable	(413		)	(1,550		)	(10		)	2,732			—			759
Accrued expenses	(5,618		)	(4,817		)	8,704			(3,102		)	—			(4,833		)
Income taxes	9,366			—			—			10,033			—			19,399
Net cash provided by (used in) operating activities	30,719			(51,273		)	16,048			44,846			—			40,340
Investing activities
Acquisition of businesses, net of cash acquired	—			(2,305		)	—			(16,203		)	—			(18,508		)
Purchases of property and equipment	(7,093		)	(71,813		)	(10,109		)	(16,287		)	—			(105,302		)
Investment in businesses	—			(9,874		)	—			—			—			(9,874		)
Proceeds from sale of assets and businesses	8			15,007			19,537			—			—			34,552
Net cash provided by (used in) investing activities	(7,085		)	(68,985		)	9,428			(32,490		)	—			(99,132		)
Financing activities
Borrowings on revolving facilities	630,000			—			—			—			—			630,000
Payments on revolving facilities	(550,000		)	—			—			—			—			(550,000		)
Proceeds from term loans	1,139,487			—			—			—			—			1,139,487
Payments on term loans	(1,150,627		)	—			—			(23,065		)	—			(1,173,692		)
Revolving facility debt issuance costs	(4,392		)	—			—			—			—			(4,392		)
Borrowings of other debt	6,572			—			105			2,767			—			9,444
Principal payments on other debt	(7,353		)	(204		)	(1,183		)	(1,697		)	—			(10,437		)
Repayments of bank overdrafts	(5,228		)	—			—			—			—			(5,228		)
Dividends paid to Holdings	(600		)	—			—			—			—			(600		)
Equity investment by Holdings	963			—			—			—			—			963
Intercompany	(93,455		)	119,528			(26,073		)	—			—			—
Proceeds from issuance of non-controlling interests	—			—			3,553			—			—			3,553
Purchase of non-controlling interests	—			—			(120		)	—			—			(120		)
Distributions to non-controlling interests	—			—			(1,868		)	(3,548		)	—			(5,416		)
Net cash provided by (used in) financing activities	(34,633		)	119,324			(25,586		)	(25,543		)	—			33,562
Net decrease in cash and cash equivalents	(10,999		)	(934		)	(110		)	(13,187		)	—			(25,230		)
Cash and cash equivalents at beginning of period	11,071			6,467			5,056			76,435			—			99,029
Cash and cash equivalents at end of period	$	72		$	5,533		$	4,946		$	63,248		$	—		$	73,799

(a) Elimination of equity in earnings of consolidated subsidiaries.

Select Medical Corporation

Condensed Consolidating Balance Sheet

December 31, 2016

(unaudited)

	Select (Parent Company Only)			Subsidiary Guarantors		Non-Guarantor Subsidiaries			Non-Guarantor Concentra		Eliminations			Consolidated Select Medical Corporation
	(in thousands)
Assets
Current Assets:
Cash and cash equivalents	$	11,071		$	6,467	$	5,056		$	76,435	$	—		$	99,029
Accounts receivable, net	—			363,470		97,770			112,512		—			573,752
Intercompany receivables	—			1,573,960		28,271			—		(1,602,231		) (a)	—
Prepaid income taxes	6,658			—		—			5,765		—			12,423
Other current assets	11,953			33,958		10,269			21,519		—			77,699
Total Current Assets	29,682			1,977,855		141,366			216,231		(1,602,231		)	762,903
Property and equipment, net	48,697			603,408		50,869			189,243		—			892,217
Investment in affiliates	4,493,684			89,288		—			—		(4,582,972		) (b) (c)	—
Goodwill	—			2,090,963		—			660,037		—			2,751,000
Identifiable intangible assets, net	—			109,132		—			231,430		—			340,562
Other assets	45,636			84,803		53,954			16,235		(26,684		) (d)	173,944
Total Assets	$	4,617,699		$	4,955,449	$	246,189		$	1,313,176	$	(6,211,887	)	$	4,920,626
Liabilities and Equity
Current Liabilities:
Bank overdrafts	$	39,362		$	—	$	—		$	—	$	—		$	39,362
Current portion of long-term debt and notes payable	7,227			445		1,324			4,660		—			13,656
Accounts payable	10,775			78,608		22,397			14,778		—			126,558
Intercompany payables	1,573,960			28,271		—			—		(1,602,231		) (a)	—
Accrued payroll	16,963			92,216		4,246			32,972		—			146,397
Accrued vacation	3,440			55,486		10,668			13,667		—			83,261
Accrued interest	20,114			—		—			2,211		—			22,325
Accrued other	39,155			62,384		4,639			33,898		—			140,076
Total Current Liabilities	1,710,996			317,410		43,274			102,186		(1,602,231		)	571,635
Long-term debt, net of current portion	2,048,154			601		9,685			626,893		—			2,685,333
Non-current deferred tax liability	—			133,852		596			91,314		(26,684		) (d)	199,078
Other non-current liabilities	42,824			53,537		5,727			34,432		—			136,520
Total Liabilities	3,801,974			505,400		59,282			854,825		(1,628,915		)	3,592,566
Redeemable non-controlling interests	—			113		10,056			411,990		—			422,159
Stockholder’s Equity:
Common stock	0			—		—			—		—			0
Capital in excess of par	925,111			—		—			—		—			925,111
Retained earnings (accumulated deficit)	(109,386		)	1,269,014		(38,313		)	1,364		(1,232,065		) (c)	(109,386		)
Subsidiary investment	—			3,180,922		128,556			41,429		(3,350,907		) (b)	—
Total Select Medical Corporation Stockholder’s Equity	815,725			4,449,936		90,243			42,793		(4,582,972		)	815,725
Non-controlling interests	—			—		86,608			3,568		—			90,176
Total Equity	815,725			4,449,936		176,851			46,361		(4,582,972		)	905,901
Total Liabilities and Equity	$	4,617,699		$	4,955,449	$	246,189		$	1,313,176	$	(6,211,887	)	$	4,920,626

(a) Elimination of intercompany balances.

(b) Elimination of investments in consolidated subsidiaries.

(c) Elimination of investments in consolidated subsidiaries’ earnings.

(d) Reclass of non-current deferred tax asset to report net non-current deferred tax liability in consolidation.

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Three Months Ended June 30, 2016

(unaudited)

	Select (Parent Company Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Eliminations			Consolidated Select Medical Corporation
	(in thousands)
Net operating revenues	$	20		$	723,859		$	118,884		$	254,868		$	—		$	1,097,631
Costs and expenses:
Cost of services	606			605,730			103,767			206,882			—			916,985
General and administrative	25,844			26			—			—			—			25,870
Bad debt expense	—			10,285			2,093			5,139			—			17,517
Depreciation and amortization	1,276			17,316			2,697			14,916			—			36,205
Total costs and expenses	27,726			633,357			108,557			226,937			—			996,577
Income (loss) from operations	(27,706		)	90,502			10,327			27,931			—			101,054
Other income and expense:
Intercompany interest and royalty fees	(1,532		)	3,274			(1,742		)	—			—			—
Intercompany management fees	38,783			(32,430		)	(6,353		)	—			—			—
Equity in earnings of unconsolidated subsidiaries	—			4,519			27			—			—			4,546
Non-operating gain	10,463			2,572			—			—			—			13,035
Interest expense	(25,544		)	(6,684		)	(1,852		)	(10,252		)	—			(44,332		)
Income (loss) before income taxes	(5,536		)	61,753			407			17,679			—			74,303
Income tax expense (benefit)	(473		)	26,370			672			6,881			—			33,450
Equity in earnings of consolidated subsidiaries	38,998			(1,133		)	—			—			(37,865		) (a)	—
Netincome(loss)	33,935			34,250			(265		)	10,798			(37,865		)	40,853
Less: Net income attributable to non-controlling interests	—			18			824			6,076			—			6,918
Net income (loss) attributable to Select Medical Corporation	$	33,935		$	34,232		$	(1,089	)	$	4,722		$	(37,865	)	$	33,935

(a) Elimination of equity in earnings of subsidiaries.

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Six Months Ended June 30, 2016

(unaudited)

	Select (Parent Company Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Eliminations			Consolidated Select Medical Corporation
	(in thousands)
Net operating revenues	$	437		$	1,439,439		$	240,340		$	505,745		$	—		$	2,185,961
Costs and expenses:
Cost of services	950			1,211,439			206,774			420,084			—			1,839,247
General and administrative	54,231			(93		)	—			—			—			54,138
Bad debt expense	—			21,003			4,058			8,853			—			33,914
Depreciation and amortization	2,487			32,648			5,295			30,292			—			70,722
Total costs and expenses	57,668			1,264,997			216,127			459,229			—			1,998,021
Income (loss) from operations	(57,231		)	174,442			24,213			46,516			—			187,940
Other income and expense:
Intercompany interest and royalty fees	(2,590		)	6,044			(3,454		)	—			—			—
Intercompany management fees	94,139			(82,127		)	(12,012		)	—			—			—
Loss on early retirement of debt	(773		)	—			—			—			—			(773		)
Equity in earnings of unconsolidated subsidiaries	—			9,146			52			—			—			9,198
Non-operating gain (loss)	40,895			(2,773		)	—			—			—			38,122
Interest expense	(45,890		)	(13,318		)	(3,491		)	(20,481		)	—			(83,180		)
Income before income taxes	28,550			91,414			5,308			26,035			—			151,307
Income tax expense	8,139			31,985			607			9,779			—			50,510
Equity in earnings of consolidated subsidiaries	68,357			1,873			—			—			(70,230		) (a)	—
Net income	88,768			61,302			4,701			16,256			(70,230		)	100,797
Less: Net income attributable to non-controlling interests	—			33			2,695			9,301			—			12,029
Net income attributable to Select Medical Corporation	$	88,768		$	61,269		$	2,006		$	6,955		$	(70,230	)	$	88,768

(a) Elimination of equity in earnings of subsidiaries.

Select Medical Corporation

Condensed Consolidating Statement of Cash Flows

For the Six Months Ended June 30, 2016

(unaudited)

	Select (Parent Company Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Eliminations			Consolidated Select Medical Corporation
	(in thousands)
Operating activities
Net income	$	88,768		$	61,302		$	4,701		$	16,256		$	(70,230	) (a)	$	100,797
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries	—			12,000			39			—			—			12,039
Depreciation and amortization	2,487			32,648			5,295			30,292			—			70,722
Provision for bad debts	—			21,003			4,058			8,853			—			33,914
Equity in earnings of unconsolidated subsidiaries	—			(9,146		)	(52		)	—			—			(9,198		)
Equity in earnings of consolidated subsidiaries	(68,357		)	(1,873		)	—			—			70,230		(a)	—
Loss on extinguishment of debt	773			—			—			—			—			773
Gain on sale of assets and businesses	(40,895		)	(2,566		)	—			—			—			(43,461		)
Loss on disposal of assets	—			37			12			6			—			55
Impairment of equity investment	—			5,339			—			—			—			5,339
Stock compensation expense	7,790			—			—			384			—			8,174
Amortization of debt discount, premium and issuance costs	5,371			—			2			1,704			—			7,077
Deferred income taxes	997			—			—			(14,283		)	—			(13,286		)
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	—			(22,896		)	(9,711		)	(11,489		)	—			(44,096		)
Other current assets	(2,938		)	7,342			(1,273		)	7,880			—			11,011
Other assets	(4,268		)	(341		)	(424		)	9,541			—			4,508
Accounts payable	(2,241		)	(17,695		)	(3,371		)	7,455			—			(15,852		)
Accrued expenses	(10,175		)	36,088			(2,441		)	(2,840		)	—			20,632
Income taxes	9,101			—			—			19,989			—			29,090
Net cash provided by (used in) operating activities	(13,587		)	121,242			(3,165		)	73,748			—			178,238
Investing activities
Acquisition of businesses, net of cash acquired	(408,654		)	(605		)	(8,395		)	(3,865		)	—			(421,519		)
Purchases of property and equipment	(8,545		)	(52,591		)	(11,195		)	(7,927		)	—			(80,258		)
Investment in businesses	—			(1,590		)	—			—			—			(1,590		)
Proceeds from sale of assets and businesses	63,418			7,942			6			—			—			71,366
Net cash used in investing activities	(353,781		)	(46,844		)	(19,584		)	(11,792		)	—			(432,001		)
Financing activities
Borrowings on revolving facilities	320,000			—			—			—			—			320,000
Payments on revolving facilities	(375,000		)	—			—			(5,000		)	—			(380,000		)
Proceeds from term loans	600,127			—			—			—			—			600,127
Payments on term loans	(227,399		)	—			—			(2,250		)	—			(229,649		)
Borrowings of other debt	9,765			—			9,500			2,817			—			22,082
Principal payments on other debt	(7,278		)	(385		)	(876		)	(1,387		)	—			(9,926		)
Repayments of bank overdrafts	(2,138		)	—			—			—			—			(2,138		)
Dividends paid to Holdings	(506		)	—			—			—			—			(506		)
Equity investment by Holdings	657			—			—			—			—			657
Intercompany	49,141			(68,206		)	19,065			—			—			—
Proceeds from issuance of non-controlling interests	—			—			3,103			—			—			3,103
Purchase of non-controlling interests	—			(1,294		)	—			—			—			(1,294		)
Distributions to non-controlling interests	—			(108		)	(3,294		)	(1,306		)	—			(4,708		)
Net cash provided by (used in) financing activities	367,369			(69,993		)	27,498			(7,126		)	—			317,748
Net increase in cash and cash equivalents	1			4,405			4,749			54,830			—			63,985
Cash and cash equivalents at beginning of period	4,070			3,706			625			6,034			—			14,435
Cash and cash equivalents at end of period	$	4,071		$	8,111		$	5,374		$	60,864		$	—		$	78,420

(a) Elimination of equity in earnings of consolidated subsidiaries.

XML

Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2017

Accounting Policies

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingencies, at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-01, Business Combinations (Topic 805), Clarifying the Definition of a Business, which clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. ASU 2017-01 states that if substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the transaction should be accounted for as an asset acquisition. In addition, the ASU clarifies the requirements for a set of activities to be considered a business and narrows the definition of an output. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill and consolidation. ASU 2017-01 is effective for annual periods beginning after December 15, 2017. Early adoption is permitted.

In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740), Intra-Entity Transfers of Assets Other Than Inventory. Current GAAP prohibits the recognition of current and deferred income taxes for an intra-entity asset transfer until the asset has been sold to an outside party. The ASU requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The standard will be effective for fiscal years beginning after December 15, 2017. The Company plans to adopt the guidance effective January 1, 2018. Adoption of the guidance will be applied on a modified retrospective approach through a cumulative effect adjustment to retained earnings as of the effective date.

In February 2016, the FASB issued ASU 2016-02, Leases. This ASU includes a lessee accounting model that recognizes two types of leases; finance and operating. This ASU requires that a lessee recognize on the balance sheet assets and liabilities for all leases with lease terms of more than twelve months. Lessees will need to recognize almost all leases on the balance sheet as a right-of-use asset and a lease liability. For income statement purposes, the FASB retained the dual model, requiring leases to be classified as either operating or finance. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee will depend on its classification as a finance or operating lease. For short-term leases of twelve months or less, lessees are permitted to make an accounting election by class of underlying asset not to recognize right-of-use assets or lease liabilities. If the alternative is elected, lease expense would be recognized generally on the straight-line basis over the respective lease term.

The amendments in ASU 2016-02 will take effect for public companies for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Earlier application is permitted as of the beginning of an interim or annual reporting period. A modified retrospective approach is required for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements.

Upon adoption, the Company will recognize significant assets and liabilities on the consolidated balance sheets as a result of the operating lease obligations of the Company. Operating lease expense will still be recognized as rent expense on a straight-line basis over the respective lease terms in the consolidated statements of operations.

The Company will implement the new standard beginning January 1, 2019. The Company’s implementation efforts are focused on designing accounting processes, disclosure processes, and internal controls in order to account for its leases under the new standard.

In May 2014, March 2016, April 2016, and December 2016, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, ASU 2016-08, Revenue from Contracts with Customers, Principal versus Agent Considerations, ASU 2016-10, Revenue from Contracts with Customers, Identifying Performance Obligations and Licensing, ASU 2016-12, Revenue from Contracts with Customers, Narrow Scope Improvements and Practical Expedients, and ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customer (collectively “the standards”), respectively, which supersede most of the current revenue recognition requirements. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. The standards require the selection of a retrospective or cumulative effect transition method.

The Company will implement the new standard beginning January 1, 2018 using the retrospective transition method.  Adoption of the new standard will result in material changes to the presentation of net operating revenues and bad debt expense in the consolidated statements of operations, but the presentation of the amount of income from operations and net income will be unchanged upon adoption of the new standards. The principal change is how the new standard requires healthcare providers to estimate the amount of variable consideration to be included in the transaction price up to an amount which is probable that a significant reversal will not occur. The most common form of variable consideration the Company experiences are amounts for services provided that are ultimately not realizable from a customer. Under the current standards, the Company’s estimate for unrealizable amounts was recorded to bad debt expense. Under the new standards, the Company’s estimate for unrealizable amounts will be recognized as a constraint to revenue and will be reflected as an allowance. Substantially all of the bad debt expense as of June 30, 2016 and June 30, 2017 will be reclassified as an allowance when the Company retrospectively applies the guidance in the standards on January 1, 2018.

The Company’s remaining implementation efforts are focused principally on refining the accounting processes, disclosure processes, and internal controls.

Recently Adopted Accounting Pronouncements

Recently Adopted Accounting Pronouncements

In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes, which changed the presentation of deferred income taxes. The standard changed the presentation of deferred income taxes through the requirement that all deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The Company adopted the standard on January 1, 2017. The consolidated balance sheet at December 31, 2016 has been retrospectively adjusted. Adoption of the new standard impacted the Company’s previously reported results as follows:

	December 31, 2016
	As Reported		As Adjusted
	(in thousands)
Current deferred tax asset	$	45,165	$	—
Total current assets	808,068		762,903
Other assets	152,548		173,944
Total assets	4,944,395		4,920,626
Non-current deferred tax liability	222,847		199,078
Total liabilities	3,616,335		3,592,566
Total liabilities and equity	4,944,395		4,920,626

Reclassifications

Reclassifications

Certain reclassifications have been made to prior year amounts in order to conform to current year presentation. As discussed above, the condensed consolidated balance sheet at December 31, 2016 has been changed in order to conform to the current year balance sheet presentation for the adoption of ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes.

XML

Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2017

Accounting Policies

Schedule of adoption of the new standard impacted our previously reported results

	December 31, 2016
	As Reported		As Adjusted
	(in thousands)
Current deferred tax asset	$	45,165	$	—
Total current assets	808,068		762,903
Other assets	152,548		173,944
Total assets	4,944,395		4,920,626
Non-current deferred tax liability	222,847		199,078
Total liabilities	3,616,335		3,592,566
Total liabilities and equity	4,944,395		4,920,626

XML

Acquisitions (Tables)

6 Months Ended

Jun. 30, 2017

Acquisitions

Schedule of pro forma unaudited results of operations

	For the Six Months Ended June 30, 2016
	(in thousands, except per share amounts)
Net revenue	$	2,239,491
Net income attributable to Holdings	86,948
Income per common share:
Basic	$	0.66
Diluted	$	0.66

Physiotherapy

Acquisitions

Schedule of reconciliation of the allocation of the consideration given for identifiable net assets and goodwill acquired to the net cash paid for the acquired business

The following table reconciles the allocation of the consideration given for identifiable net assets and goodwill acquired to the net cash paid for the acquired business (in thousands):

Cash and cash equivalents	$	12,340
Identifiable tangible assets, excluding cash and cash equivalents	87,832
Identifiable intangible assets	32,484
Goodwill	343,187
Total assets	475,843
Total liabilities	54,685
Acquired non-controlling interests	2,514
Net assets acquired	418,644
Less: Cash and cash equivalents acquired	(12,340		)
Net cash paid	$	406,304

XML

Intangible Assets and Liabilities (Tables)

6 Months Ended

Jun. 30, 2017

Intangible Assets and Liabilities

Schedule of changes in goodwill

	Specialty Hospitals			Outpatient Rehabilitation		Concentra		Total
	(in thousands)
Balance as of December 31, 2016	$	1,447,406		$	643,557	$	660,037	$	2,751,000
Acquired	654			311		14,505		15,470
Measurement period adjustment	(342		)	168		—		(174		)
Balance as of June 30, 2017	$	1,447,718		$	644,036	$	674,542	$	2,766,296

Schedule of identifiable intangible assets and liabilities

	December 31, 2016							June 30, 2017
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
	(in thousands)
Indefinite-lived assets:
Trademarks	$	166,698	$	—		$	166,698	$	166,698	$	—		$	166,698
Certificates of need	17,026		—			17,026		19,207		—			19,207
Accreditations	2,235		—			2,235		2,074		—			2,074
Finite-lived assets:
Customer relationships	142,198		(23,185		)	119,013		143,953		(30,681		)	113,272
Favorable leasehold interests	13,089		(2,317		)	10,772		13,295		(3,255		)	10,040
Non-compete agreements	26,655		(1,837		)	24,818		27,267		(2,854		)	24,413
Total identifiable intangible assets	$	367,901	$	(27,339	)	$	340,562	$	372,494	$	(36,790	)	$	335,704
Finite-lived liabilities:
Unfavorable leasehold interests	$	5,139	$	(1,410	)	$	3,729	$	5,343	$	(1,957	)	$	3,386

XML

Long-Term Debt and Notes Payable (Tables)

6 Months Ended

Jun. 30, 2017

Long-Term Debt and Notes Payable

Schedule of Company's long-term debt and notes payable

The Company’s long-term debt and notes payable as of June 30, 2017 are as follows (in thousands):

	Principal Outstanding		Unamortized Premium (Discount)			Unamortized Issuance Costs			Carrying Value		Fair Value
Select:
6.375% senior notes	$	710,000	$	892		$	(7,510	)	$	703,382	$	732,152
Credit facilities:
Revolving facility	300,000		—			—			300,000		276,000
Term loan	1,147,125		(13,480		)	(13,540		)	1,120,105		1,158,596
Other	25,700		—			—			25,700		25,700
Total Select debt	$	2,182,825	$	(12,588	)	$	(21,050	)	$	2,149,187	$	2,192,448
Concentra:
Credit facilities:
Term loan	$	619,175	$	(2,513	)	$	(11,867	)	$	604,795	$	617,434
Other	6,727		—			—			6,727		6,727
Total Concentra debt	$	625,902	$	(2,513	)	$	(11,867	)	$	611,522	$	624,161
Total debt	$	2,808,727	$	(15,101	)	$	(32,917	)	$	2,760,709	$	2,816,609

The Company’s long-term debt and notes payable as of December 31, 2016 are as follows (in thousands):

	Principal Outstanding		Unamortized Premium (Discount)			Unamortized Issuance Costs			Carrying Value		Fair Value
Select:
6.375% senior notes	$	710,000	$	1,006		$	(8,461	)	$	702,545	$	710,000
Credit facilities:
Revolving facility	220,000		—			—			220,000		204,600
Term loans	1,147,751		(11,967		)	(13,581		)	1,122,203		1,165,860
Other	22,688		—			—			22,688		22,688
Total Select debt	$	2,100,439	$	(10,961	)	$	(22,042	)	$	2,067,436	$	2,103,148
Concentra:
Credit facilities:
Term loan	$	642,239	$	(2,773	)	$	(13,091	)	$	626,375	$	644,648
Other	5,178		—			—			5,178		5,178
Total Concentra debt	$	647,417	$	(2,773	)	$	(13,091	)	$	631,553	$	649,826
Total debt	$	2,747,856	$	(13,734	)	$	(35,133	)	$	2,698,989	$	2,752,974

Schedule of principal maturities of the Company's long-term debt and notes payable

Principal maturities of the Company’s long-term debt and notes payable are approximately as follows (in thousands):

	2017		2018		2019		2020		2021		Thereafter		Total
Select:
6.375% senior notes	$	—	$	—	$	—	$	—	$	710,000	$	—	$	710,000
Credit facilities:
Revolving facility	—		—		—		—		—		300,000		300,000
Term loan	5,750		11,500		11,500		11,500		11,500		1,095,375		1,147,125
Other	10,251		3,530		11,827		68		14		10		25,700
Total Select debt	$	16,001	$	15,030	$	23,327	$	11,568	$	721,514	$	1,395,385	$	2,182,825
Concentra:
Credit facilities:
Term loan	$	—	$	—	$	—	$	3,016	$	6,520	$	609,639	$	619,175
Other	1,309		1,394		144		161		160		3,559		6,727
Total Concentra debt	$	1,309	$	1,394	$	144	$	3,177	$	6,680	$	613,198	$	625,902
Total debt	$	17,310	$	16,424	$	23,471	$	14,745	$	728,194	$	2,008,583	$	2,808,727

XML

Segment Information (Tables)

6 Months Ended

Jun. 30, 2017

Segment Information

Schedule of selected financial data for the Company's reportable segments

	Three Months Ended June 30,						Six Months Ended June 30,
	2016			2017			2016			2017
	(in thousands)
Net operating revenues:
Specialty hospitals	$	585,816		$	600,960		$	1,184,770		$	1,199,747
Outpatient rehabilitation(1)	256,928			258,106			495,010			513,923
Concentra	254,868			261,586			505,745			517,735
Other	19			23			436			631
Total Company	$	1,097,631		$	1,120,675		$	2,185,961		$	2,232,036
Adjusted EBITDA:
Specialty hospitals	$	82,739		$	98,172		$	169,495		$	186,837
Outpatient rehabilitation(1)	38,132			41,926			67,011			73,277
Concentra	43,039			43,061			77,192			85,653
Other	(22,453		)	(24,479		)	(43,626		)	(48,197		)
Total Company	$	141,457		$	158,680		$	270,072		$	297,570
Total assets:(2)
Specialty hospitals	$	2,457,948		$	2,655,617		$	2,457,948		$	2,655,617
Outpatient rehabilitation	959,748			982,811			959,748			982,811
Concentra	1,328,243			1,310,483			1,328,243			1,310,483
Other	73,950			105,300			73,950			105,300
Total Company	$	4,819,889		$	5,054,211		$	4,819,889		$	5,054,211
Purchases of property and equipment, net:
Specialty hospitals	$	21,313		$	36,691		$	54,988		$	69,048
Outpatient rehabilitation(1)	3,825			6,201			8,798			12,874
Concentra	4,716			7,601			7,927			16,287
Other	3,636			4,156			8,545			7,093
Total Company	$	33,490		$	54,649		$	80,258		$	105,302

Schedule of reconciliation of Adjusted EBITDA to income before income taxes

	Three Months Ended June 30, 2016
	Specialty Hospitals			Outpatient Rehabilitation(1)			Concentra			Other			Total
	(in thousands)
Adjusted EBITDA	$	82,739		$	38,132		$	43,039		$	(22,453	)
Depreciation and amortization	(13,812		)	(6,202		)	(14,916		)	(1,275		)
Stock compensation expense	—			—			(192		)	(4,006		)
Income (loss) from operations	$	68,927		$	31,930		$	27,931		$	(27,734	)	$	101,054
Equity in earnings of unconsolidated subsidiaries													4,546
Non-operating gain													13,035
Interest expense													(44,332		)
Income before income taxes													$	74,303

	Three Months Ended June 30, 2017
	Specialty Hospitals			Outpatient Rehabilitation			Concentra			Other			Total
	(in thousands)
Adjusted EBITDA	$	98,172		$	41,926		$	43,061		$	(24,479	)
Depreciation and amortization	(15,454		)	(5,878		)	(15,429		)	(1,572		)
Stock compensation expense	—			—			(264		)	(4,420		)
Income (loss) from operations	$	82,718		$	36,048		$	27,368		$	(30,471	)	$	115,663
Equity in earnings of unconsolidated subsidiaries													5,666
Interest expense													(37,655		)
Income before income taxes													$	83,674

	Six Months Ended June 30, 2016
	Specialty Hospitals			Outpatient Rehabilitation(1)			Concentra			Other			Total
	(in thousands)
Adjusted EBITDA	$	169,495		$	67,011		$	77,192		$	(43,626	)
Depreciation and amortization	(27,705		)	(10,238		)	(30,292		)	(2,487		)
Stock compensation expense	—			—			(384		)	(7,790		)
Physiotherapy acquisition costs	—			—			—			(3,236		)
Income (loss) from operations	$	141,790		$	56,773		$	46,516		$	(57,139	)	$	187,940
Loss on early retirement of debt													(773		)
Equity in earnings of unconsolidated subsidiaries													9,198
Non-operating gain													38,122
Interest expense													(83,180		)
Income before income taxes													$	151,307

	Six Months Ended June 30, 2017
	Specialty Hospitals			Outpatient Rehabilitation			Concentra			Other			Total
	(in thousands)
Adjusted EBITDA	$	186,837		$	73,277		$	85,653		$	(48,197	)
Depreciation and amortization	(33,954		)	(12,218		)	(31,552		)	(3,148		)
Stock compensation expense	—			—			(570		)	(8,700		)
Income (loss) from operations	$	152,883		$	61,059		$	53,531		$	(60,045	)	$	207,428
Loss on early retirement of debt													(19,719		)
Equity in earnings of unconsolidated subsidiaries													11,187
Non-operating loss													(49		)
Interest expense													(78,508		)
Income before income taxes													$	120,339

(1) The outpatient rehabilitation segment includes the operating results of the Company’s contract therapy businesses through March 31, 2016 and Physiotherapy beginning March 4, 2016.

(2) Reflects the retrospective adoption of ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. Total assets as of June 30, 2016 were retrospectively conformed to reflect the adoption of the standard, resulting in a reduction to total assets of $18.5 million.

XML

Income per Common Share (Tables)

6 Months Ended

Jun. 30, 2017

Income per Common Share

Schedule of computation of basic and diluted earnings per share

	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2017		2016		2017
	(in thousands, except per share amounts)
Numerator:
Net income attributable to Select Medical Holdings Corporation	$	33,935	$	42,055	$	88,768	$	57,925
Less: Earnings allocated to unvested restricted stockholders	972		1,341		2,552		1,849
Net income available to common stockholders	$	32,963	$	40,714	$	86,216	$	56,076
Denominator:
Weighted average shares—basic	127,626		128,624		127,563		128,544
Effect of dilutive securities:
Stock options	194		153		146		159
Weighted average shares—diluted	127,820		128,777		127,709		128,703
Basic income per common share:	$	0.26	$	0.32	$	0.68	$	0.44
Diluted income per common share:	$	0.26	$	0.32	$	0.68	$	0.44

XML

Condensed Consolidating Financial Information (Tables) - Select Medical Corporation

6 Months Ended

Jun. 30, 2017

Schedule of Condensed Consolidating Balance Sheet

Select Medical Corporation

Condensed Consolidating Balance Sheet

June 30, 2017

(unaudited)

	Select (Parent Company Only)			Subsidiary Guarantors		Non-Guarantor Subsidiaries			Non-Guarantor Concentra		Eliminations			Consolidated Select Medical Corporation
	(in thousands)
Assets
Current Assets:
Cash and cash equivalents	$	72		$	5,533	$	4,946		$	63,248	$	—		$	73,799
Accounts receivable, net	—			467,412		120,272			126,552		—			714,236
Intercompany receivables	—			1,489,631		58,333			—		(1,547,964		) (a)	—
Other current assets	17,584			28,326		12,786			24,515		—			83,211
Total Current Assets	17,656			1,990,902		196,337			214,315		(1,547,964		)	871,246
Property and equipment, net	56,568			620,364		54,964			179,636		—			911,532
Investment in affiliates	4,523,727			118,248		—			—		(4,641,975		) (b) (c)	—
Goodwill	—			2,091,754		—			674,542		—			2,766,296
Identifiable intangible assets, net	—			109,913		—			225,791		—			335,704
Other assets	42,452			98,649		36,528			16,199		(24,395		) (d)	169,433
Total Assets	$	4,640,403		$	5,029,830	$	287,829		$	1,310,483	$	(6,214,334	)	$	5,054,211
Liabilities and Equity
Current Liabilities:
Bank overdrafts	$	34,134		$	—	$	—		$	—	$	—		$	34,134
Current portion of long-term debt and notes payable	23,052			644		244			2,637		—			26,577
Accounts payable	10,362			75,105		22,387			15,777		—			123,631
Intercompany payables	1,489,631			58,333		—			—		(1,547,964		) (a)	—
Accrued payroll	7,526			80,245		3,545			27,871		—			119,187
Accrued vacation	3,927			58,895		12,214			17,214		—			92,250
Accrued interest	17,096			5		4			2,172		—			19,277
Accrued other	44,032			60,078		10,533			32,210		—			146,853
Income taxes payable	2,709			—		—			4,267		—			6,976
Total Current Liabilities	1,632,469			333,305		48,927			102,148		(1,547,964		)	568,885
Long-term debt, net of current portion	2,115,318			266		9,663			608,885		—			2,734,132
Non-current deferred tax liability	—			136,920		736			84,150		(24,395		) (d)	197,411
Other non-current liabilities	44,297			54,100		7,688			35,194		—			141,279
Total Liabilities	3,792,084			524,591		67,014			830,377		(1,572,359		)	3,641,707
Redeemable non-controlling interests	—			—		10,079			458,771		—			468,850
Stockholder’s Equity:
Common stock	0			—		—			—		—			0
Capital in excess of par	936,428			—		—			—		—			936,428
Retained earnings (accumulated deficit)	(88,109		)	1,314,773		(37,110		)	12,447		(1,290,110		) (c)	(88,109		)
Subsidiary investment	—			3,190,466		156,262			5,137		(3,351,865		) (b)	—
Total Select Medical Corporation Stockholder’s Equity	848,319			4,505,239		119,152			17,584		(4,641,975		)	848,319
Non-controlling interests	—			—		91,584			3,751		—			95,335
Total Equity	848,319			4,505,239		210,736			21,335		(4,641,975		)	943,654
Total Liabilities and Equity	$	4,640,403		$	5,029,830	$	287,829		$	1,310,483	$	(6,214,334	)	$	5,054,211

(a) Elimination of intercompany balances.

(b) Elimination of investments in consolidated subsidiaries.

(c) Elimination of investments in consolidated subsidiaries’ earnings.

(d) Reclass of non-current deferred tax asset to report net non-current deferred tax liability in consolidation.

Select Medical Corporation

Condensed Consolidating Balance Sheet

December 31, 2016

(unaudited)

	Select (Parent Company Only)			Subsidiary Guarantors		Non-Guarantor Subsidiaries			Non-Guarantor Concentra		Eliminations			Consolidated Select Medical Corporation
	(in thousands)
Assets
Current Assets:
Cash and cash equivalents	$	11,071		$	6,467	$	5,056		$	76,435	$	—		$	99,029
Accounts receivable, net	—			363,470		97,770			112,512		—			573,752
Intercompany receivables	—			1,573,960		28,271			—		(1,602,231		) (a)	—
Prepaid income taxes	6,658			—		—			5,765		—			12,423
Other current assets	11,953			33,958		10,269			21,519		—			77,699
Total Current Assets	29,682			1,977,855		141,366			216,231		(1,602,231		)	762,903
Property and equipment, net	48,697			603,408		50,869			189,243		—			892,217
Investment in affiliates	4,493,684			89,288		—			—		(4,582,972		) (b) (c)	—
Goodwill	—			2,090,963		—			660,037		—			2,751,000
Identifiable intangible assets, net	—			109,132		—			231,430		—			340,562
Other assets	45,636			84,803		53,954			16,235		(26,684		) (d)	173,944
Total Assets	$	4,617,699		$	4,955,449	$	246,189		$	1,313,176	$	(6,211,887	)	$	4,920,626
Liabilities and Equity
Current Liabilities:
Bank overdrafts	$	39,362		$	—	$	—		$	—	$	—		$	39,362
Current portion of long-term debt and notes payable	7,227			445		1,324			4,660		—			13,656
Accounts payable	10,775			78,608		22,397			14,778		—			126,558
Intercompany payables	1,573,960			28,271		—			—		(1,602,231		) (a)	—
Accrued payroll	16,963			92,216		4,246			32,972		—			146,397
Accrued vacation	3,440			55,486		10,668			13,667		—			83,261
Accrued interest	20,114			—		—			2,211		—			22,325
Accrued other	39,155			62,384		4,639			33,898		—			140,076
Total Current Liabilities	1,710,996			317,410		43,274			102,186		(1,602,231		)	571,635
Long-term debt, net of current portion	2,048,154			601		9,685			626,893		—			2,685,333
Non-current deferred tax liability	—			133,852		596			91,314		(26,684		) (d)	199,078
Other non-current liabilities	42,824			53,537		5,727			34,432		—			136,520
Total Liabilities	3,801,974			505,400		59,282			854,825		(1,628,915		)	3,592,566
Redeemable non-controlling interests	—			113		10,056			411,990		—			422,159
Stockholder’s Equity:
Common stock	0			—		—			—		—			0
Capital in excess of par	925,111			—		—			—		—			925,111
Retained earnings (accumulated deficit)	(109,386		)	1,269,014		(38,313		)	1,364		(1,232,065		) (c)	(109,386		)
Subsidiary investment	—			3,180,922		128,556			41,429		(3,350,907		) (b)	—
Total Select Medical Corporation Stockholder’s Equity	815,725			4,449,936		90,243			42,793		(4,582,972		)	815,725
Non-controlling interests	—			—		86,608			3,568		—			90,176
Total Equity	815,725			4,449,936		176,851			46,361		(4,582,972		)	905,901
Total Liabilities and Equity	$	4,617,699		$	4,955,449	$	246,189		$	1,313,176	$	(6,211,887	)	$	4,920,626

(a) Elimination of intercompany balances.

(b) Elimination of investments in consolidated subsidiaries.

(c) Elimination of investments in consolidated subsidiaries’ earnings.

(d) Reclass of non-current deferred tax asset to report net non-current deferred tax liability in consolidation.

Schedule of Condensed Consolidating Statement of Operations

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Three Months Ended June 30, 2017

(unaudited)

	Select (Parent Company Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Eliminations			Consolidated Select Medical Corporation
	(in thousands)
Net operating revenues	$	23		$	687,886		$	171,180		$	261,586		$	—		$	1,120,675
Costs and expenses:
Cost of services	644			561,304			144,211			214,071			—			920,230
General and administrative	28,227			48			—			—			—			28,275
Bad debt expense	—			9,829			3,627			4,718			—			18,174
Depreciation and amortization	1,573			18,149			3,182			15,429			—			38,333
Total costs and expenses	30,444			589,330			151,020			234,218			—			1,005,012
Income (loss) from operations	(30,421		)	98,556			20,160			27,368			—			115,663
Other income and expense:
Intercompany interest and royalty fees	(2,263		)	3,596			(1,333		)	—			—			—
Intercompany management fees	63,504			(53,435		)	(10,069		)	—			—			—
Equity in earnings of unconsolidated subsidiaries	—			5,646			20			—			—			5,666
Interest expense	(19,623		)	(8,234		)	(2,360		)	(7,438		)	—			(37,655		)
Income before income taxes	11,197			46,129			6,418			19,930			—			83,674
Income tax expense (benefit)	(2,324		)	27,307			309			7,082			—			32,374
Equity in earnings of consolidated subsidiaries	28,534			4,200			—			—			(32,734		) (a)	—
Net income	42,055			23,022			6,109			12,848			(32,734		)	51,300
Less: Net income attributable to non-controlling interests	—			—			2,175			7,070			—			9,245
Net income attributable to Select Medical Corporation	$	42,055		$	23,022		$	3,934		$	5,778		$	(32,734	)	$	42,055

(a) Elimination of equity in earnings of subsidiaries.

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Six Months Ended June 30, 2017

(unaudited)

	Select (Parent Company Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Eliminations			Consolidated Select Medical Corporation
	(in thousands)
Net operating revenues	$	631		$	1,377,279		$	336,391		$	517,735		$	—		$	2,232,036
Costs and expenses:
Cost of services	1,176			1,142,527			282,521			422,363			—			1,848,587
General and administrative	56,263			87			—			—			—			56,350
Bad debt expense	—			21,577			6,933			10,289			—			38,799
Depreciation and amortization	3,148			39,489			6,683			31,552			—			80,872
Total costs and expenses	60,587			1,203,680			296,137			464,204			—			2,024,608
Income (loss) from operations	(59,956		)	173,599			40,254			53,531			—			207,428
Other income and expense:
Intercompany interest and royalty fees	(4,159		)	6,914			(2,755		)	—			—			—
Intercompany management fees	125,202			(106,069		)	(19,133		)	—			—			—
Loss on early retirement of debt	(19,719		)	—			—			—			—			(19,719		)
Equity in earnings of unconsolidated subsidiaries	—			11,139			48			—			—			11,187
Non-operating loss	—			(49		)	—			—			—			(49		)
Interest expense	(42,431		)	(16,307		)	(4,833		)	(14,937		)	—			(78,508		)
Income (loss) before income taxes	(1,063		)	69,227			13,581			38,594			—			120,339
Income tax expense (benefit)	(2,198		)	33,243			613			13,918			—			45,576
Equity in earnings of consolidated subsidiaries	56,790			9,775			—			—			(66,565		) (a)	—
Net income	57,925			45,759			12,968			24,676			(66,565		)	74,763
Less: Net income attributable to non-controlling interests	—			—			3,244			13,594			—			16,838
Net income attributable to Select Medical Corporation	$	57,925		$	45,759		$	9,724		$	11,082		$	(66,565	)	$	57,925

(a) Elimination of equity in earnings of subsidiaries.

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Three Months Ended June 30, 2016

(unaudited)

	Select (Parent Company Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Eliminations			Consolidated Select Medical Corporation
	(in thousands)
Net operating revenues	$	20		$	723,859		$	118,884		$	254,868		$	—		$	1,097,631
Costs and expenses:
Cost of services	606			605,730			103,767			206,882			—			916,985
General and administrative	25,844			26			—			—			—			25,870
Bad debt expense	—			10,285			2,093			5,139			—			17,517
Depreciation and amortization	1,276			17,316			2,697			14,916			—			36,205
Total costs and expenses	27,726			633,357			108,557			226,937			—			996,577
Income (loss) from operations	(27,706		)	90,502			10,327			27,931			—			101,054
Other income and expense:
Intercompany interest and royalty fees	(1,532		)	3,274			(1,742		)	—			—			—
Intercompany management fees	38,783			(32,430		)	(6,353		)	—			—			—
Equity in earnings of unconsolidated subsidiaries	—			4,519			27			—			—			4,546
Non-operating gain	10,463			2,572			—			—			—			13,035
Interest expense	(25,544		)	(6,684		)	(1,852		)	(10,252		)	—			(44,332		)
Income (loss) before income taxes	(5,536		)	61,753			407			17,679			—			74,303
Income tax expense (benefit)	(473		)	26,370			672			6,881			—			33,450
Equity in earnings of consolidated subsidiaries	38,998			(1,133		)	—			—			(37,865		) (a)	—
Netincome(loss)	33,935			34,250			(265		)	10,798			(37,865		)	40,853
Less: Net income attributable to non-controlling interests	—			18			824			6,076			—			6,918
Net income (loss) attributable to Select Medical Corporation	$	33,935		$	34,232		$	(1,089	)	$	4,722		$	(37,865	)	$	33,935

(a) Elimination of equity in earnings of subsidiaries.

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Six Months Ended June 30, 2016

(unaudited)

	Select (Parent Company Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Eliminations			Consolidated Select Medical Corporation
	(in thousands)
Net operating revenues	$	437		$	1,439,439		$	240,340		$	505,745		$	—		$	2,185,961
Costs and expenses:
Cost of services	950			1,211,439			206,774			420,084			—			1,839,247
General and administrative	54,231			(93		)	—			—			—			54,138
Bad debt expense	—			21,003			4,058			8,853			—			33,914
Depreciation and amortization	2,487			32,648			5,295			30,292			—			70,722
Total costs and expenses	57,668			1,264,997			216,127			459,229			—			1,998,021
Income (loss) from operations	(57,231		)	174,442			24,213			46,516			—			187,940
Other income and expense:
Intercompany interest and royalty fees	(2,590		)	6,044			(3,454		)	—			—			—
Intercompany management fees	94,139			(82,127		)	(12,012		)	—			—			—
Loss on early retirement of debt	(773		)	—			—			—			—			(773		)
Equity in earnings of unconsolidated subsidiaries	—			9,146			52			—			—			9,198
Non-operating gain (loss)	40,895			(2,773		)	—			—			—			38,122
Interest expense	(45,890		)	(13,318		)	(3,491		)	(20,481		)	—			(83,180		)
Income before income taxes	28,550			91,414			5,308			26,035			—			151,307
Income tax expense	8,139			31,985			607			9,779			—			50,510
Equity in earnings of consolidated subsidiaries	68,357			1,873			—			—			(70,230		) (a)	—
Net income	88,768			61,302			4,701			16,256			(70,230		)	100,797
Less: Net income attributable to non-controlling interests	—			33			2,695			9,301			—			12,029
Net income attributable to Select Medical Corporation	$	88,768		$	61,269		$	2,006		$	6,955		$	(70,230	)	$	88,768

(a) Elimination of equity in earnings of subsidiaries.

Schedule of Condensed Consolidating Statement of Cash Flows

Select Medical Corporation

Condensed Consolidating Statement of Cash Flows

For the Six Months Ended June 30, 2017

(unaudited)

	Select (Parent Company Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Eliminations			Consolidated Select Medical Corporation
	(in thousands)
Operating activities
Net income	$	57,925		$	45,759		$	12,968		$	24,676		$	(66,565	) (a)	$	74,763
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries	—			10,902			31			—			—			10,933
Depreciation and amortization	3,148			39,489			6,683			31,552			—			80,872
Provision for bad debts	—			21,577			6,933			10,289			—			38,799
Equity in earnings of unconsolidated subsidiaries	—			(11,139		)	(48		)	—			—			(11,187		)
Equity in earnings of consolidated subsidiaries	(56,790		)	(9,775		)	—			—			66,565		(a)	—
Loss on extinguishment of debt	6,527			—			—			—			—			6,527
Gain on sale of assets and businesses	(8		)	(4,828		)	(4,687		)	—			—			(9,523		)
Stock compensation expense	8,700			—			—			570			—			9,270
Amortization of debt discount, premium and issuance costs	4,342			—			—			1,632			—			5,974
Deferred income taxes	5,987			—			—			(7,461		)	—			(1,474		)
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	—			(125,418		)	(29,435		)	(24,150		)	—			(179,003		)
Other current assets	(5,631		)	5,452			(2,517		)	(2,861		)	—			(5,557		)
Other assets	3,184			(16,925		)	17,426			936			—			4,621
Accounts payable	(413		)	(1,550		)	(10		)	2,732			—			759
Accrued expenses	(5,618		)	(4,817		)	8,704			(3,102		)	—			(4,833		)
Income taxes	9,366			—			—			10,033			—			19,399
Net cash provided by (used in) operating activities	30,719			(51,273		)	16,048			44,846			—			40,340
Investing activities
Acquisition of businesses, net of cash acquired	—			(2,305		)	—			(16,203		)	—			(18,508		)
Purchases of property and equipment	(7,093		)	(71,813		)	(10,109		)	(16,287		)	—			(105,302		)
Investment in businesses	—			(9,874		)	—			—			—			(9,874		)
Proceeds from sale of assets and businesses	8			15,007			19,537			—			—			34,552
Net cash provided by (used in) investing activities	(7,085		)	(68,985		)	9,428			(32,490		)	—			(99,132		)
Financing activities
Borrowings on revolving facilities	630,000			—			—			—			—			630,000
Payments on revolving facilities	(550,000		)	—			—			—			—			(550,000		)
Proceeds from term loans	1,139,487			—			—			—			—			1,139,487
Payments on term loans	(1,150,627		)	—			—			(23,065		)	—			(1,173,692		)
Revolving facility debt issuance costs	(4,392		)	—			—			—			—			(4,392		)
Borrowings of other debt	6,572			—			105			2,767			—			9,444
Principal payments on other debt	(7,353		)	(204		)	(1,183		)	(1,697		)	—			(10,437		)
Repayments of bank overdrafts	(5,228		)	—			—			—			—			(5,228		)
Dividends paid to Holdings	(600		)	—			—			—			—			(600		)
Equity investment by Holdings	963			—			—			—			—			963
Intercompany	(93,455		)	119,528			(26,073		)	—			—			—
Proceeds from issuance of non-controlling interests	—			—			3,553			—			—			3,553
Purchase of non-controlling interests	—			—			(120		)	—			—			(120		)
Distributions to non-controlling interests	—			—			(1,868		)	(3,548		)	—			(5,416		)
Net cash provided by (used in) financing activities	(34,633		)	119,324			(25,586		)	(25,543		)	—			33,562
Net decrease in cash and cash equivalents	(10,999		)	(934		)	(110		)	(13,187		)	—			(25,230		)
Cash and cash equivalents at beginning of period	11,071			6,467			5,056			76,435			—			99,029
Cash and cash equivalents at end of period	$	72		$	5,533		$	4,946		$	63,248		$	—		$	73,799

(a) Elimination of equity in earnings of consolidated subsidiaries.

Select Medical Corporation

Condensed Consolidating Statement of Cash Flows

For the Six Months Ended June 30, 2016

(unaudited)

	Select (Parent Company Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Eliminations			Consolidated Select Medical Corporation
	(in thousands)
Operating activities
Net income	$	88,768		$	61,302		$	4,701		$	16,256		$	(70,230	) (a)	$	100,797
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries	—			12,000			39			—			—			12,039
Depreciation and amortization	2,487			32,648			5,295			30,292			—			70,722
Provision for bad debts	—			21,003			4,058			8,853			—			33,914
Equity in earnings of unconsolidated subsidiaries	—			(9,146		)	(52		)	—			—			(9,198		)
Equity in earnings of consolidated subsidiaries	(68,357		)	(1,873		)	—			—			70,230		(a)	—
Loss on extinguishment of debt	773			—			—			—			—			773
Gain on sale of assets and businesses	(40,895		)	(2,566		)	—			—			—			(43,461		)
Loss on disposal of assets	—			37			12			6			—			55
Impairment of equity investment	—			5,339			—			—			—			5,339
Stock compensation expense	7,790			—			—			384			—			8,174
Amortization of debt discount, premium and issuance costs	5,371			—			2			1,704			—			7,077
Deferred income taxes	997			—			—			(14,283		)	—			(13,286		)
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	—			(22,896		)	(9,711		)	(11,489		)	—			(44,096		)
Other current assets	(2,938		)	7,342			(1,273		)	7,880			—			11,011
Other assets	(4,268		)	(341		)	(424		)	9,541			—			4,508
Accounts payable	(2,241		)	(17,695		)	(3,371		)	7,455			—			(15,852		)
Accrued expenses	(10,175		)	36,088			(2,441		)	(2,840		)	—			20,632
Income taxes	9,101			—			—			19,989			—			29,090
Net cash provided by (used in) operating activities	(13,587		)	121,242			(3,165		)	73,748			—			178,238
Investing activities
Acquisition of businesses, net of cash acquired	(408,654		)	(605		)	(8,395		)	(3,865		)	—			(421,519		)
Purchases of property and equipment	(8,545		)	(52,591		)	(11,195		)	(7,927		)	—			(80,258		)
Investment in businesses	—			(1,590		)	—			—			—			(1,590		)
Proceeds from sale of assets and businesses	63,418			7,942			6			—			—			71,366
Net cash used in investing activities	(353,781		)	(46,844		)	(19,584		)	(11,792		)	—			(432,001		)
Financing activities
Borrowings on revolving facilities	320,000			—			—			—			—			320,000
Payments on revolving facilities	(375,000		)	—			—			(5,000		)	—			(380,000		)
Proceeds from term loans	600,127			—			—			—			—			600,127
Payments on term loans	(227,399		)	—			—			(2,250		)	—			(229,649		)
Borrowings of other debt	9,765			—			9,500			2,817			—			22,082
Principal payments on other debt	(7,278		)	(385		)	(876		)	(1,387		)	—			(9,926		)
Repayments of bank overdrafts	(2,138		)	—			—			—			—			(2,138		)
Dividends paid to Holdings	(506		)	—			—			—			—			(506		)
Equity investment by Holdings	657			—			—			—			—			657
Intercompany	49,141			(68,206		)	19,065			—			—			—
Proceeds from issuance of non-controlling interests	—			—			3,103			—			—			3,103
Purchase of non-controlling interests	—			(1,294		)	—			—			—			(1,294		)
Distributions to non-controlling interests	—			(108		)	(3,294		)	(1,306		)	—			(4,708		)
Net cash provided by (used in) financing activities	367,369			(69,993		)	27,498			(7,126		)	—			317,748
Net increase in cash and cash equivalents	1			4,405			4,749			54,830			—			63,985
Cash and cash equivalents at beginning of period	4,070			3,706			625			6,034			—			14,435
Cash and cash equivalents at end of period	$	4,071		$	8,111		$	5,374		$	60,864		$	—		$	78,420

(a) Elimination of equity in earnings of consolidated subsidiaries.

XML

Accounting Policies (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016	Jun. 30, 2016
Recently Adopted Accounting Pronouncements
Total current assets	$ 871,246	$ 762,903
Other assets	169,433	173,944
Total assets	5,054,211	4,920,626	$ 4,819,889
Non-current deferred tax liability	197,411	199,078
Total liabilities	3,641,707	3,592,566
Total liabilities and equity	$ 5,054,211	4,920,626
ASU 2015-17
Recently Adopted Accounting Pronouncements
Total current assets		762,903
Other assets		173,944
Total assets		4,920,626
Non-current deferred tax liability		199,078
Total liabilities		3,592,566
Total liabilities and equity		4,920,626
As Reported | ASU 2015-17
Recently Adopted Accounting Pronouncements
Current deferred tax asset		45,165
Total current assets		808,068
Other assets		152,548
Total assets		4,944,395
Non-current deferred tax liability		222,847
Total liabilities		3,616,335
Total liabilities and equity		$ 4,944,395

XML

Acquisitions - Physiotherapy Acquisition (Details) - USD ($) $ in Thousands		3 Months Ended	6 Months Ended
	Mar. 04, 2016	Mar. 31, 2017	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Mar. 03, 2016
Consideration given for identifiable net assets and goodwill acquired to the net cash paid
Goodwill			$ 2,766,296		$ 2,751,000
Net cash paid			$ 18,508	$ 421,519
Physiotherapy
Acquisitions
Voting equity interests acquired	100.00%
Consideration given for identifiable net assets and goodwill acquired to the net cash paid
Cash and cash equivalents	$ 12,300	$ 12,340
Identifiable tangible assets, excluding cash and cash equivalents		87,832
Identifiable intangible assets		32,484
Goodwill		343,187
Total assets		475,843
Total liabilities		54,685
Acquired non-controlling interests		2,514
Net assets acquired		418,644
Net cash paid	$ 406,300	$ 406,304
Estimated value of goodwill, deductible for tax purposes						$ 8,800

XML

Acquisitions - Proforma Results and Other Acquisitions (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended	6 Months Ended
	Mar. 04, 2016	Mar. 31, 2017	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Acquisitions
Net cash paid			$ 18,508	$ 421,519
Goodwill			2,766,296		$ 2,751,000
Pro Forma
Pro forma results of operations
Net revenue				2,239,491
Net income attributable to Holdings				$ 86,948
Income per common share:
Basic (in dollars per share)				$ 0.66
Diluted (in dollars per share)				$ 0.66
Specialty Hospitals
Acquisitions
Goodwill			1,447,718		1,447,406
Outpatient Rehabilitation
Acquisitions
Goodwill			644,036		643,557
Concentra
Acquisitions
Goodwill			674,542		$ 660,037
Physiotherapy
Acquisitions
Net cash paid	$ 406,300	$ 406,304
Goodwill		$ 343,187
Physiotherapy | Pro Forma
Proforma acquisition costs
Acquisition costs excluded from proforma results				$ 3,200
Other Acquisitions
Acquisitions
Total consideration (net of cash acquired)			20,200
Net cash paid			18,500
Other Acquisitions | Specialty Hospitals
Acquisitions
Goodwill			700
Other Acquisitions | Outpatient Rehabilitation
Acquisitions
Goodwill			300
Other Acquisitions | Concentra
Acquisitions
Goodwill			$ 14,500

XML

Intangible Assets and Liabilities - Changes in the Carrying Amount of Goodwill (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2017 USD ($)
Goodwill
Balance at the beginning of the period	$ 2,751,000
Acquired	15,470
Measurement period adjustment	(174)
Balance at the end of the period	2,766,296
Specialty Hospitals
Goodwill
Balance at the beginning of the period	1,447,406
Acquired	654
Measurement period adjustment	(342)
Balance at the end of the period	1,447,718
Outpatient Rehabilitation
Goodwill
Balance at the beginning of the period	643,557
Acquired	311
Measurement period adjustment	168
Balance at the end of the period	644,036
Concentra
Goodwill
Balance at the beginning of the period	660,037
Acquired	14,505
Balance at the end of the period	$ 674,542

XML

Intangible Assets and Liabilities - Identifiable Intangible Assets and Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Finite-lived assets:
Accumulated Amortization	$ (36,790)		$ (36,790)		$ (27,339)
Total identifiable intangible assets, Gross Carrying Amount	372,494		372,494		367,901
Total identifiable intangible assets, Net (Excluding Goodwill), Total	335,704		335,704		340,562
Identifiable intangibles-Finite lived liabilities:
Unfavorable leasehold interests, Gross Carrying Amount	5,343		5,343		5,139
Unfavorable leasehold interests, Accumulated Amortization	(1,957)		(1,957)		(1,410)
Unfavorable leasehold interests, Net Carrying Amount	3,386		3,386		3,729
Customer relationships
Finite-lived assets:
Identifiable intangibles - Finite lived assets, Gross Carrying Amount	143,953		143,953		142,198
Accumulated Amortization	(30,681)		(30,681)		(23,185)
Identifiable intangibles - Finite lived assets, Net Carrying Amount	113,272		113,272		119,013
Favorable leasehold interests
Finite-lived assets:
Identifiable intangibles - Finite lived assets, Gross Carrying Amount	13,295		13,295		13,089
Accumulated Amortization	(3,255)		(3,255)		(2,317)
Identifiable intangibles - Finite lived assets, Net Carrying Amount	10,040		10,040		10,772
Non-compete agreements
Finite-lived assets:
Identifiable intangibles - Finite lived assets, Gross Carrying Amount	27,267		27,267		26,655
Accumulated Amortization	(2,854)		(2,854)		(1,837)
Identifiable intangibles - Finite lived assets, Net Carrying Amount	24,413		24,413		24,818
Customer relationships and non-compete agreements
Finite-lived assets:
Amortization expense	4,300	$ 4,300	$ 8,700	$ 8,100
Trademarks
Identifiable Intangible Assets and Liabilities
Weighted average time until next renewal			2 years 4 months 24 days
Indefinite-lived assets:
Identifiable intangibles - Indefinite lived assets	166,698		$ 166,698		166,698
Certificates of need
Indefinite-lived assets:
Identifiable intangibles - Indefinite lived assets	19,207		$ 19,207		17,026
Accreditations
Identifiable Intangible Assets and Liabilities
Weighted average time until next renewal			1 year 6 months
Indefinite-lived assets:
Identifiable intangibles - Indefinite lived assets	$ 2,074		$ 2,074		$ 2,235

XML

Long-Term Debt and Notes Payable - Components of Long-Term Debt And Notes Payable (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Long-term debt and notes payable
Principal Outstanding	$ 2,808,727	$ 2,747,856
Unamortized Premium (Discount)	(15,101)	(13,734)
Unamortized Issuance Costs	(32,917)	(35,133)
Carrying Value	2,760,709	2,698,989
Fair Value	2,816,609	2,752,974
Select Excluding Concentra
Long-term debt and notes payable
Principal Outstanding	2,182,825	2,100,439
Unamortized Premium (Discount)	(12,588)	(10,961)
Unamortized Issuance Costs	(21,050)	(22,042)
Carrying Value	2,149,187	2,067,436
Fair Value	$ 2,192,448	2,103,148
Select Excluding Concentra | 6.375% senior notes
Long-term debt and notes payable
Interest rate of debt (as a percent)	6.375%
Principal Outstanding	$ 710,000	710,000
Unamortized Premium (Discount)	892	1,006
Unamortized Issuance Costs	(7,510)	(8,461)
Carrying Value	703,382	702,545
Fair Value	732,152	710,000
Select Excluding Concentra | Revolving facility
Long-term debt and notes payable
Principal Outstanding	300,000	220,000
Carrying Value	300,000	220,000
Fair Value	276,000	204,600
Select Excluding Concentra | Term loan
Long-term debt and notes payable
Principal Outstanding	1,147,125	1,147,751
Unamortized Premium (Discount)	(13,480)	(11,967)
Unamortized Issuance Costs	(13,540)	(13,581)
Carrying Value	1,120,105	1,122,203
Fair Value	1,158,596	1,165,860
Select Excluding Concentra | Other
Long-term debt and notes payable
Principal Outstanding	25,700	22,688
Carrying Value	25,700	22,688
Fair Value	25,700	22,688
Concentra Inc
Long-term debt and notes payable
Principal Outstanding	625,902	647,417
Unamortized Premium (Discount)	(2,513)	(2,773)
Unamortized Issuance Costs	(11,867)	(13,091)
Carrying Value	611,522	631,553
Fair Value	624,161	649,826
Concentra Inc | Term loan
Long-term debt and notes payable
Principal Outstanding	619,175	642,239
Unamortized Premium (Discount)	(2,513)	(2,773)
Unamortized Issuance Costs	(11,867)	(13,091)
Carrying Value	604,795	626,375
Fair Value	617,434	644,648
Concentra Inc | Other
Long-term debt and notes payable
Principal Outstanding	6,727	5,178
Carrying Value	6,727	5,178
Fair Value	$ 6,727	$ 5,178

XML

Long-Term Debt and Notes Payable - Maturities Of Long-Term Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Long-term debt and notes payable
2017	$ 17,310
2018	16,424
2019	23,471
2020	14,745
2021	728,194
Thereafter	2,008,583
Total	2,808,727	$ 2,747,856
Select Excluding Concentra
Long-term debt and notes payable
2017	16,001
2018	15,030
2019	23,327
2020	11,568
2021	721,514
Thereafter	1,395,385
Total	$ 2,182,825	2,100,439
Select Excluding Concentra | 6.375% senior notes
Long-term debt and notes payable
Interest rate of debt (as a percent)	6.375%
2021	$ 710,000
Total	710,000	710,000
Select Excluding Concentra | Revolving facility
Long-term debt and notes payable
Thereafter	300,000
Total	300,000	220,000
Select Excluding Concentra | Term loan
Long-term debt and notes payable
2017	5,750
2018	11,500
2019	11,500
2020	11,500
2021	11,500
Thereafter	1,095,375
Total	1,147,125	1,147,751
Select Excluding Concentra | Other
Long-term debt and notes payable
2017	10,251
2018	3,530
2019	11,827
2020	68
2021	14
Thereafter	10
Total	25,700	22,688
Concentra Inc
Long-term debt and notes payable
2017	1,309
2018	1,394
2019	144
2020	3,177
2021	6,680
Thereafter	613,198
Total	625,902	647,417
Concentra Inc | Term loan
Long-term debt and notes payable
2020	3,016
2021	6,520
Thereafter	609,639
Total	619,175	642,239
Concentra Inc | Other
Long-term debt and notes payable
2017	1,309
2018	1,394
2019	144
2020	161
2021	160
Thereafter	3,559
Total	$ 6,727	$ 5,178
Select Medical Corporation | 6.375% senior notes
Long-term debt and notes payable
Interest rate of debt (as a percent)	6.375%

XML

Long-Term Debt and Notes Payable - Select Credit Facilities (Details) $ in Thousands				3 Months Ended	6 Months Ended
	Apr. 01, 2019	Jun. 30, 2017	Mar. 06, 2017 USD ($)	Mar. 31, 2017 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2016 USD ($)
Long-term debt and notes payable
Loss on extinguishment of debt					$ 6,527	$ 773
Select Medical Corporation
Long-term debt and notes payable
Loss on extinguishment of debt					$ 6,527	$ 773
Capital stock of foreign subsidiaries pledged (as a percent)			65.00%
Select Medical Corporation | Credit agreement
Long-term debt and notes payable
Current borrowing capacity			$ 1,600,000
Loss on extinguishment of debt				$ 6,500
Debt modification losses				$ 13,200
Percentage of net cash proceeds received from non-ordinary course asset sales or other dispositions, or as a result of a casualty or condemnation to be used for prepayment of debt			100.00%
Percentage of net proceeds received from the issuance of debt obligations other than certain permitted debt obligations to be used for prepayment of debt			100.00%
Leverage ratio of financial maintenance covenant		5.86
Select Medical Corporation | Credit agreement | Leverage ratio greater than 4.50 to 1.00
Long-term debt and notes payable
Percentage of excess cash flow to be used for prepayment of debt			50.00%
Leverage ratio of financial maintenance covenant			4.50
Select Medical Corporation | Credit agreement | Leverage ratio less than or equal to 4.50 to 1.00 and greater than 4.00 to 1.00
Long-term debt and notes payable
Percentage of excess cash flow to be used for prepayment of debt			25.00%
Leverage ratio of financial maintenance covenant			4.00
Select Medical Corporation | Credit agreement | Leverage ratio less than 6.25 to 1.00
Long-term debt and notes payable
Leverage ratio of financial maintenance covenant			6.25
Select Medical Corporation | Credit agreement | Future leverage ratio less than 6.00 to 1.00
Long-term debt and notes payable
Leverage ratio of financial maintenance covenant	6.00
Select Medical Corporation | Credit agreement | Term loan
Long-term debt and notes payable
Aggregate principal amount			$ 1,150,000
Debt instrument term (in years)			7 years
Percentage of amortization of term loan			0.25%
Select Medical Corporation | Credit agreement | Term loan | Adjusted LIBO
Long-term debt and notes payable
Interest rate margin (as a percent)			3.50%
Select Medical Corporation | Credit agreement | Term loan | Alternate Base Rate
Long-term debt and notes payable
Interest rate margin (as a percent)			2.50%
Select Medical Corporation | Credit agreement | Term loan | Alternate Base Rate floor
Long-term debt and notes payable
Interest rate margin (as a percent)			2.00%
Select Medical Corporation | Credit agreement | Term loan | Adjusted LIBO Rate floor
Long-term debt and notes payable
Interest rate margin (as a percent)			1.00%
Select Medical Corporation | Credit agreement | Revolving facility
Long-term debt and notes payable
Current borrowing capacity			$ 450,000
Debt instrument term (in years)			5 years
Select Medical Corporation | Credit agreement | Revolving facility | Adjusted LIBO | Minimum
Long-term debt and notes payable
Interest rate margin (as a percent)			3.00%
Select Medical Corporation | Credit agreement | Revolving facility | Adjusted LIBO | Maximum
Long-term debt and notes payable
Interest rate margin (as a percent)			3.25%
Select Medical Corporation | Credit agreement | Revolving facility | Alternate Base Rate | Minimum
Long-term debt and notes payable
Interest rate margin (as a percent)			2.00%
Select Medical Corporation | Credit agreement | Revolving facility | Alternate Base Rate | Maximum
Long-term debt and notes payable
Interest rate margin (as a percent)			2.25%
Select Medical Corporation | Credit agreement | Standby letter of credit
Long-term debt and notes payable
Current borrowing capacity			$ 75,000

XML

Long-Term Debt and Notes Payable - Loss on Early Retirement of Debt and Excess Cash Flow Payment (Details) $ in Millions	Mar. 01, 2017 USD ($)
Select Medical Corporation | First Lien Credit Agreement - Term Loan
Long-term debt and notes payable
Principal prepayments from excess cash flow	$ 23.1

XML

Segment Information - Selected Financial Data (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Segment information
Net operating revenues	$ 1,120,675	$ 1,097,631	$ 2,232,036	$ 2,185,961
Adjusted EBITDA	158,680	141,457	297,570	270,072
Total assets	5,054,211	4,819,889	5,054,211	4,819,889	$ 4,920,626
Purchases of property and equipment, net	54,649	33,490	105,302	80,258
Operating Segments | Specialty Hospitals
Segment information
Net operating revenues	600,960	585,816	1,199,747	1,184,770
Adjusted EBITDA	98,172	82,739	186,837	169,495
Total assets	2,655,617	2,457,948	2,655,617	2,457,948
Purchases of property and equipment, net	36,691	21,313	69,048	54,988
Operating Segments | Outpatient Rehabilitation
Segment information
Net operating revenues	258,106	256,928	513,923	495,010
Adjusted EBITDA	41,926	38,132	73,277	67,011
Total assets	982,811	959,748	982,811	959,748
Purchases of property and equipment, net	6,201	3,825	12,874	8,798
Operating Segments | Concentra
Segment information
Net operating revenues	261,586	254,868	517,735	505,745
Adjusted EBITDA	43,061	43,039	85,653	77,192
Total assets	1,310,483	1,328,243	1,310,483	1,328,243
Purchases of property and equipment, net	7,601	4,716	16,287	7,927
Other
Segment information
Net operating revenues	23	19	631	436
Adjusted EBITDA	(24,479)	(22,453)	(48,197)	(43,626)
Total assets	105,300	73,950	105,300	73,950
Purchases of property and equipment, net	4,156	3,636	7,093	8,545
Other | Specialty Hospitals
Segment information
Adjusted EBITDA	98,172	82,739	186,837	169,495
Other | Outpatient Rehabilitation
Segment information
Adjusted EBITDA	41,926	38,132	73,277	67,011
Other | Concentra
Segment information
Adjusted EBITDA	$ 43,061	$ 43,039	$ 85,653	$ 77,192

XML

Segment Information - Reconciliation of Adjusted EBITDA to Income Before Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Segment information
Adjusted EBITDA	$ 158,680	$ 141,457	$ 297,570	$ 270,072
Depreciation and amortization	(38,333)	(36,205)	(80,872)	(70,722)
Income from operations	115,663	101,054	207,428	187,940
Loss on early retirement of debt			(19,719)	(773)
Write Off Of Deferred Debt Issuance Cost And Discounts			6,527	773
Equity in earnings of unconsolidated subsidiaries	5,666	4,546	11,187	9,198
Non-operating gain (loss)		13,035	(49)	38,122
Interest expense	(37,655)	(44,332)	(78,508)	(83,180)
Income before income taxes	83,674	74,303	120,339	151,307
Total assets	5,054,211	4,819,889	5,054,211	4,819,889	$ 4,920,626
ASU 2015-17
Segment information
Total assets					4,920,626
ASU 2015-17 | Restatement Adjustment
Segment information
Total assets		18,500		18,500
Operating Segments | Specialty Hospitals
Segment information
Adjusted EBITDA	98,172	82,739	186,837	169,495
Depreciation and amortization	(15,454)	(13,812)	(33,954)	(27,705)
Income from operations	82,718	68,927	152,883	141,790
Total assets	2,655,617	2,457,948	2,655,617	2,457,948
Operating Segments | Outpatient Rehabilitation
Segment information
Adjusted EBITDA	41,926	38,132	73,277	67,011
Depreciation and amortization	(5,878)	(6,202)	(12,218)	(10,238)
Income from operations	36,048	31,930	61,059	56,773
Total assets	982,811	959,748	982,811	959,748
Operating Segments | Concentra
Segment information
Adjusted EBITDA	43,061	43,039	85,653	77,192
Depreciation and amortization	(15,429)	(14,916)	(31,552)	(30,292)
Stock compensation expense	(264)	(192)	(570)	(384)
Income from operations	27,368	27,931	53,531	46,516
Total assets	1,310,483	1,328,243	1,310,483	1,328,243
Other
Segment information
Adjusted EBITDA	(24,479)	(22,453)	(48,197)	(43,626)
Depreciation and amortization	(1,572)	(1,275)	(3,148)	(2,487)
Stock compensation expense	(4,420)	(4,006)	(8,700)	(7,790)
Income from operations	(30,471)	(27,734)	(60,045)	(57,139)
Total assets	105,300	73,950	105,300	73,950
Other | Physiotherapy
Segment information
Acquisition costs				(3,236)
Other | Specialty Hospitals
Segment information
Adjusted EBITDA	98,172	82,739	186,837	169,495
Other | Outpatient Rehabilitation
Segment information
Adjusted EBITDA	41,926	38,132	73,277	67,011
Other | Concentra
Segment information
Adjusted EBITDA	43,061	43,039	85,653	77,192
Select Medical Corporation
Segment information
Depreciation and amortization	(38,333)	(36,205)	(80,872)	(70,722)
Income from operations	115,663	101,054	207,428	187,940
Loss on early retirement of debt			(19,719)	(773)
Write Off Of Deferred Debt Issuance Cost And Discounts			6,527	773
Equity in earnings of unconsolidated subsidiaries	5,666	4,546	11,187	9,198
Non-operating gain (loss)		13,035	(49)	38,122
Interest expense	(37,655)	(44,332)	(78,508)	(83,180)
Income before income taxes	83,674	$ 74,303	120,339	$ 151,307
Total assets	$ 5,054,211		$ 5,054,211		$ 4,920,626

XML

Income per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Numerator:
Net income attributable to Select Medical Corporation	$ 42,055	$ 33,935	$ 57,925	$ 88,768
Less: Earnings allocated to unvested restricted stockholders	1,341	972	1,849	2,552
Net income available to common stockholders	$ 40,714	$ 32,963	$ 56,076	$ 86,216
Denominator:
Weighted average shares - basic	128,624	127,626	128,544	127,563
Effect of dilutive securities: Stock options (in shares)	153	194	159	146
Weighted average shares - diluted	128,777	127,820	128,703	127,709
Income per common share
Basic income per common share: (in dollars per share)	$ 0.32	$ 0.26	$ 0.44	$ 0.68
Diluted income per common share: (in dollars per share)	$ 0.32	$ 0.26	$ 0.44	$ 0.68

XML

Commitments and Contingencies - Litigation (Details) $ in Millions			6 Months Ended
	Oct. 19, 2015 item	Jul. 13, 2015 item	Jun. 30, 2017 USD ($)
Select, SSH-Knoxville, and SSH-North Knoxville
Commitments and Contingencies
Number of current or former employees named as defendants | item		10
Professional liability claims
Commitments and Contingencies
Self insurance retention per occurrence | $			$ 2.0
General liability claims
Commitments and Contingencies
Self insurance retention per occurrence | $			$ 2.0
Amended complaint | SSH-Evansville
Commitments and Contingencies
Number of case managers identified as plaintiff | item	2

XML

Condensed Consolidating Financial Information (Details)	Jun. 30, 2017
6.375% senior notes | Select Medical Corporation
Condensed Consolidating Financial Information
Interest rate of debt (as a percent)	6.375%

XML

Condensed Consolidating Financial Information - Condensed Consolidating Balance Sheet (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016	Jun. 30, 2016	Dec. 31, 2015
Current Assets:
Cash and cash equivalents	$ 73,799	$ 99,029	$ 78,420	$ 14,435
Accounts receivable, net	714,236	573,752
Prepaid income taxes		12,423
Other current assets	83,211	77,699
Total Current Assets	871,246	762,903
Property and equipment, net	911,532	892,217
Goodwill	2,766,296	2,751,000
Identifiable intangible assets, net	335,704	340,562
Other assets	169,433	173,944
Total Assets	5,054,211	4,920,626	4,819,889
Current Liabilities:
Bank overdrafts	34,134	39,362
Current portion of long-term debt and notes payable	26,577	13,656
Accounts payable	123,631	126,558
Accrued payroll	119,187	146,397
Accrued vacation	92,250	83,261
Accrued interest	19,277	22,325
Accrued other	146,853	140,076
Income taxes payable	6,976
Total Current Liabilities	568,885	571,635
Long-term debt, net of current portion	2,734,132	2,685,333
Non-current deferred tax liability	197,411	199,078
Other non-current liabilities	141,279	136,520
Total Liabilities	3,641,707	3,592,566
Redeemable non-controlling interests	468,850	422,159
Stockholder's Equity:
Common stock	133	132
Capital in excess of par	454,892	443,908
Retained earnings (accumulated deficit)	393,294	371,685
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	848,319	815,725
Non-controlling interests	95,335	90,176
Total Equity	943,654	905,901
Total Liabilities and Equity	5,054,211	4,920,626
Select Medical Corporation
Current Assets:
Cash and cash equivalents	73,799	99,029	78,420	14,435
Accounts receivable, net	714,236	573,752
Prepaid income taxes		12,423
Other current assets	83,211	77,699
Total Current Assets	871,246	762,903
Property and equipment, net	911,532	892,217
Goodwill	2,766,296	2,751,000
Identifiable intangible assets, net	335,704	340,562
Other assets	169,433	173,944
Total Assets	5,054,211	4,920,626
Current Liabilities:
Bank overdrafts	34,134	39,362
Current portion of long-term debt and notes payable	26,577	13,656
Accounts payable	123,631	126,558
Accrued payroll	119,187	146,397
Accrued vacation	92,250	83,261
Accrued interest	19,277	22,325
Accrued other	146,853	140,076
Income taxes payable	6,976
Total Current Liabilities	568,885	571,635
Long-term debt, net of current portion	2,734,132	2,685,333
Non-current deferred tax liability	197,411	199,078
Other non-current liabilities	141,279	136,520
Total Liabilities	3,641,707	3,592,566
Redeemable non-controlling interests	468,850	422,159
Stockholder's Equity:
Common stock	0	0
Capital in excess of par	936,428	925,111
Retained earnings (accumulated deficit)	(88,109)	(109,386)
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	848,319	815,725
Non-controlling interests	95,335	90,176
Total Equity	943,654	905,901
Total Liabilities and Equity	5,054,211	4,920,626
Select Medical Corporation | Reportable legal entities | Select (Parent Company Only)
Current Assets:
Cash and cash equivalents	72	11,071	4,071	4,070
Prepaid income taxes		6,658
Other current assets	17,584	11,953
Total Current Assets	17,656	29,682
Property and equipment, net	56,568	48,697
Investment in affiliates	4,523,727	4,493,684
Other assets	42,452	45,636
Total Assets	4,640,403	4,617,699
Current Liabilities:
Bank overdrafts	34,134	39,362
Current portion of long-term debt and notes payable	23,052	7,227
Accounts payable	10,362	10,775
Intercompany payables	1,489,631	1,573,960
Accrued payroll	7,526	16,963
Accrued vacation	3,927	3,440
Accrued interest	17,096	20,114
Accrued other	44,032	39,155
Income taxes payable	2,709
Total Current Liabilities	1,632,469	1,710,996
Long-term debt, net of current portion	2,115,318	2,048,154
Other non-current liabilities	44,297	42,824
Total Liabilities	3,792,084	3,801,974
Stockholder's Equity:
Common stock	0	0
Capital in excess of par	936,428	925,111
Retained earnings (accumulated deficit)	(88,109)	(109,386)
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	848,319	815,725
Total Equity	848,319	815,725
Total Liabilities and Equity	4,640,403	4,617,699
Select Medical Corporation | Reportable legal entities | Subsidiary Guarantors
Current Assets:
Cash and cash equivalents	5,533	6,467	8,111	3,706
Accounts receivable, net	467,412	363,470
Intercompany receivables	1,489,631	1,573,960
Other current assets	28,326	33,958
Total Current Assets	1,990,902	1,977,855
Property and equipment, net	620,364	603,408
Investment in affiliates	118,248	89,288
Goodwill	2,091,754	2,090,963
Identifiable intangible assets, net	109,913	109,132
Other assets	98,649	84,803
Total Assets	5,029,830	4,955,449
Current Liabilities:
Current portion of long-term debt and notes payable	644	445
Accounts payable	75,105	78,608
Intercompany payables	58,333	28,271
Accrued payroll	80,245	92,216
Accrued vacation	58,895	55,486
Accrued interest	5
Accrued other	60,078	62,384
Total Current Liabilities	333,305	317,410
Long-term debt, net of current portion	266	601
Non-current deferred tax liability	136,920	133,852
Other non-current liabilities	54,100	53,537
Total Liabilities	524,591	505,400
Redeemable non-controlling interests		113
Stockholder's Equity:
Retained earnings (accumulated deficit)	1,314,773	1,269,014
Subsidiary investment	3,190,466	3,180,922
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	4,505,239	4,449,936
Total Equity	4,505,239	4,449,936
Total Liabilities and Equity	5,029,830	4,955,449
Select Medical Corporation | Reportable legal entities | Non-Guarantor Subsidiaries
Current Assets:
Cash and cash equivalents	4,946	5,056	5,374	625
Accounts receivable, net	120,272	97,770
Intercompany receivables	58,333	28,271
Other current assets	12,786	10,269
Total Current Assets	196,337	141,366
Property and equipment, net	54,964	50,869
Other assets	36,528	53,954
Total Assets	287,829	246,189
Current Liabilities:
Current portion of long-term debt and notes payable	244	1,324
Accounts payable	22,387	22,397
Accrued payroll	3,545	4,246
Accrued vacation	12,214	10,668
Accrued interest	4
Accrued other	10,533	4,639
Total Current Liabilities	48,927	43,274
Long-term debt, net of current portion	9,663	9,685
Non-current deferred tax liability	736	596
Other non-current liabilities	7,688	5,727
Total Liabilities	67,014	59,282
Redeemable non-controlling interests	10,079	10,056
Stockholder's Equity:
Retained earnings (accumulated deficit)	(37,110)	(38,313)
Subsidiary investment	156,262	128,556
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	119,152	90,243
Non-controlling interests	91,584	86,608
Total Equity	210,736	176,851
Total Liabilities and Equity	287,829	246,189
Select Medical Corporation | Reportable legal entities | Non-Guarantor Concentra
Current Assets:
Cash and cash equivalents	63,248	76,435	$ 60,864	$ 6,034
Accounts receivable, net	126,552	112,512
Prepaid income taxes		5,765
Other current assets	24,515	21,519
Total Current Assets	214,315	216,231
Property and equipment, net	179,636	189,243
Goodwill	674,542	660,037
Identifiable intangible assets, net	225,791	231,430
Other assets	16,199	16,235
Total Assets	1,310,483	1,313,176
Current Liabilities:
Current portion of long-term debt and notes payable	2,637	4,660
Accounts payable	15,777	14,778
Accrued payroll	27,871	32,972
Accrued vacation	17,214	13,667
Accrued interest	2,172	2,211
Accrued other	32,210	33,898
Income taxes payable	4,267
Total Current Liabilities	102,148	102,186
Long-term debt, net of current portion	608,885	626,893
Non-current deferred tax liability	84,150	91,314
Other non-current liabilities	35,194	34,432
Total Liabilities	830,377	854,825
Redeemable non-controlling interests	458,771	411,990
Stockholder's Equity:
Retained earnings (accumulated deficit)	12,447	1,364
Subsidiary investment	5,137	41,429
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	17,584	42,793
Non-controlling interests	3,751	3,568
Total Equity	21,335	46,361
Total Liabilities and Equity	1,310,483	1,313,176
Select Medical Corporation | Eliminations
Current Assets:
Intercompany receivables	(1,547,964)	(1,602,231)
Total Current Assets	(1,547,964)	(1,602,231)
Investment in affiliates	(4,641,975)	(4,582,972)
Other assets	(24,395)	(26,684)
Total Assets	(6,214,334)	(6,211,887)
Current Liabilities:
Intercompany payables	(1,547,964)	(1,602,231)
Total Current Liabilities	(1,547,964)	(1,602,231)
Non-current deferred tax liability	(24,395)	(26,684)
Total Liabilities	(1,572,359)	(1,628,915)
Stockholder's Equity:
Retained earnings (accumulated deficit)	(1,290,110)	(1,232,065)
Subsidiary investment	(3,351,865)	(3,350,907)
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	(4,641,975)	(4,582,972)
Total Equity	(4,641,975)	(4,582,972)
Total Liabilities and Equity	$ (6,214,334)	$ (6,211,887)

XML

Condensed Consolidating Financial Information - Condensed Consolidating Statement of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Condensed Consolidating Statement of Operations
Net operating revenues	$ 1,120,675	$ 1,097,631	$ 2,232,036	$ 2,185,961
Costs and expenses:
Cost of services	920,230	916,985	1,848,587	1,839,247
General and administrative	28,275	25,870	56,350	54,138
Bad debt expense	18,174	17,517	38,799	33,914
Depreciation and amortization	38,333	36,205	80,872	70,722
Total costs and expenses	1,005,012	996,577	2,024,608	1,998,021
Income from operations	115,663	101,054	207,428	187,940
Other income and expense:
Loss on early retirement of debt			(19,719)	(773)
Equity in earnings of unconsolidated subsidiaries	5,666	4,546	11,187	9,198
Non-operating gain (loss)		13,035	(49)	38,122
Interest expense	(37,655)	(44,332)	(78,508)	(83,180)
Income before income taxes	83,674	74,303	120,339	151,307
Income tax expense (benefit)	32,374	33,450	45,576	50,510
Net income (loss)	51,300	40,853	74,763	100,797
Less: Net income attributable to non-controlling interests	9,245	6,918	16,838	12,029
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	42,055	33,935	57,925	88,768
Select Medical Corporation
Condensed Consolidating Statement of Operations
Net operating revenues	1,120,675	1,097,631	2,232,036	2,185,961
Costs and expenses:
Cost of services	920,230	916,985	1,848,587	1,839,247
General and administrative	28,275	25,870	56,350	54,138
Bad debt expense	18,174	17,517	38,799	33,914
Depreciation and amortization	38,333	36,205	80,872	70,722
Total costs and expenses	1,005,012	996,577	2,024,608	1,998,021
Income from operations	115,663	101,054	207,428	187,940
Other income and expense:
Loss on early retirement of debt			(19,719)	(773)
Equity in earnings of unconsolidated subsidiaries	5,666	4,546	11,187	9,198
Non-operating gain (loss)		13,035	(49)	38,122
Interest expense	(37,655)	(44,332)	(78,508)	(83,180)
Income before income taxes	83,674	74,303	120,339	151,307
Income tax expense (benefit)	32,374	33,450	45,576	50,510
Net income (loss)	51,300	40,853	74,763	100,797
Less: Net income attributable to non-controlling interests	9,245	6,918	16,838	12,029
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	42,055	33,935	57,925	88,768
Select Medical Corporation | Reportable legal entities | Select (Parent Company Only)
Condensed Consolidating Statement of Operations
Net operating revenues	23	20	631	437
Costs and expenses:
Cost of services	644	606	1,176	950
General and administrative	28,227	25,844	56,263	54,231
Depreciation and amortization	1,573	1,276	3,148	2,487
Total costs and expenses	30,444	27,726	60,587	57,668
Income from operations	(30,421)	(27,706)	(59,956)	(57,231)
Other income and expense:
Intercompany interest and royalty fees	(2,263)	(1,532)	(4,159)	(2,590)
Intercompany management fees	63,504	38,783	125,202	94,139
Loss on early retirement of debt			(19,719)	(773)
Non-operating gain (loss)		10,463		40,895
Interest expense	(19,623)	(25,544)	(42,431)	(45,890)
Income before income taxes	11,197	(5,536)	(1,063)	28,550
Income tax expense (benefit)	(2,324)	(473)	(2,198)	8,139
Equity in earnings of subsidiaries	28,534	38,998	56,790	68,357
Net income (loss)	42,055	33,935	57,925	88,768
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	42,055	33,935	57,925	88,768
Select Medical Corporation | Reportable legal entities | Subsidiary Guarantors
Condensed Consolidating Statement of Operations
Net operating revenues	687,886	723,859	1,377,279	1,439,439
Costs and expenses:
Cost of services	561,304	605,730	1,142,527	1,211,439
General and administrative	48	26	87	(93)
Bad debt expense	9,829	10,285	21,577	21,003
Depreciation and amortization	18,149	17,316	39,489	32,648
Total costs and expenses	589,330	633,357	1,203,680	1,264,997
Income from operations	98,556	90,502	173,599	174,442
Other income and expense:
Intercompany interest and royalty fees	3,596	3,274	6,914	6,044
Intercompany management fees	(53,435)	(32,430)	(106,069)	(82,127)
Equity in earnings of unconsolidated subsidiaries	5,646	4,519	11,139	9,146
Non-operating gain (loss)		2,572	(49)	(2,773)
Interest expense	(8,234)	(6,684)	(16,307)	(13,318)
Income before income taxes	46,129	61,753	69,227	91,414
Income tax expense (benefit)	27,307	26,370	33,243	31,985
Equity in earnings of subsidiaries	4,200	(1,133)	9,775	1,873
Net income (loss)	23,022	34,250	45,759	61,302
Less: Net income attributable to non-controlling interests		18		33
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	23,022	34,232	45,759	61,269
Select Medical Corporation | Reportable legal entities | Non-Guarantor Subsidiaries
Condensed Consolidating Statement of Operations
Net operating revenues	171,180	118,884	336,391	240,340
Costs and expenses:
Cost of services	144,211	103,767	282,521	206,774
Bad debt expense	3,627	2,093	6,933	4,058
Depreciation and amortization	3,182	2,697	6,683	5,295
Total costs and expenses	151,020	108,557	296,137	216,127
Income from operations	20,160	10,327	40,254	24,213
Other income and expense:
Intercompany interest and royalty fees	(1,333)	(1,742)	(2,755)	(3,454)
Intercompany management fees	(10,069)	(6,353)	(19,133)	(12,012)
Equity in earnings of unconsolidated subsidiaries	20	27	48	52
Interest expense	(2,360)	(1,852)	(4,833)	(3,491)
Income before income taxes	6,418	407	13,581	5,308
Income tax expense (benefit)	309	672	613	607
Net income (loss)	6,109	(265)	12,968	4,701
Less: Net income attributable to non-controlling interests	2,175	824	3,244	2,695
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	3,934	(1,089)	9,724	2,006
Select Medical Corporation | Reportable legal entities | Non-Guarantor Concentra
Condensed Consolidating Statement of Operations
Net operating revenues	261,586	254,868	517,735	505,745
Costs and expenses:
Cost of services	214,071	206,882	422,363	420,084
Bad debt expense	4,718	5,139	10,289	8,853
Depreciation and amortization	15,429	14,916	31,552	30,292
Total costs and expenses	234,218	226,937	464,204	459,229
Income from operations	27,368	27,931	53,531	46,516
Other income and expense:
Interest expense	(7,438)	(10,252)	(14,937)	(20,481)
Income before income taxes	19,930	17,679	38,594	26,035
Income tax expense (benefit)	7,082	6,881	13,918	9,779
Net income (loss)	12,848	10,798	24,676	16,256
Less: Net income attributable to non-controlling interests	7,070	6,076	13,594	9,301
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	5,778	4,722	11,082	6,955
Select Medical Corporation | Eliminations
Other income and expense:
Equity in earnings of subsidiaries	(32,734)	(37,865)	(66,565)	(70,230)
Net income (loss)	(32,734)	(37,865)	(66,565)	(70,230)
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	$ (32,734)	$ (37,865)	$ (66,565)	$ (70,230)

XML

Condensed Consolidating Financial Information - Condensed Consolidating Statement of Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Operating activities
Net income	$ 51,300	$ 40,853	$ 74,763	$ 100,797
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries			10,933	12,039
Depreciation and amortization	38,333	36,205	80,872	70,722
Provision for bad debts	18,174	17,517	38,799	33,914
Equity in earnings of unconsolidated subsidiaries	(5,666)	(4,546)	(11,187)	(9,198)
Loss on extinguishment of debt			6,527	773
Gain on sale of assets and businesses			(9,523)	(43,461)
Loss on disposal of assets				55
Impairment of equity investment				5,339
Stock compensation expense			9,270	8,174
Amortization of debt discount, premium and issuance costs			5,974	7,077
Deferred income taxes			(1,474)	(13,286)
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable			(179,003)	(44,096)
Other current assets			(5,557)	11,011
Other assets			4,621	4,508
Accounts payable			759	(15,852)
Accrued expenses			(4,833)	20,632
Income taxes			19,399	29,090
Net cash provided by operating activities			40,340	178,238
Investing activities
Acquisition of businesses, net of cash acquired			(18,508)	(421,519)
Purchases of property and equipment	(54,649)	(33,490)	(105,302)	(80,258)
Investment in businesses			(9,874)	(1,590)
Proceeds from sale of assets and businesses			34,552	71,366
Net cash used in investing activities			(99,132)	(432,001)
Financing activities
Borrowings on revolving facilities			630,000	320,000
Payments on revolving facilities			(550,000)	(380,000)
Proceeds from term loans			1,139,487	600,127
Payments on term loans			(1,173,692)	(229,649)
Revolving facility debt issuance costs			(4,392)
Borrowings of other debt			9,444	22,082
Principal payments on other debt			(10,437)	(9,926)
Repayments of bank overdrafts			(5,228)	(2,138)
Proceeds from issuance of non-controlling interests			3,553	3,103
Purchase of non-controlling interests			(120)	(1,294)
Distributions to non-controlling interests			(5,416)	(4,708)
Net cash provided by financing activities			33,562	317,748
Net increase (decrease) in cash and cash equivalents			(25,230)	63,985
Cash and cash equivalents at beginning of period			99,029	14,435
Cash and cash equivalents at end of period	73,799	78,420	73,799	78,420
Select Medical Corporation
Operating activities
Net income	51,300	40,853	74,763	100,797
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries			10,933	12,039
Depreciation and amortization	38,333	36,205	80,872	70,722
Provision for bad debts	18,174	17,517	38,799	33,914
Equity in earnings of unconsolidated subsidiaries	(5,666)	(4,546)	(11,187)	(9,198)
Loss on extinguishment of debt			6,527	773
Gain on sale of assets and businesses			(9,523)	(43,461)
Loss on disposal of assets				55
Impairment of equity investment				5,339
Stock compensation expense			9,270	8,174
Amortization of debt discount, premium and issuance costs			5,974	7,077
Deferred income taxes			(1,474)	(13,286)
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable			(179,003)	(44,096)
Other current assets			(5,557)	11,011
Other assets			4,621	4,508
Accounts payable			759	(15,852)
Accrued expenses			(4,833)	20,632
Income taxes			19,399	29,090
Net cash provided by operating activities			40,340	178,238
Investing activities
Acquisition of businesses, net of cash acquired			(18,508)	(421,519)
Purchases of property and equipment			(105,302)	(80,258)
Investment in businesses			(9,874)	(1,590)
Proceeds from sale of assets and businesses			34,552	71,366
Net cash used in investing activities			(99,132)	(432,001)
Financing activities
Borrowings on revolving facilities			630,000	320,000
Payments on revolving facilities			(550,000)	(380,000)
Proceeds from term loans			1,139,487	600,127
Payments on term loans			(1,173,692)	(229,649)
Revolving facility debt issuance costs			(4,392)
Borrowings of other debt			9,444	22,082
Principal payments on other debt			(10,437)	(9,926)
Repayments of bank overdrafts			(5,228)	(2,138)
Dividends paid to Holdings			(600)	(506)
Equity investment by Holdings			963	657
Proceeds from issuance of non-controlling interests			3,553	3,103
Purchase of non-controlling interests			(120)	(1,294)
Distributions to non-controlling interests			(5,416)	(4,708)
Net cash provided by financing activities			33,562	317,748
Net increase (decrease) in cash and cash equivalents			(25,230)	63,985
Cash and cash equivalents at beginning of period			99,029	14,435
Cash and cash equivalents at end of period	73,799	78,420	73,799	78,420
Select Medical Corporation | Reportable legal entities | Select (Parent Company Only)
Operating activities
Net income	42,055	33,935	57,925	88,768
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization	1,573	1,276	3,148	2,487
Equity in earnings of consolidated subsidiaries	(28,534)	(38,998)	(56,790)	(68,357)
Loss on extinguishment of debt			6,527	773
Gain on sale of assets and businesses			(8)	(40,895)
Stock compensation expense			8,700	7,790
Amortization of debt discount, premium and issuance costs			4,342	5,371
Deferred income taxes			5,987	997
Changes in operating assets and liabilities, net of effects of business combinations:
Other current assets			(5,631)	(2,938)
Other assets			3,184	(4,268)
Accounts payable			(413)	(2,241)
Accrued expenses			(5,618)	(10,175)
Income taxes			9,366	9,101
Net cash provided by operating activities			30,719	(13,587)
Investing activities
Acquisition of businesses, net of cash acquired				(408,654)
Purchases of property and equipment			(7,093)	(8,545)
Proceeds from sale of assets and businesses			8	63,418
Net cash used in investing activities			(7,085)	(353,781)
Financing activities
Borrowings on revolving facilities			630,000	320,000
Payments on revolving facilities			(550,000)	(375,000)
Proceeds from term loans			1,139,487	600,127
Payments on term loans			(1,150,627)	(227,399)
Revolving facility debt issuance costs			(4,392)
Borrowings of other debt			6,572	9,765
Principal payments on other debt			(7,353)	(7,278)
Repayments of bank overdrafts			(5,228)	(2,138)
Dividends paid to Holdings			(600)	(506)
Equity investment by Holdings			963	657
Intercompany			(93,455)	49,141
Net cash provided by financing activities			(34,633)	367,369
Net increase (decrease) in cash and cash equivalents			(10,999)	1
Cash and cash equivalents at beginning of period			11,071	4,070
Cash and cash equivalents at end of period	72	4,071	72	4,071
Select Medical Corporation | Reportable legal entities | Subsidiary Guarantors
Operating activities
Net income	23,022	34,250	45,759	61,302
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries			10,902	12,000
Depreciation and amortization	18,149	17,316	39,489	32,648
Provision for bad debts	9,829	10,285	21,577	21,003
Equity in earnings of unconsolidated subsidiaries	(5,646)	(4,519)	(11,139)	(9,146)
Equity in earnings of consolidated subsidiaries	(4,200)	1,133	(9,775)	(1,873)
Gain on sale of assets and businesses			(4,828)	(2,566)
Loss on disposal of assets				37
Impairment of equity investment				5,339
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable			(125,418)	(22,896)
Other current assets			5,452	7,342
Other assets			(16,925)	(341)
Accounts payable			(1,550)	(17,695)
Accrued expenses			(4,817)	36,088
Net cash provided by operating activities			(51,273)	121,242
Investing activities
Acquisition of businesses, net of cash acquired			(2,305)	(605)
Purchases of property and equipment			(71,813)	(52,591)
Investment in businesses			(9,874)	(1,590)
Proceeds from sale of assets and businesses			15,007	7,942
Net cash used in investing activities			(68,985)	(46,844)
Financing activities
Principal payments on other debt			(204)	(385)
Intercompany			119,528	(68,206)
Purchase of non-controlling interests				(1,294)
Distributions to non-controlling interests				(108)
Net cash provided by financing activities			119,324	(69,993)
Net increase (decrease) in cash and cash equivalents			(934)	4,405
Cash and cash equivalents at beginning of period			6,467	3,706
Cash and cash equivalents at end of period	5,533	8,111	5,533	8,111
Select Medical Corporation | Reportable legal entities | Non-Guarantor Subsidiaries
Operating activities
Net income	6,109	(265)	12,968	4,701
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries			31	39
Depreciation and amortization	3,182	2,697	6,683	5,295
Provision for bad debts	3,627	2,093	6,933	4,058
Equity in earnings of unconsolidated subsidiaries	(20)	(27)	(48)	(52)
Gain on sale of assets and businesses			(4,687)
Loss on disposal of assets				12
Amortization of debt discount, premium and issuance costs				2
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable			(29,435)	(9,711)
Other current assets			(2,517)	(1,273)
Other assets			17,426	(424)
Accounts payable			(10)	(3,371)
Accrued expenses			8,704	(2,441)
Net cash provided by operating activities			16,048	(3,165)
Investing activities
Acquisition of businesses, net of cash acquired				(8,395)
Purchases of property and equipment			(10,109)	(11,195)
Proceeds from sale of assets and businesses			19,537	6
Net cash used in investing activities			9,428	(19,584)
Financing activities
Borrowings of other debt			105	9,500
Principal payments on other debt			(1,183)	(876)
Intercompany			(26,073)	19,065
Proceeds from issuance of non-controlling interests			3,553	3,103
Purchase of non-controlling interests			(120)
Distributions to non-controlling interests			(1,868)	(3,294)
Net cash provided by financing activities			(25,586)	27,498
Net increase (decrease) in cash and cash equivalents			(110)	4,749
Cash and cash equivalents at beginning of period			5,056	625
Cash and cash equivalents at end of period	4,946	5,374	4,946	5,374
Select Medical Corporation | Reportable legal entities | Non-Guarantor Concentra
Operating activities
Net income	12,848	10,798	24,676	16,256
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization	15,429	14,916	31,552	30,292
Provision for bad debts	4,718	5,139	10,289	8,853
Loss on disposal of assets				6
Stock compensation expense			570	384
Amortization of debt discount, premium and issuance costs			1,632	1,704
Deferred income taxes			(7,461)	(14,283)
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable			(24,150)	(11,489)
Other current assets			(2,861)	7,880
Other assets			936	9,541
Accounts payable			2,732	7,455
Accrued expenses			(3,102)	(2,840)
Income taxes			10,033	19,989
Net cash provided by operating activities			44,846	73,748
Investing activities
Acquisition of businesses, net of cash acquired			(16,203)	(3,865)
Purchases of property and equipment			(16,287)	(7,927)
Net cash used in investing activities			(32,490)	(11,792)
Financing activities
Payments on revolving facilities				(5,000)
Payments on term loans			(23,065)	(2,250)
Borrowings of other debt			2,767	2,817
Principal payments on other debt			(1,697)	(1,387)
Distributions to non-controlling interests			(3,548)	(1,306)
Net cash provided by financing activities			(25,543)	(7,126)
Net increase (decrease) in cash and cash equivalents			(13,187)	54,830
Cash and cash equivalents at beginning of period			76,435	6,034
Cash and cash equivalents at end of period	63,248	60,864	63,248	60,864
Select Medical Corporation | Eliminations
Operating activities
Net income	(32,734)	(37,865)	(66,565)	(70,230)
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Equity in earnings of consolidated subsidiaries	$ 32,734	$ 37,865	$ 66,565	$ 70,230